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who,	 in	 1896,	 described	 a	 five-year-old	 girl	 named	 Gabrielle	 P.,	 taking	 particular	 note	 of	
her	extraordinarily	 long	limbs	and	fingers.	 It	was	only	 later	appreciated	that	Gabrielle	P.	




of	 the	 syndromes	 included	 in	 the	 differential	 diagnosis	 of	 Marfan	 syndrome	 (Beals	 and	
Hecht,	 1971;	 Hecht	 and	 Beals,	 1972).	 Clinical	 descriptions	 of	 patients	 potentially	 affected	













have	 a	 high	 risk	 for	 aortic	 root	 aneurysm	 and	 dissection.	 This	 life-threatening	 aspect	







have	 ectopia	 lentis	 (Maumenee,	 1981).	 Other	 less	 specific	 ocular	 features	 are	 myopia,	





Clinical	 criteria	 required	 to	 diagnose	 the	 syndrome	 were	 defined	 by	 an	 international	
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tissue	 throughout	 the	 body.	 Fibrillin-1	 is	 characterised	 by	 a	 highly	 conserved	 modular	





for	 stabilisation	 of	 the	 tertiary	 structure,	 prevention	 of	 proteolytic	 degradation	 and	 for	
protein-protein	interaction	(Cooke	et	al.,	1987;	Dietz	et	al.,	1993;	Handford	et	al.,	1991).	The	
EGF	domains	are	interrupted	by	seven	transforming	growth	factor	(TGF)-binding	protein	
domains,	 which	 are	 characterised	 by	 eight	 cysteine	 residues	 involved	 in	 intra-domain	
disulfide	bonds	(Figure	1a)	(Pereira	et	al.,	1993;	Robinson	et	al.,	2006).	
In	 a	 study	 of	 FBN1	 mutations	 and	 clinical	 correlations	 in	 1,013	 probands	 with	 Marfan	
syndrome	 and	 related	 phenotypes,	 the	 mutations	 were	 classified	 as	 missense	 in	 56%	
of	 cases,	 frameshift	 in	 17%,	 nonsense	 in	 14%,	 splicing	 in	 11%,	 and	 in-frame	 deletions	
or	 insertions	 in	 2%	 of	 cases.	 The	 majority	 of	 FBN1	 missense	 mutations	 are	 cysteine	








individual	 basis,	 the	 following	 phenotype-genotype	 correlations	 have	 been	 established:	
Missense	 mutations	 substituting	 or	 creating	 a	 cysteine	 show	 a	 higher	 correlation	 with	
ectopia	 lentis	 than	 other	 missense	 mutations.	 Patients	 with	 major	 skeletal	 and	 skin	
involvement	 show	 a	 PTC	 mutation	 more	 frequently	 than	 patients	 with	 an	 in-frame	
mutation.	Mutations	in	exons	24-32	are	more	often	associated	with	a	neonatal	onset	of	
the	 disease	 or	 a	 significantly	 higher	 probability	 of	 a	 more	 severe	 cardiovascular,	 ocular	
and/or	skeletal	phenotype,	with	a	younger	age	at	diagnosis	and	a	shorter	overall	survival.	
Patients	with	mutations	located	in	the	5’	region	of	the	gene	have	a	higher	probability	of	
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Fibrillin	 monomers	 polymerise	 into	 the	 microfibrils	 that	 form	 the	 outer	 sheet	 of	 elastic	













determinant	 of	 the	 phenotype	 of	 Marfan	 syndrome.	 However,	 features	 such	 as	 bone	
overgrowth,	 facial	 characteristics,	 lung	 abnormalities,	 myxomatous	 changes	 of	 mitral	
valves,	and	hypoplasia	of	muscle	and	fat	 tissue	could	not	be	explained	by	 loss	of	 tissue	
integrity.	 It	 is	 now	 appreciated	 that	 fibrillin-1	 not	 only	 has	 a	 structural	 function,	 but	 is	






attachment	 to	 the	 latency	 associated	 peptide	 (LAP),	 a	 peptide	 formed	 when	 immature	
TGFb	 is	 proteolytically	 cleaved	 into	 LAP	 and	 mature	 TGFb.	 In	 turn,	 LAP	 binds	 to	 one	 of	
four	 large	 latent	 TGFb-binding	 proteins	 (LTBP).	 This	 complex,	 named	 the	 large	 latent	
complex	(LLC),	is	linked	to	fibrillin-1	(Figure	2).	Degradation	of	microfibrils	by	inflammatory	
proteolytic	enzymes	will	initiate	the	release	of	TGFb	from	the	LLC,	and	TGFb	consequently	
becomes	 available	 for	 binding	 to	 the	 receptors	 TGFBR2	 and	 TGFBR1	 (ALK5)	 (Ten	 Dijke	
and	 Arthur,	 2007).	 Activation	 of	 TGFBR2	 leads	 to	 the	 phosphorylation	 and	 activation	 of	
TGFBR1,	 which	 in	 turn	 phosphorylates	 the	 receptor-activated	 SMAD	 proteins	 (R-SMAD2	
and	3)	that	form	a	heterotrimer	with	SMAD4	(two	R-SMADs	to	one	SMAD4).	This	complex	
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1
chapterbinds	 to	 DNA	 in	 the	 nucleus,	 together	 with	 transcription	 factors	 to	 activate	 or	 repress	
gene	transcription	(Massague	et	al.,	2005).	It	was	reported	in	2003	that	mice	deficient	in	
fibrillin-1	exhibit	dysregulation	of	TGFb	activation	and	signalling,	showing	impairment	of	
distal	 alveolar	 septation	 during	 development	 and	 rescue	 of	 the	 phenotype	 by	 perinatal	





a	TGFb	neutralising	antibody	or	 the	angiotensin	 II	 type	 1	 receptor	 (AT1)	blocker,	 losartan	
(Habashi	et	al.,	2006).	Recent	results	in	mouse	models	of	Marfan	syndrome	showed	that	






















known	 as	 Loeys-Dietz	 syndrome	 (LDS)	 (Loeys	 et	 al.,	 2005).	 FTAAD	 caused	 by	 TGFBR2	
mutations,	 but	 without	 additional	 features	 typical	 of	 LDS,	 is	 also	 known	 as	 Marfan	
syndrome	type	II.	While	some	affected	FTAAD	family	members	may	indeed	show	minor	
hoofdstuk 1.indd   15 19-04-13   09:52
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Figure	1.	The	fibrillin-1	protein	from	gene	to	microfibrils.	(a)	Schematic	diagram	showing	the	
modular	 structure	 of	 FBN1,	 the	 gene	 encoding	 fibrillin-1.	 The	 Epidermal	 Growth	 Factor-like	
(EGF)	 domain	 is	 present	 47	 times	 and	 each	 domain	 contains	 six	 highly	 conserved	 cysteine	
residues	that	stabilise	domain	structure	via	three	disulfide	bonds.	Of	the	EGF	domains,	43	have	
a	 consensus	 sequence	 for	 calcium	 binding	 (cbEGF)	 in	 the	 N-terminal	 pocket	 of	 the	 domain	




in	 the	 endoplasmic	 reticulum,	 the	 fibrillin-1	 molecules	 are	 secreted	 and	 incorporated	 into	
the	 extracellular	 matrix	 (ECM).	 The	 fibrillin-1	 molecules	 form	 a	 network	 with	 a	 head-to-tail	
orientation	 and	 intermolecular	 cross-links.	 Through	 specific	 folding,	 a	 beads-on-a-string	
structure	 with	 characteristic	 elastic	 properties	 is	 formed.	 Depending	 on	 the	 location,	 the	
microfibrils	either	form	elastic	fibres	with	a	core	of	elastin	or	occur	independently	in	the	ECM.	
Reprinted	with	permission	from	Elsevier	(Ramirez	and	Dietz,	2007).




Figure	 2.	 Schematic	 representation	 of	 the	 TGFb	 signalling	 pathway	 regulated	 by	












Mutations	 in	 known	 genes	 are	 found	 in	 up	 to	 20%	 of	 FTAAD	 and	 genetic	 testing	 is	
available	 for	 FBN1,	 TGFBR1,	 TGFBR2,	 ACTA2,	 MYH11,	 MYLK,	 SMAD3,	 TGFB2	 and	 NOTCH1.	
Table	1	shows	the	clinical	characteristics	of	FTAAD	for	the	genes	identified	to	date.	These	
genes	 encode	 structural	 proteins	 involved	 in	 connective	 tissue,	 members	 of	 the	 TGFb	
pathway,	or	components	or	regulators	of	the	contractile	unit	of	vascular	smooth	muscle	
cells	(SMCs).	A	recent	example	is	the	discovery	of	mutations	in	SMAD3,	which	is	another	
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member	of	the	TGFb	pathway	essential	for	TGFb	signal	transduction.	Using	genome-wide	
linkage	analysis,	 this	gene	was	discovered	 in	a	 large	family	with	arterial	aneurysms	and	
dissections.	




medium-sized	 arteries	 and	 arterial	 tortuosity.	 Furthermore,	 aortic	 dissections	 occurred	
in	 some	 family	 members	 at	 a	 young	 age	 and	 affected	 only	 mildly	 dilated	 aortas.	 Apart	
from	aspecific	dysmorphic	and	cutaneous	features,	most	of	the	family	members	presented	
with	 early	 onset	 osteoarthritis	 of	 the	 knees,	 spine	 and	 thumbs,	 and	 intervertebral	 disc	




Recently,	 two	 independent	 studies	 showed	 that	 haploinsufficiency	 for	 TGFB2	 causes	
FTAAD	with	overlapping	features	of	Marfan	and	Loeys-Dietz	syndrome	(Boileau	et	al.,	2012;	
Lindsay	 et	 al.,	 2012).	 In	 TGFB2,	 which	 encodes	 a	 TGFb	 ligand,	 loss	 of	 function	 mutations	
affecting	 the	 TGFb	 signalling	 pathway	 were	 again	 found.	 As	 with	 mutations	 in	 FBN1,	
TGFBR1,	 TGFBR2	 and	 SMAD3,	 mutations	 in	 TGFB2	 lead	 to	 paradoxical	 (late)	 activation	 of	
the	 TGFb	 signalling	 pathway.	 Several	 hypotheses	 have	 been	 presented	 to	 explain	 this	
effect,	including	an	overshoot	of	a	negative	feedback	loop,	signalling	through	alternative	

















Table 1. Overview of FTAAD or syndromes associated with thoracic aortic aneurysms or dissections
Syndrome Gene Chromosome 
location
Protein name Protein function Phenotype % of 
FTAAD
TAAD as a main feature
Marfan 
syndrome
FBN1 15q21.1 fibrillin-1 structural component of elastic 
fibres; binding inactive TGFβ
Marfan syndrome; ectopia lentis 
syndrome; acromicric and geleophysic 
dysplasia; Weill-Marchesani syndrome; 
stiff skin syndrome; Shprintzen-
Goldberg syndrome
syndromic
FTAAD/LDS TGFBR2 3p24.1 transforming growth 
factor receptor type 2
transmembrane receptor for 
TGFβ, together with TGFBR1 
regulation of  cell proliferation 
and differentiation, 
extracellular matrix production
FTAAD; aortic aneurysms and 
dissections, arterial tortuosity and 
aneurysms, skeletal, craniofacial and 
cutaneous features (LDS)
4%
FTAAD/LDS TGFBR1 9q22.33 transforming growth 
factor receptor type 1
as TGFBR2 FTAAD; aortic aneurysms and 
dissections, arterial tortuosity and 
aneurysms, skeletal, craniofacial and 
cutaneous features (LDS)
1%
FTAAD4 MYH11 16p13.11 myosin light chain 
kinase
part of contractile unit of SMC FTAAD with PDA 1%
FTAAD6 ACTA2 10q23.31 actin, alpha2, smooth 
muscle aorta
part of contractile unit of SMC FTAAD with tortuosity, premature 
stroke and coronary artery disease; 
multisystemic smooth muscle 
dysfunction
10-14%
FTAAD7 MYLK 3q21.1 myosin light chain 
kinase, smooth 
muscle
controlling SMC contractile 
function
FTAAD 1%
AOS SMAD3 15q22.33 mothers against 
decapentaplegic 
homolog 3
signal transducer downstream 
from TGFBR 1 and 2
Tortuosity, aneurysms and dissections 
of arteries and aorta, osteoarthritis, 
intervertebral disc degeneration
2%
FTAAD/MFS-like TGFB2 1q41 transforming growth 
factor beta-2
cytokine regulating multiple 
aspects of cellular behaviour
FTAAD with tortuosity, 
cerebrovascular disease and some 
features shared with LDS and MFS
2%
Frequently associated with TAAD




transmembrane receptor that 
regulates cell fate decisions 
during development
Bicuspid aortic valve with ascending 




ATS SLC2A10 20q13.12 glucose transporter 
10
glucose homeostasis; regulation 
of TGFβ pathway
Tortuosity, stenosis and aneurysms 
of arteries and aorta, cutis laxa, joint 
laxity, contractures
syndromic
ARCL1 FBLN4 11q13.1 fibulin-4 extracellular matrix proteins 
regulating elastic fibre 
formation and connective tissue 
development
Cutis laxa, arterial tortuosity, (aortic) 
aneurysms and stenosis, retrognathia, 
joint laxity and arachnodactyly
syndromic
ADCL1 ELN 7q11.23 elastin amorphous component of 
elastic fibres
Cutis laxa, gastrointestinal diverticula, 
hernia, genital prolapse, pulmonary 
artery stenosis, bicuspid aortic valve, 
aortic aneurysm, emphysema
syndromic
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Table 1. Overview of FTAAD or syndromes associated with thoracic aortic aneurysms or dissections
Syndrome Gene Chromosome 
location
Protein name Protein function Phenotype % of 
FTAAD
Occasionally associated with TAAD
EDS vascular type COL3A1 2q31 collagen type III structural component in 
extracellular matrix
Thin translucent skin, easy bruising, 
characteristic facial appearance 
(in some individuals), and arterial, 
intestinal, and/or uterine fragility
syndromic
SGS SKI 1p36 V-SKI avian sarcoma 
viral oncogene 
homolog
regulating TGFβ pathway by 
binding at Smad4
Severe marfanoid habitus, intellectual 
disability, camptodactyly, typical facial 
dysmorphism, craniosynostosis, aortic 
aneurysm
syndromic
ADPKD1 PKD1 14q12 polycystin 1 regulation of multiple signalling 
pathways to maintain normal 
renal tubular structure and 
function
Progressive renal cystic disease, extra-
renal cysts, intracranial aneurysms, 
aneurysms and dissections of aorta or 
other arteries
syndromic
ADPKD2 PKD2 4q22.1 polycystin 2 nonselective cat ion channel 
involved in Ca(2+) transport 
and Ca(2+) signalling in renal 
epithelial cells
Progressive renal cystic disease, extra-
renal cysts, intracranial aneurysms, 
aneurysms and dissections of aorta or 
other arteries
syndromic
PH EDS variant FLNA Xq28 filamin A actin binding protein, interacts 
with the actin cytoskeleton 
and thereby regulates various 
aspects of cell shape, motility 
and function
periventricular heterotopia, joint 
and skin hyperextensibility, aortic 
dilatation and dissection
syndromic









regulating the responses of 
eukaryotic cells to extracellular 
signals in the RAS/MAPK 
signalling pathway
short stature, a short neck with 
webbing or redundancy of skin, 
cardiac anomalies, deafness, motor 
delay, bleeding diathesis, dysmorphic 
features
syndromic
NF1 NF1 17q11.2 neurofibromin 1 cytoplasmic protein, regulatory 
function in several intracellular 
processes including RAS/MAPK 
signalling pathway
café-au-lait spots, Lisch noduli in the 







17q31.33, 7q21.3 collagen, type 1, 
alpha-1; collagen, type 
1 alpha-2
two alpha -1 and one alpha-2 
chains form the triple helical 
structure of collagen type I ion 
the extracellular matrix
susceptibility to bone fractures with a 




JAG1 20p12.2 jagged-1 ligand of Notch receptor, 
their binding play a role 
in cell differentiation and 
morphogenesis through 
transcription factors 
cholestasis, cardiac disease, skeletal 
abnormalities, ocular abnormalities, 









a receptor, type 




endoglin is a homodimeric 
glycoprotein and component 
of the TGFBR complex; activin 
a receptor, type II-like kinase 1 
is a type I cell surface receptor 
for the TGFβ ligands; SMAD4 is 
a signal transducer downstream 
from TGFBR 1 and 2
arteriovenous malformations in liver, 
lung and brain; smal telangiectases 
on lips, tongue, buccal mucosa, face, 
chest, and fingers; juvenile polyposis 




COL4A5 Xq23.3 collagen, type 4, 
alpha-5
alpha-5 forms together with 
alpha-3 and -4 heterotrimers 
of type IV collagen that 
form networks that serve as 
scaffolding for the deposition of 
other matrix glycoproteins and 
for cell attachment
progressive renal insufficiency, 
progressive sensorineurla hearing loss, 
ocular lesions, aortic aneurysms
syndromic
ADPKD autosomal dominant polycystic kidney disease; AOS aneurysms-osteoarthritis syndrome; ADCL1 autosomal dominant cutis laxa type 1; ARCL1 autosomal 
recessive cutis laxa type 1; ATS arterial tortuosity syndrome; BAV bicuspid aortic valve; Ca calcium; CCA congenital contractural arachnodactyly; EDS Ehlers-Danlos 
syndrome; FTAAD familial thoracic aortic aneurysms and dissections; HHT Hereditary Hemorrhagic Telangiectasia; LDS Loeys-Dietz syndrome; MFS Marfan 
syndrome; na not applicable; NF1 Neurofibromatosis type 1; OI osteogenesis imperfecta; PDA patent ductus arteriosus; PH periventricular heterotopia; SGS 
Shprintzen-Goldberg syndrome; SKS stiff skin syndrome; SMC smooth muscle cell; TGFβ transforming growth factor β; TGFBR1 transforming growth factor, β 
receptor 1; WMS Weill-Marchesani syndrome; XL -linked






and	 transcriptional	 regulator	 NOTCH1	 were	 discovered	 in	 dominant	 pedigrees	 and	 were	
associated	with	a	spectrum	of	developmental	aortic	valve	anomalies,	 including	bicuspid	
aortic	valves	and	severe	valve	calcification	 (Garg	et	al.,	 2005;	Garg,	2006).	Mutations	 in	




























Autosomal	 dominant	 polycystic	 kidney	 disease	 (ADPKD)	 is	 a	 relatively	 common	 chronic	
kidney	disease.	The	majority	of	ADPKD	patients	carry	mutations	in	PKD1	or	PKD2,	encoding	
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1	and	2	are	expressed	 in	vascular	SMCs	 in	arteries	and	are	 thought	 to	play	a	 role	 in	 the	
interaction	between	SMCs	and	adjacent	elastic	tissue	-	and	may	be	involved	in	the	vascular	
complications	seen	in	ADPKD	(Griffin	et	al.,	1997;	Hassane	et	al.,	2007;	Torres	et	al.,	2001).	
FLNA	 mutations	 cause	 an	 X-linked	 dominant	 disorder	 characterised	 by	 periventricular	
heterotopia	 with	 seizures	 and	 dyslexia,	 but	 also	 including	 features	 of	 EDS	 such	 as	 joint	
and	 skin	 hyperextensibility.	 Patients	 have	 also	 been	 reported	 to	 show	 cardiovascular	
abnormalities	 including	aortic	dilatation	and	dissection	(Sheen	and	Walsh,	2005).	Turner	
syndrome	 is	 a	 well-known	 chromosomal	 disorder	 and	 is	 most	 commonly	 caused	 by	












aortic	 aneurysms.	 Patients	 with	 Marfan	 syndrome	 not	 only	 have	 an	 increased	 risk	 of	
aortic	aneurysms	and	dissections	but	also	suffer	from	other	pathology	affecting	the	eyes,	
the	 skeletal	 system	 and	 the	 skin,	 leading	 to	 significant	 morbidity.	 The	 management	 of	
this	 multisystemic	 disorder	 is	 a	 challenge	 for	 the	 clinicians	 involved.	 Chapter	 2	 presents	




clear	 that	 several	 aspects	 lacked	 scientific	 support	 and	 were	 solely	 based	 upon	 expert	
opinion.	The	following	chapters	discuss	the	presentation	of	Marfan	syndrome	and	FTAAD	






pathogenetic	 mechanism	 of	 specific	 mutations	 is	 of	 utmost	 importance.	 Novel	 insights	









The	 clinical	 features	 of	 these	 patients	 illustrate	 that	 pure	 haploinsufficiency	 of	 FBN1	 is	
sufficient	for	the	expression	of	the	complete	phenotype	of	Marfan	syndrome.	Chapter	6	
reports	an	unexpected	result	of	a	microarray	analysis	performed	 in	a	boy	with	 learning	
difficulties	 and	 behavioural	 problems.	 The	 identification	 of	 an	 interstitial	 deletion	 of	
chromosome	15	that	disrupts	the	SMAD3	gene	was	a	finding	with	major	health	implications	
for	family	members,	and	revealed	a	significant	familial	risk	for	aortic	and	arterial	aneurysms	
and	 dissections.	 In	 Chapter	 7,	 two	 patients	 with	 Marfan	 syndrome	 are	 described	 with	
unexplained	intracranial	hypertension.	
Chapter	8	includes	a	general	summary,	together	with	a	discussion	of	the	implications	of	
the	 studies	 in	 this	 thesis,	 and	 future	 prospects	 for	 diagnosis	 and	 treatment	 of	 thoracic	
aortic	aneurysms	and	dissections.	This	is	followed	by	a	Dutch	summary	in	Chapter	9.
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Section 1  General Introduction
1.1  Motivation for guideline development  
Few original data on the birth prevalence of Marfan syndrome are available in the medical 
literature. The prevalence at birth was originally estimated at around 1/10,000 and the 
prevalence at 1/14,217 (Gray et al, 1994), but later estimates assume a prevalence of 2-3 per 
10,000 (Judge & Dietz, 2005; Pyeritz, 2000), although the basis for these higher estimates 
is unclear. Based on the figures of Gray (1994) and a life expectancy with Marfan syndrome 
of 70 years (a figure based on little data), one arrives at an estimate of around 1,200 to 1,300 
patients in the Netherlands, with 18 newborns per year. 
Marfan syndrome is an autosomal dominant, multisystem disorder in which the heart 
and aorta, skeleton and eyes are the major affected organs. Due to the variety of disease 
expression, the wide variability and the hereditary nature of the condition, there is often a 
range of specialists involved in the care of a patient with Marfan syndrome.
Because the disease is relatively rare, 4 expert centres (Marfan clinics) have been established 
in the Netherlands. These centers provide Marfan syndrome diagnostics when a diagnosis 
is suspected on clinical grounds and ensure adequate clinical assessment and treatment. 
While the Marfan clinics are in close contact with one another, there are nevertheless 
differences in the approach to and organisation of care.
Moreover, there is currently no uniform policy for referral from primary and secondary 
centres to a Marfan clinic. In order to develop a uniform policy regarding the referral, 
diagnosis and treatment of Marfan patients, the scientific societies involved in the care 
for Marfan patients have decided, following an initiative of the Dutch Society of Clinical 
Genetics (VKGN), to develop a guideline with uniform, and as far as possible, evidence-
based recommendations.
The development of the guideline was funded by the Stichting Kwaliteitsgelden Medisch 
Specialisten (SKMS). The Department of Professional Quality Support of the Dutch Order of 
Medical Specialists provided methodological support.
1.2  Aim of the guideline
The guideline provides recommendations for physicians regarding referral policy, 
which amongst others provides guidelines regarding the characteristics required to 
indicate a referral to a Marfan clinic. In addition, recommendations are made for care 
providers at Marfan clinics regarding the diagnostic procedure, the logistics thereof, 
the clinical assessment and treatment of Marfan patients and family studies. Specific 
recommendations regarding prenatal diagnosis, pregnancy and childbirth are also made. 
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No recommendations are provided for the treatment of disorders or problems that occur 
more frequently in Marfan syndrome than in the normal population, but which do not 
require treatment other than that appropriate in non-Marfan patients.
Patients with Marfan syndrome, organised in the Contactgroup Marfan Netherlands, were 
involved in the creation of this guideline and made recommendations for the organisation 
of care.
With this guideline, the working group hopes to create a tool for the provision of uniform 
care in Marfan syndrome.
1.3  Delineation of the guideline
Description of the problem and clinical questions. 
The working group has formulated a number of clinical questions (see Appendix 1) that 
form the basis for the various sections of this guideline. The guideline does not aim to 
describe the entire process of clinical care, but focuses on specific bottlenecks.
The guideline covers the diagnosis and treatment of patients with Marfan syndrome and 
is based on new criteria established in 2010, “the revised Ghent nosology for the Marfan 
syndrome” (Loeys et al, 2010), subsequently referred to as the Ghent II criteria. The guideline 
refers to the original Ghent criteria as Ghent I (De Paepe et al, 1996).
1.4  The intended users of the guideline 
The guideline is primarily aimed at all healthcare professionals involved in the detection, 
diagnosis, monitoring and treatment of patients with Marfan syndrome: GPs, (paediatric) 
cardiologists, paediatricians, thoracic surgeons, clinical geneticists, ophthalmologists, 
gynaecologists, orthopaedic surgeons, midwives, paediatricians and doctors at health 
clinics. The directive is therefore not only intended for specialists linked to a Marfan clinic. 
The secondary target group is that of patients with Marfan syndrome.
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Section 2  Methodology of Guideline Development
2.1  AGREE
This guideline has been prepared on the basis of the “Appraisal of Guidelines for Research 
& Evaluation II” (AGREE II) instrument (www.agreecollaboration.org). This is a widely 
accepted international instrument for the assessment of the quality of guidelines.
2.2  Working group 
For the development of the guideline, a multidisciplinary working group was established in 
2010, consisting of representatives from all relevant specialties involved in the assessment 
and care of Marfan syndrome. The working group consisted of clinical geneticists, 
cardiologists, a cardiothoracic surgeon, ophthalmologists, a gynaecologist, a paediatrician/-
cardiologist, orthopaedic surgeons, a molecular geneticist and an anaesthetist (see 
Members of the Working Group).
The working group members were mandated to participate by their professional 
associations. The group worked for two years on the creation of the guideline.
2.3  Declarations of conflicts of interest
Members of the working group have declared in writing whether they have maintained, 
over the last five years, a (financially supportive) relationship with commercial enterprises, 
organisations or institutions related to the subject of the guideline. 
2.4  Patient participation
During the development of the guideline, a specific focus was to appraise the perspective 
of the patient. The working group included a representative of the patient organisation 
Contact Group Marfan Netherlands. In addition, a patient focus group was organised. The 
discussions within the focus group were summarised in a report that was made available 
to members for verification and possible additional comments. A summary of this report 
(Appendix 3) was used by the working group in the preparation of the guideline, and finally, 
members of the focus group were asked to comment on the draft guideline.
2.5  Analysis of critical issues
Particularly difficult issues were identified during the preparatory phase, in cooperation 
with the chair of the working group. These issues were discussed in the working group, and 
on this basis clinical questions were formulated.




















2.6  Clinical questions and outcome measures
Clinical questions were formulated by the working group based on critical issues. When 
possible, the most important and patient-relevant outcome measures were identified for 
each clinical question.
2.7  Literature search strategy 
The basis for the guideline is provided by evidence from published scientific research. 
During the exploratory search, the Cochrane Library was searched and existing guidelines 
were specifically sought in (inter)national guideline clearinghouses that allow online 
searches.
Because not all clinical questions lend themselves to a systematic literature search, prior 
agreement was made to limit systematic literature searches to questions regarding 
treatment and to those related to pregnancy and childbirth.
Based on specific search terms, the electronic databases Medline and Embase were 
searched for published scientific studies relevant to the clinical questions formulated. If 
necessary, searching for additional studies was carried out. Initial searching focused on 
(systematic reviews or meta-analyses of) randomised controlled trials (RCTs). In the absence 
of RCTs, searching was resumed; now focusing on prospective comparative controlled 
trials and prospective non-comparative studies. Languages were limited to English, Dutch 
and German. 
The working group members selected items by relevance. In addition, studies were 
extracted from reference lists of retrieved literature. For certain clinical questions, this 
resulted in additional relevant articles. The selected articles were used to answer the 
clinical question.
For the remaining clinical questions, the available scientific evidence proved to be 
insufficient. To answer these questions, the expertise of the working group members 
was elicited, supported by scientific literature when available. Because Marfan syndrome 
is a rare disorder, the available literature is often limited to case series and small patient 
groups. 
2.8  Strategy for assessing literature
Literature reviews were carried using the EBRO methodology. Individual studies were 
assessed for study approach/design. Following this assessment, the level of study evidence 
was determined according to the classification described in Table 2.1 and Table 2.2. A 
summary of the literature and the level of evidence of the relevant studies can be found in 
the guideline text under the headings, ‘summary of the literature’ and ‘conclusion’.
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2.9  Considerations 
Before making a specific recommendation, in addition to the scientific evidence, other 
factors must be considered including the expertise of the working group members, 
patient preferences, costs, availability of facilities or organisational aspects. These factors 
are, in sofar as they have not been scientifically investigated, listed under the heading 
‘considerations’.
2.10  Recommendations
The recommendations provide an answer to the central clinical question and are based on 
both the available scientific evidence and on the most important considerations.
Tabel 2.1. EBRO classification of individual study quality 
Evidence 
level 
Diagnostic accuracy of research Injury or side effects, etiology, 
prognosis
A1 Meta-analysis of at least 2 independently conducted studies of A2-level
A2 Research conducted in relation to a reference test 
(gold standard) with predefined cut-off values 
and independent assessment of results, with a 
sufficiently large series of consecutive patients, 
all of whom have undergone both the index and 
reference tests
Prospective cohort study of 
sufficient size and follow-up, 
which adequately controlled for 
confounding and with sufficient 
exclusion of selective follow-up
B Research relative to a reference test, but not with all 
the features listed under A2
Prospective cohort study, but not 
with all the features listed under A2 
or a retrospective cohort or case-
control study
C Non-comparative study
Table 2.2. Level of evidence supporting a conclusion
Conclusion based on
1 Study of level A1 or at least two independently conducted studies of level A2
2 One study of level A2 or at least two independently conducted studies of level B
3 One study of level B or C
4 Expert opinion
le 2 1. EBRO classif catio  of individual study quality 
le 2.2. Level of evid nce supporting a c nclusion




















2.11  Comment and authorisation phase 
The draft guideline was presented to the relevant (scientific) associations for comments. 
The comments were gathered and discussed within the working group. In response to the 
comments, the draft guideline was adapted and finalised by the working group. The final 
guideline was then sent to the directors of the (scientific) associations for authorisation.
2.12  Implementation
During the development of the guideline, the implementation and feasibility of the 
recommendations were already taken into account. Consideration was given to factors 
that could either promote or hinder the introduction of the guideline in practice. The 
guideline has been distributed to all relevant professional groups and institutions, and an 
electronic version of the guideline will be published. The electronic version will be available 
for download from the VKGN website and from other participating organisations, and 
from the Kwaliteitskoepel: www.kwaliteitskoepel.nl. A summary of the guideline will be 
submitted to the Netherlands Journal of Medicine and to other relevant journals. In order 
to bring the guideline to the attention of the target audience, a symposium will also be 
organised.
2.13  Legal implications of the guideline 
Guidelines are not laws, but are based on evidence-based insights and recommendations 
that caregivers must satisfy in order to provide high-quality care. Since these 
recommendations are mainly based on ‘general evidence for optimal care of the average 
patient’, the professional autonomy of healthcare providers allows them deviate from the 
guidelines in individual cases, where necessary. Even deviation from the guidelines may be 
necessary in certain situations. In cases where the guideline is not followed, any deviation 
should be justified and documented and, where relevant, this should be following 
consultation with the patient.
2.14  Revision 
The board of the VKGN will decide whether the guideline is still current, not later than 2017. 
If necessary, a new working group will be formed to revise the guideline. The validity of 
the guideline will be earlier curtailed if new developments necessitate the initiation of a 
revision process.
The Dutch Society of Clinical Genetics (VKGN) is the originator of this guideline and is as 
such primarily responsible for the topicality of the guideline. Other scientific associations 
participating in the guideline or users of the guideline share responsibility, and should 
inform the VKGN on relevant developments within their field.
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Section 3  Diagnostics
Introduction
Marfan syndrome is a multisystem disorder with a highly variable expression, leading to 
difficulties in detection and diagnosis. A diagnosis of Marfan syndrome is made on the 
basis of clinical and genetic findings, whereby use is made of the Ghent II criteria (Loeys 
et al, 2010).  These criteria are a revision of the Ghent I criteria (Chapter 3 of this thesis, De 
Paepe et al, 1996). Based on these criteria and related critical comments, recommendations 
are made which form the basis for a diagnosis of Marfan syndrome.
From the question of the selection of an appropriate diagnostic procedure, the question 
arises as to the minimum characteristics indicating diagnostics. Again, recommendations 
are made, including the most appropriate diagnostic procedure.
Summary of the literature
What are the diagnostic criteria for Marfan syndrome?
The possible characteristics of Marfan syndrome are listed in Appendix 2. This table shows 
the characteristics used in the Ghent I (De Paepe et al, 1996) and Ghent II criteria (Loeys et 
al, 2010). The list is not comprehensive, and although not all features are included in the 
Ghent criteria, they may nevertheless contribute to the recognition of Marfan syndrome.
Sponseller et al. (2010) have compared the frequency of occurrence of a number of Ghent 
criteria (mainly facial and skeletal abnormalities) in genetically confirmed Marfan patients 
(n = 183) and in a control group (n = 1257) and based on this, determined the sensitivity and 
specificity of the different characteristics (Sponseller et al, 2010).
1.    Facial features
All facial features are subjective and are almost never objectified in size or number. 
Despite this, facial features show a high sensitivity. A high palate with irregular dentition 
is no longer included as a diagnostic criterion in Ghent II, due to a low specificity.
2.   Skeletal features  
Skeletal features can be partly objectively determined using measurements and 
radiographic examination. This is the case for arachnodactyly, in which use is made of 
the wrist and thumb sign. The thumb sign is positive if the distal phalanx of the thumb 
protrudes beyond the ulnar border of the hand at maximum adduction. The wrist sign 
is considered positive if the top of the thumb overlaps the entire nail of the little finger 
when circling the wrist.




















Bodily proportions can be measured, with a span/length ratio of 1.05 or more being 
considered abnormal in the absence of scoliosis. When determining relatively long legs 
using the Ghent II criteria, normal values for the upper and lower ratios are given but 
these lack literature references. For acetabular protrusion and scoliose, standardised 
measurements are applied to a radiograph of either the pelvis or the spine (Sponseller 
et al, 2006).
3.   Cardiovascular features 
In the most recent criteria, the greatest weight is given to a dilatation of the aortic root 
or aortic dissection type A. The combination of a dilated aortic root and a dilatation 
of the pulmonary artery is a strong indicator of Marfan syndrome (Nollen et al, 2002). 
Mitral valve prolapse is included in the systematic score. In a study of 52 relatively young 
patients with Marfan syndrome, aged between 3 and 28 years, 43 patients (83%) showed 
an aortic root dilatation and 46 (88%) showed a mitral valve prolapse (van Karnebeek 
et al, 2001).
For the implementation and interpretation of cardiovascular imaging, see section 4.
4.   Ocular features
Until recently, diagnosis based on the Ghent I criteria included scoring for both major 
and minor criteria in which various ophthalmologic abnormalities were attributed 
a diagnostic value. The number of ophthalmologic abnormalities that contribute to 
the diagnosis of Marfan syndrome is greatly reduced in the Ghent II criteria, and only 
lens (sub)luxation and myopia of more than three diopters are still included. Lens (sub)
luxation is the only major ophthalmologic criterion in both the Ghent I and Ghent II 
criteria.
A literature review by Nemet et al. (2006) describes the main ocular features of Marfan 
syndrome. Maumenee (1981) described eye diseases in a population of 160 Marfan 
patients from 0-60 years of age. Lens (sub)luxation or ectopia lentis is a known feature 
of Marfan syndrome, with a reported incidence varying from 50 to 87% (Nemet et 
al, 2006). The luxation is usually (but not always) bilateral and towards temporal-top 
(Maumenee, 1981; Nemet et al, 2006). In rare cases (2-3%) full luxatio lentis may occur, 
resulting in a lens free in the vitreous humourand (non-iatrogenic) aphakia (Nemet et al, 
2006). A literature review by Dureau (2008) described the pathophysiology of lens (sub)
luxation and attributed it to poor quality zonular fibres. In the case of Marfan syndrome, 
these fibres are stretched or even broken, permitting the lens to luxate (Dureau, 2008).
Myopia greater than 3D is poorly indicative and is thus considered a less important 
criterion in the systematic score for the Ghent II criteria. Myopia is believed to occur in 
34-44% of Marfan patients, compared with 4.8% of the normal population (Nemet et al, 
2006). In a study of the level of myopia in Marfan syndrome patients, 50% of patients 
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showed myopia of 3D or more (Nemet et al, 2006).
Other ophthalmic characteristics that often affect the eyes of Marfan patients include 
iris hypoplasia, iris transillumination and iridodonesis. A flat cornea has also been 
described in the eyes of patients with Marfan syndrome. Heur (2008) compared the 
results of keratometry and central cornea thickness (CCT) from 62 Marfan patients 
(mean age 22.3 years) with those of 98 controls (mean age 19.3 yrs). The Marfan patients 
had a significantly lower outcome on keratometry and CCT than the controls. Peripheral 
retinal degeneration and retinal detachments occur in between 5 to 25.6% of patients 
with Marfan syndrome. These complications are more common in eyes with lens(sub)
luxation and/or a long axis length (Nemet et al, 2006).
5.   Pulmonary
Spontaneous pneumothorax contributes to the systematic score. In a retrospective 
study of 166 patients aged 13 or older, 4.8% had experienced pneumothorax one or 
more times. Two of the 8 patients had experienced a pneumothorax twice or even 
several times (Karpman et al, 2011).
6.   Skin 
Conspicuous striae at unusual locations count towards the systematic score, under the 
condition that the striae are not the result of significant weight change or pregnancy. 
Locations defined as unusual under the Ghent II criteria include the middle of the back, 
the lumbar region, upper arm, axilla region and hips (Loeys et al, 2010).
7.   Dura
Under the latest criteria, lumbosacral dural ectasia are now included in the systematic 
score. The method commonly used in the Netherlands to determine dural ectasia is that 
of Oosterhof (Oosterhof et al, 2001); this method has a high sensitivity and specificity, 
of 95% and 98%, respectively. The gold standard used was the presence (n = 44) or 
absence (n = 44) of Marfan syndrome based on clinical and genetic criteria. However, 
when comparing the method of Oosterhof with two other methods, a strikingly high 
level of dural ectasia was found in the control group. Using the Oosterhof method, 
Weigang found a sensitivity of 94% and a specificity of 57% (Weigang et al, 2006). In an 
observational study of 33 patients with features of Marfan or Loeys-Dietz but without 
genetic abnormalities, Sheikzadeh reported high levels of dural ectasia in individuals 
with non-specific connective tissue abnormalities but without Marfan syndrome 
(Sheikhzadeh et al, 2010).
8.   Other organ systems
Recurrent inguinal or umbilical hernia, incisional hernia, and reduced fat and muscle are 
not specific to Marfan syndrome but are very common. These features are no longer 
part of the diagnostic criteria.




















9.   Family
Having a first-degree relative with Marfan syndrome carries significant weight in the 
Ghent II criteria.
10. DNA
Marfan syndrome is usually caused by mutations in the FBN1 gene, which codes for 
the protein, fibrillin-1. In a recent publication by Sheikzadeh, a mutation in FBN1 was 
detected in 80% of the patients who met the original, the new or both Ghent criteria 
(Sheikhzadeh et al, 2011). The Ghent II criteria attributes considerable weight to causal 
mutations in the FBN1 gene.
Neonatal Marfan syndrome
The debate in literature as to whether neonatal Marfan syndrome should be seen as a 
separate entity, or as a very severe form of Marfan syndrome, remains unresolved. 
Hennekam provided arguments supporting the limitation of the term ‘neonatal Marfan 
syndrome’ to newborns with severe mitral and/or tricuspid valve insufficiency and 
infantile emphysema (Hennekam, 2005). These children almost always die before the 2nd 
year of life due to progressive valve dysfunction and heart failure. Similarly to children 
with neonatal Marfan syndrome, children with a severe expression of Marfan syndrome 
may display serious skeletal abnormalities, lens (sub)luxation, aortic root dilatation and 
elastic skin, but almost never show life-threatening valve dysfunction. Neonatal Marfan 
syndrome (as defined by Hennekam) is almost always de novo (Stheneur et al, 2011).
What is the policy in the case of a newborn with 50% risk of Marfan syndrome?
This question leads to the question of what is the earliest age at which Marfan syndrome 
can present with features that may require treatment. The literature indicates that it is 
extremely rare for a child with classic Marfan syndrome to undergo cardiovascular surgery 
in the first year of life. Everitt et al. (2009) conducted a retrospective study in children with 
Marfan syndrome, and of the 196 patients, 18 (9%) had surgery in childhood. The youngest 
age at the time of the first cardiovascular surgery was 8 years. This is in contrast to the age 
of 1 in cases of neonatal Marfan syndrome and Loeys-Dietz syndrome (Everitt et al., 2009).
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Conclusions
The clinical diagnostic criteria for Marfan syndrome include abnormalities of the face, the 
skeleton, the cardiovascular system, the eyes, lungs, skin and the dura. In addition, DNA 
abnormalities (pathogenic mutations) and family history are also important. 
Aortic root dilatation, lens (sub)luxation, a first-degree relative with Marfan syndrome and a 
pathogenic mutation are the main criteria on which the diagnosis is based.
D Loeys et al., 2010
Level 4
Considerations 
In this guideline the diagnostics of Marfan syndrome are based on the Ghent II criteria. In 
addition, the following considerations are taken into account:
1. General
In order to avoid unnecessary diagnostics in cases of individuals with non-specific 
features of Marfan syndrome, an initial examination by a clinical geneticist affiliated 
to a Marfan clinic should be considered. The geneticist can assess whether additional 
diagnosis is necessary. Specific characteristics, such as aortic root dilatation/dissection 
without an obvious cause or a lens (sub)luxation, warrant extensive investigation.
2. Physical examination
The physical examination is preferably carried out by a specialist with experience in 
Marfan syndrome. Most of the external characteristics of Marfan syndrome are non-
specific and can only be subjectively determined. Appendix 2 describes the physical 
characteristics of Marfan syndrome.
The Ghent II criteria assume a specific upper/lower segment ratio when determining 
relative leg length, but this is challenging to measure. The preference of the working 
group is for the measurement of the sitting height/length ratio, as robust normal 
values are available (Talma, 2010).
The working group notes that striae are common in the middle of the back, the hips 
and lumbar region in the general population, and therefore expresses reservations 
regarding the inclusion of this criterion in the Ghent II criteria. The working group 
therefore recommends the inclusion of striae as a systematic criterion only when 




















present in places other than the abovementioned locations and when not associated 
with weight change. Marfan syndrome is characterised by striae particularly on the 
shoulders, upper arms and around the axilla. 
3. Ophthalmological examination
Only two ophthalmological features score points on the diagnosis under the Ghent II 
criteria, lens (sub)luxation and myopia of more than three diopters.
Assessing lens position should occur at maximum mydriasis, using slit lamp examination. 
This is the only way in which lens (sub)luxation can be determined with certainty, as the 
condition can manifest itself in a very subtle manner. In some cases, only an irregular 
lens edge (notching) due to a single stretched zonula fibre is noted.
A refraction test should take place in all patients. The strength of existing spectacles 
or contact lenses is often the starting point in such cases. In young children, where 
subjective visual acuity and refraction measurement is not possible, the objective 
refraction should be determined using cycloplegic retinoscopy.
In order to calculate the degree of myopia, the value determined for the spherical 
equivalent of the cylinder is added to the value of the spherical refraction.
4. DNA research
The pathogenic effect of mutations, and thus the causal relation to Marfan syndrome, 
is insufficiently treated in the Ghent II criteria.
If the presence of an FBN1 mutation is important for the diagnosis, this can only be 
taken into account if, in the opinion of an appropriately qualified clinical molecular 
geneticist, the mutation is pathogenic. When in doubt as to the pathogenicity of the 
mutation, it should not be included in the diagnostic criteria. When a mutation is not 
clearly pathogenic, additional research can be considered such as analysis of mRNA or 
protein from cultured fibroblasts, or DNA analysis of the mutation in the family.
If no clearly pathogenic mutation in FBN1 is found, this should give rise to serious doubts 
regarding the diagnosis of Marfan syndrome and invoke a differential diagnostic 
consideration of whether there are grounds to investigate other genes.
5. X-ray diagnosis
X-ray diagnosis for acetabular protrusion and scoliosis is rarely necessary in the context 
of diagnosis, but can be indicated in the case of complaints or as an adjunct to therapy.
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6. Diagnosis in children
The exclusion of a diagnosis of Marfan syndrome in children on clinical grounds alone 
is either not possible or difficult, especially in young children, as symptoms may arise 
later in life.
a.  Child with a parent with both Marfan syndrome and a mutation in FBN1. 
DNA testing can determine whether the children of a parent carrying a pathogenic 
mutation in the FBN1 gene will themselves develop Marfan syndrome. DNA testing 
can be offered in the first year of life so that, following confirmation of a mutation, an 
initial paediatric cardiological examination can be carried out to exclude rare aortic 
or valve problems that already require care in the first year of life. If possible, the 
first physical and ophthalmic examinations can also be conducted by a Marfan clinic. 
An initial ophthalmological examination in the first year of life is indicated for the 
early detection of cases at risk for serious lens luxation with a danger of amblyopia. 
The child will be monitored more or less frequently, depending on the findings.
b.  Child with a parent with Marfan syndrome, but without a known FBN1 mutation. 
In children with a 50% chance of developing Marfan syndrome but with an affected 
parent in whom no FBN1 gene mutation was found, it is recommended that the 
initial study take place in the first year of life (physical, paediatric cardiological and 
ophthalmological examinations). If no indications are found, it is recommended 
that the child be re-examined at around the ages of 5, 12, and 17 years (Canadas et al, 
2010). If there is still no evidence of Marfan syndrome, then after multidisciplinary 
consultation, the child can be discharged from follow-up and depending on the 
presentation in the family, a cardiologist at a peripheral centre can monitor the 
individual every five years. If evidence of Marfan syndrome is noted by the first 
birthday, more frequent monitoring can be agreed, depending on the findings.
c. Child with a negative family history.  
In non-familial cases of children suspect for Marfan syndrome, without a DNA 
abnormality and with adequate clinical suspicion, it is recommended that the clinical 
examination be repeated at the ages of 5, 12 and 17 years. Given the high sensitivity 
of DNA analysis in the diagnosis of Marfan syndrome, only a very small number 
of children will fall into this group. If an FBN1 mutation is found, the child will be 
treated as a confirmed Marfan syndrome case even if the clinical criteria are not yet 
met. This situation is referred to as ‘potential Marfan syndrome’ in Ghent II, a rather 
confusing term.





















I.  Refer all patients with the following features for assesment by a specialist in Marfan syndrome, 
preferably in association with a Marfan clinic:
 -  Aortic root dilatation or dissection of the thoracic aorta without obvious cause, or
 -  (Sub)luxation of the lens, or
 -   First-degree relative with Marfan syndrome.
II.  Refer patients with less specific features of Marfan syndrome to an experienced specialist in 
Marfan syndrome, assessing the appropriate diagnostic route based on the features.
III.  Criteria used to diagnose Marfan syndrome:
 The Ghent II criteria are applied but with the following reservations: 
 -   Striae in the middle of the back, the hips and lumbar region are not counted as 
systematic criteria. Striae on the shoulders, upper arms and around the axilla are counted if not 
associated with weight change. 
 -  In the adult population, absolute values are used for diagnosis of aortic root dilatation. See 
section 4.
IV. Standard diagnostic examination in cases of suspected Marfan syndrome:
   The following tests are advised in cases with an adequate suspicion of  
syndrome: 
 -  Complete physical examination and family history;
 -  Cardiological examination including ultrasound of the heart and thoracic aorta;
 -  Eye examinations, including slit lamp examination in full mydriasis and measurement  
of the refractive error;
 - DNA-analysis.
V. Diagnosis in children
 -   Perform DNA-analysis in the first year of life, in a child with a 50% chance of Marfan  
syndrome and a known FBN1 mutation in the father or mother, to exclude or confirm the 
diagnosis Marfan syndrome. 
 -  If the diagnosis cannot be established or excluded with certainty in a child with a 
50% chance of Marfan syndrome, re-examine the child around the ages of 5, 12, and 17 years.
 -  A neonate with pronounced physical characteristics of Marfan syndrome should be examined 
by a paediatric cardiologist, for suspected neonatal Marfan syndrome, at the first suitable 
moment.
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Section 4  Diagnostic Imaging of Aortic Root Dilatation 
Introduction
The presence and extent of aortic root dilatation plays a central role in the diagnosis, 
monitoring and treatment of patients with Marfan syndrome. Various non-invasive 
techniques can be used for imaging of the aorta, with echocardiography as the standard 
approach, and MRI and CT providing additional information where necessary. Since 
absolute cut-off values are used in adults, both for the diagnosis of aortic root dilatation 
and as an indicator for preventive aortic root replacement, standardised methods of 
measurement and uniform normal values of great importance.
Summary of the literature
Echocardiography
International guidelines for the performance of echocardiography are available for both 
adults and children (Lang et al., 2005; Lopez et al., 2010).
The proximal portion of the ascending aorta is imaged in a parasternal long-axis view. 
Diameters are measured at the level of the aortic annulus, aortic root (largest diameter at 
the level of the sinus of Valsalva), sinotubular (ST)-junction and the ascending aorta half a 
centimetre above the ST-junction. Confusion arises because, according to the guidelines of 
the American Society of Echocardiography (Lang et al., 2005), these measurements should 
be taken at end diastole in adults, while the paediatric guideline (Lopez et al., 2010) of the 
same American Society advises the measurement of the dimensions during mid-systole.
Discussion is still ongoing as to whether the front wall of the aorta should or should not 
be included. This will be concurrently measured during the leading edge to leading edge 
measurement, but not by the inner edge to inner edge measurement technique. Commonly 
used normal curves, such as those of Roman (Roman et al., 1989), are based on leading 
edge to leading edge measurements and this seems to be the main reason why this 
measurement is recommended in the existing echocardiography guidelines for adults 
(Lang et al., 2005). 
In contrast, the paediatric guidelines recommend the inner edge to inner edge measurement 
technique (Lopez et al., 2010).
The international guidelines (Lang et al., 2005, Lopez et al., 2010) favour two-dimensional 
aortic measurements rather than M-mode measurements because the aortic root moves 




















relative to the cursor line during the cardiac cycle, resulting in a systematic underestimation 
(of 2 mm) of the maximum diameter of the aortic root at the level of the sinus of Valsalva 
(Roman et al., 1989). It is worth noting that this observation was not confirmed in a study 
by Rozendaal et al. (1998).
The normal aortic root dimensions in adults differ between males and females, and are 
also influenced by posture and age. Nevertheless, absolute cut-off values are generally 
used for the diagnosis of aortic root dilatation or as indications for aortic root replacement. 
Biaggi et al. (2009) analysed ultrasound data (leading edge to leading edge in end systole) 
for 1,799 patients without cardiac disease and found that a size of ≥46 mm in men and ≥43 
mm in women was abnormal. According to the curves developed by Biaggi, the maximum 
P95 diameter is 42 mm for men (age 70 years, BSA 2.1) and 38 mm for women (age 70 years, 
BSA 1.9).
Depending on age and BSA, smaller diameters can already be considered abnormal. Pelliccia 
et al. (2010) examined 2,317 athletes and found that a diameter of >40 mm in men and >34 
mm in women fell outside the normal range (leading edge to leading edge in end diastole). 
Radonic et al. (2011) studied 38 healthy subjects with a large BSA and found a maximal 
aortic root diameter of 38 mm (echo, leading edge to leading edge in end diastole). Based 
on these findings and the literature, these authors suggested that an aortic root of >40 
mm is always dilated. According to Radonic et al. the use of Z-scores, as recommended in 
the Ghent II criteria, may therefore lead to the diagnosis of Marfan syndrome being missed 
in patients with a large BSA.
A 1993 study of 182 tall men and women showed that the aortic root diameter does not 
increase linearly with a length of >P95, and that the aortic root diameter no longer increases 
with a larger BSA. The P95 does not exceed 39 mm (Reed et al., 1993). Kinoshita et al. 
(2000) investigated the prevalence of aortic dilatation amongst 1,929 athletes (particularly 
basketball players) and also found that the relationship between aortic root diameter 
in relation to the BSA does not increase linearly. The measured P95 was smaller than 39 
mm. They considered an aortic root of >40 mm to be pathological and this was confirmed 
in 7 of the 1,929 athletes, including two for whom a diagnosis of Marfan syndrome was 
established. All other measurements were <40 mm.
In children, the measured dimensions are normally expressed as Z-scores. Standardisation 
by body surface is common, although the aortic root dimensions also seem to show a good 
correlation with height (Sheil et al., 1995). Separate nomograms have also been developed 
for tall children and adolescents, adapted to the specific build of this group (Rozendaal et 
al., 1998).
The nomograms for children recently published by Gautier and by Pettersen are based on 
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measurements in larger groups of children than the original Roman nomograms (353 or 782 
versus 53) (Gautier et al., 2010; Pettersen et al., 2008). The Roman and Gautier nomograms 
were developed from leading edge to leading edge measurements in diastole, in 
accordance with the guidelines for adults from the American Society of Echocardiography. 
The Pettersen nomograms are based on inner edge to inner edge measurements in systole, 
in accordance with paediatric guidelines. Z-scores can easily be calculated using 
www.parameterz.blogspot.com or via www.marfan.org.
Conclusions
Guidelines for adults and children recommend that ultrasound examination of the 
aortic root in patients suspect for Marfan syndrome measure in the parasternal long-
axis view. Diameters are measured at the level of the aortic annulus, aortic root, ST 
junction and at the ascending aorta, one centimeter above the ST junction.
D Lang et al., 2005; Lopez et al., 2010
Level 4
Literature cites various cut-off values for determining aortic root dilatation in adults 
with normal stature, with an aortic root diameter greater than 40 mm usually 
considered as abnormal. Depending on age and BSA, smaller diameters can already 
be considered abnormal.
C Biaggi et al., 2009; Pellicia etl, 2010; Radonic et al., 2011; Kinoshita et al., 2000
Level 3
Most of the normal values for echocardiography in adults quoted in the literature are 
based on leading edge to leading edge measurements in diastole.
D Lang et al., 2005; Roman et al., 1989
Level 4
Ultrasonography in children generally utilises Z scores for the expression of measured 
dimensions. Published nomograms specific for children are based on different 
methods of measurement.
D Lopez et al., 2010; Gautier et al., 2010; Pettersen, 2008  
Level 4





















Aortic root Z-scores have a central role in the Ghent II criteria. In addition to the 
determination of the absolute diameter, it can sometimes also be useful to express the 
measured aortic root diameter as a standardised Z-score using one of the published 
nomograms, under the condition that the method of measurement corresponds to that 
of the nomogram. However, the Z-score is unreliable in patients with a large body surface 
area (>2 m2), such as is often the case in Marfan syndrome (Radonic et al., 2011).
In the opinion of the working group, an aortic root diameter of >40 mm is always dilated, 
although this figure may still fall within the norm on the extrapolated data in the Roman 
nomograms. In individuals with a normal posture, the aortic root is usually smaller than 
38 mm. When in doubt as to a dilatation, the form of the aortic root (pear shape) and the 
relation of the aortic root to the immediate area, left atrium and ascending aorta may help 
to confirm the diagnosis of aortic root dilatation.
The three sinuses of Valsalva can be visualised in the parasternal long -axis view. In cases of 
aortic root dilatation, a typical cloverleaf shape is seen, which is sometimes accompanied 
by an asymmetric dilatation of the sinus of Valsalva. This can mean that the diameter in the 
long-axisview may not be the maximal diameter.
Imaging the aorta with cardiovascular MRI (CMR) and/or CT
The entire aorta can be visualised using magnetic resonance techniques. This is especially 
important for adult Marfan patients because aortic dilatation can also occur beyond 
the aortic root in the distal aorta, especially following aortic root replacement and with 
increasing age. In adult Marfan patients, the entire aorta should therefore be visualised 
with MRI as soon as the diagnosis is made. The frequency of follow-up MRI depends on the 
conditions at baseline. In young children, the entire aorta can usually be clearly visualised 
using ultrasound, in addition to the fact that widening of the distal aorta occurs only rarely 
in young children. MRI is performed in this age group as indicated.
General MRI guidelines indicate that the aortic root should be measured on triggered 
Specific nomograms have been developed for ultrasound measurements of aortic 
root dimensions in tall children and adolescents.
D Rozendaal et al., 1998 
Level 4
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MR images in the short axis, from leading edge to leading edge. Magnetic resonance 
angiography (MRA) is not reliable when measuring the aortic root diameter because only 
the aortic lumen is depicted.
MRI is preferred for routine assessment of (young) adults. The advantage of MRI is that 
any cross-sectional plane can be chosen, allowing the aortic diameter to be measured in 
the longitudinal plane. This can be of importance in aortas with considerable tortuosity. In 
addition, radiation exposure and the administration of contrast agents is avoided.
For the frequency of surveillance, please refer to section 10.
Postoperative assessment
Because the chosen projection surfaces of consecutive MRI tests are not always exactly the 
same, an increase in the diameter of the aorta can sometimes be better assessed with CT 
scans. The CT scan is preferred for postoperative assessment in some clinics for this reason 
(for example, after a type A dissection or for following the growth of the descending 
aorta in the case of a persistent type B dissection). The possible development of pseudo-
aneurysms after surgery can be determined at an early stage using CT. MRI is preferred 
where a patient shows a contrast allergy.
Recommendations 
Perform ultrasound aortic measurements at 4 levels in the 2D parasternal long-axis perpendicular 
to the direction of blood flow, with the aim of visualising the maximum diameter of the aortic root. 
Also evaluate the asymmetry of the root in the short axis. Carefully asses the largest diameter at 
follow-up.
For adults, in the context of standardisation, follow the guidelines of the American Society of 
Echocardiography, with the ultrasonographic measurements in diastolic stop-frame, from leading 
edge to leading edge.
In an adult, an aortic root diameter of more than 40 mm should generally be regarded as dilated. 
In the assessment of aortic root diameter, always take into account the age, sex and BSA of the 
patient, and depending on these factors, smaller diameters may already be considered abnormal. 
The use of a Z-score may be helpful in these cases.
In children, express the values obtained by ultrasound in Z-scores, using published nomograms or 
digital formulas. Document the measurement technique and the matching nomograms used. 
Image the entire aorta in adult Marfan patients with MRI once the diagnosis is established.  
The frequency of follow-up MRIs depends on the conditions at baseline.
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Section 5  Differential Diagnosis
Introduction
The diagnosis of Marfan syndrome is based on internationally agreed criteria. The latest 
criteria were published in July 2010 (Loeys et al., 2010; Dietz et al., 1993).
A diagnosis of Marfan syndrome is based on a combination of cardiovascular, ophthalmic, 
and systemic (including skeletal) characteristics, together with molecular analysis.
These ‘revised Ghent criteria’ (Ghent II criteria) are still under discussion and no consensus 
has yet been reached.
Since no individual symptom is specific for Marfan syndrome, other diagnoses should 
always be considered. This also applies for individuals with Marfan syndrome, in whom 
no pathogenic FBN1 mutation has been found. The Ghent II criteria incorporate the 
criteria for Ectopia Lentis syndrome (ELS), Myopia-Mitral valve prolapse-borderline and 
non-progressive Aortic root dilatation-Skeletal Findings-Striae (MASS) and Mitral Valve 
Prolapse Syndrome (MVPs) (see Table 5.1 ). In addition, in cases of ectopia lentis with aortic 
root dilatation or aortic root dilatation with a high systemic score, indications for other 
syndromes must be absent in order to establish a diagnosis of Marfan syndrome.
This distinction is also clinically important because the different diagnoses all have 
differing inheritance, prognosis and needs for guidance. Knowledge of differential 
diagnostic considerations is therefore essential.
Summary of the literature
Describing the medical conditions that must be considered in a differential diagnosis 
required an alternative literature search, because the scientific justification of this aspect 
is less relevant. 
Table 5.1 has been prepared on the basis of two core articles, Loeys et al. (2010) and Dietz et 
al. (1993), and the first column includes the characteristics of Marfan syndrome. In addition, 
the specific characteristics of the other syndromes are described (and core articles were 
sought on these syndromes). Genereviews.org was frequently consulted (also available via 
Pubmed).
The table attempts to provide a summary of the alternative diagnoses for the main 
features of Marfan syndrome, ectopia lentis and aortic root dilatation. Since most referrals 




















to a Marfan clinic – including the question of presence or absence of Marfan syndrome 
- are based on the existence of an aortic root dilatation or dissection, ectopia lentis and 
distinctive habitus (usually tall stature), marfanoïde habitus is also included as an entry 
in the table, with its specific differential diagnosis. The characteristics appropriate to 
Marfan syndrome are in regular letters. Characteristics in in italics are appropriate to (one 
of the) differential diagnoses. The presence of a characteristic in italics indicates that the 
diagnosis of Marfan syndrome needs to be reconsidered.
The characteristics of each syndrome are classified as possibly overlapping with Marfan 
syndrome, or specific for the syndrome.
Ectopia Lentis syndrome (ELS) (Ades et al., 2004; Aragon-Martin et al., 2010)
Autosomal dominant and recessive inheritance (dominant: sometimes FBN1, which is not 
associated with aortic root dilatation / recessive: LTBP2 and ADAMTSL4 mutations).
Overlapping features: lens luxation, skeletal features.
Specific characteristics: none, the lens luxation is usually bilateral and congenital, without 
ectopia pupillae. N.B. Whether there is a long term risk of aortic root dilatation in the event 
of a FBN1 mutation is unclear.
Myopia-Mitral valve prolapse-borderline and non-progressive Aortic root dilatation-
Skeletal findings-Striae (MASS) (Loeys et al., 2010) 
Autosomal dominant inheritance.
Overlapping features: Myopia, Mitral valve prolapse, borderline and non-progressive Aortic 
root dilatation, Skin and Skeletal features.
Specific characteristics: none.
Mitralis valve prolapse syndrome (MVPS) (Loeys et al.,  2010) 
Autosomal dominant inheritance.
Overlapping features: mitral valve prolapse, (subtle) skeletal features.
Specific characteristics: none.
Shprintzen Goldberg syndrome (SGS) (Greally, 2010) 
Inheritance uncertain (a few FBN1 or TGFBR2 mutations described).
Overlapping features: phenotype: dolichostenomelia, arachnodactyly, pectus, scoliosis, 
aortic root dilatation (rarely), high palate.
Specific characteristics: Craniosynostosis, mental retardation, Chiari malformation, 
hypertelorism, proptosis, rib anomalies, clubfoot.
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(tall stature, long legs)
Mitral valve prolapse







































Table 5.1. Differential diagnostic consi erations - Marfan syndrome
^ Also consider MEN2B, Cohen, and certain genes involved in X-linked mental retardation (SMS, ZDHHC9)
* facial features: d=dolichocephaly, e=enophthalmos, pf=downslant palpebral fissures, m=malar hypoplasia, r=retrognathia
# Skeletal  features:  wt=wrist/thumb sign, pe=pectus, pl=pes planus, sc=scoliosis/kyphosis, ar=arachnodactyly 
& McDonnell et al. (2006) described a mildly dilated aortic root in the classic and hypermobility type EDS patients; however, the 
cohort was small, aortic diameters were not normalised to BSA, and Marfan syndrome cannot be excluded in patients with aortic 
root dilatation. Furthermore, this publication seems to be the only one in which an aortic root dilatation is described.
Dark grey: frequent/pronounced.
Light grey: less frequent/less pronounced.
ELS : Ectopia Lentis Syndrome
MASS :  Myopia, Mitral valve prolapse, borderline  
Aortic root dilatation, Striae, Skeletal features
MVPS : Mitral Valve Prolapse syndrome
SGS : Sprintzen-Goldberg syndrome
AOS : Aneurysms-Osteoarthritis syndrome
LDS : Loeys-Dietz syndrome
CCA : Congenital Contractural Arachnodactyly
FTAAD : Familial Thoracic Aorta Aneurysms 
                         and Dissections 
WMS : Weill-Marchesani syndrome
EDS-CT : Ehlers-Danlos Syndrome, classic type
EDS-HT : Ehlers-Danlos Syndrome, hypermobile type
EDS-VT : Ehlers-Danlos Syndrome, vascular type
EDS-KST : Ehlers-Danlos Syndrome, kyphoscoliosis type
FraX : Fragile-X syndrome
HHC : Hyperhomocysteinuria
AT : Arterial Tortuositas




















Loeys-Dietz syndrome (LDS) (Loeys & Dietz, 2008) 
Type 1
Autosomal dominant inheritance (mutations in TGFBR1, TGFBR2).
Overlapping features: long face, downward slanting palpebral fissures, high palate, malar 
hypoplasia, micrognatie, retrognathism, pectus, scoliosis, arachnodactyly, hypermobility, 
dural ectasia, aortic root dilatation or dissection.
Specific characteristics: hypertelorism, broad or bifid uvula, cleft palate, learning disabilities, 
hydrocephalus, chiari malformation, blue sclerae, exotropia, craniosynostosis, cervical 
spine instability, club foot, soft pasty skin, translucent skin, easy bruising, generalised 
arterial tortuosity and aneurysms and/or dissection.
Type 2 (formerly: Marfan syndrome type 2)
Autosomal dominant inheritance (mutations TGFBR1, TGFBR2).
Absent LDS type 1 characteristics: arterial tortuosity and almost all other characteristics 
except aneurysms and/or dissection of aorta and other arteries.
Features overlapping with Marfan syndrome: sometimes marfanoid habitus and 
arachnodactyly.
Absent Marfa features: ectopia lentis.
Aneurysms-Osteoarhritis syndrome (van de Laar et al. 2011)
Autosomal dominant inheritance (mutations SMAD3)
Features overlapping with Marfan syndrome: aortic dilatation or dissection, mitral valve 
prolapse, hypermobility, marfanoid habitus, pectus deformities, scoliosis
Specific characteristics: hypertelorism, cleft palate/uvula, explicit osteoarthritis
Congenital Contractures and Arachnodactyly (Godfrey, 2012)
Autosomal dominant inheritance (heterozygous mutations in FBN2).
Overlapping features: long, thin fingers and toes, kyphosis, scoliosis, aortic root dilatation 
(occasionally).
Specific characteristics: ear abnormalities (“crumpled ears”, “folded upper helix”), 
contractures of knees and ankles, flexion contracture at the proximal interphalangeal 
joints of fingers and toes, hip contractures, adducted thumbs, clubfeet, muscle hypoplasia.
(Familial) thoracic aortic aneurysms and dissections ([F] TAAD) (Milewicz & Regalado 2012)
Autosomal dominant inheritance (mutations in MYH11, ACTA2, TGFBR1/2, Smad3, MyLK 
and as yet undiscovered genes). (F)TAAD associated with mutations in TBFBR1/2 without 
features of LDS is sometimes called LDS type 2 or Marfan syndrome type 2.
Overlapping features: aortic dilatation (but usually of the ascending aorta and not of the 
aortic root).
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Specific characteristics: none.
Weill-Marchesani syndrooem (WMS) (Tsilou & MacDonald, 2007)
Autosomal dominant and recessive inheritance (ADAMTS10 mutations).
Overlapping features: lens luxation, myopia, contractures.
Specific characteristics: small stature, microspherophakia, brachydactyly.
Ehlers-Danlos syndrome (EDS) classical type, type 1 (Malfait et al.,  2011) 
Autosomal dominant inheritance (mutations in COL5A1, COL5A2).
Overlapping features: hypermobility (more pronounced in EDS).
Specific characteristics: hyperelastic skin, abnormal wound healing, soft pasty skin.
EDS hypermobile type, type III (Levy, 2010)
Autosomal dominant inheritance.
Overlapping features: hypermobility.
Specific characteristics: None; there is overlap with familial and physiological hypermobility.
EDS vascular type, type IV (Pepin & Byers 2011)
Autosomal dominant inheritance (COL3A1 mutations).
Overlapping features: hypermobility (limited to distal finger joints), Ao aneurysm/dissection.
Specific characteristics: thin skin (dark under the eyes), easy bruising, wide dystrophic scars; 
Facial: prominent eyes, sharp facial features, organ ruptures, artery dilatation/dissection, 
especially abdominal aorta (generalised).
Absent Marfan characteristics: Marfanoid habitus.
EDS kyphoscoliotic type, Type VI (Yeowell et al., 2008)
Autosomal recessive inheritance (mutations in PLOD1, CHST14).
Overlapping features: kyphoscoliosis, hypermobility, hypotonia, sometimes eye problems 
(sclerae weakness with globe rupture, myopia), MVP.
Specific characteristics: rupture of medium-sized arteries.
Homocysteinuria (HHC) (Picker & Levy, 2011)
Autosomal recessive inheritance (mutations in CBS).
Overlapping features: myopia, ectopia lentis, skeletal abnormalities, physique, pectus 
excavatum/carinatum, scoliosis, mitral valve prolapse, high palate, inguinal hernia.
Specific characteristics: mental retardation, intravascular thrombosis, thromboembolism.




















Stickler syndrome (Robin et al., 2011) 
Autosomal recessive inheritance (mutations in COL2A1, COL11A1, COL11A2).
Overlapping features: myopia, retinal detachment, mid-face hypoplasia.
Specific characteristics: hearing loss, cleft palate, spondyloepiphyseal dysplasia, premature 
arthritis, congenital abnormality of vitreous humor.
Fragile X syndrome (Saul & Tarleton, 2012) 
Sex-linked inheritance (FMR1 mutations).
Overlapping features: long face, hypermobility.
Specific characteristics: mild/moderate mental retardation, large head, prominent forehead 
and chin, large ears, large testes, behavioural problems.
Lujan-Fryns syndrome (van Buggenhout & Fryns, 2006) 
Sex-linked inheritance, especially reflected in men.
Overlapping features: long narrow face, maxillary hypoplasia, small mandible,
tall stature, marfanoid habitus.
Specific characteristics: prominent forehead, mental retardation, behavioural problems.
Arterial Tortuosity (Canadas et al., 2010; Callewaert et al., 2008)
Autosomal dominant inheritance (mutations GLUT10).
Overlapping features: long face, dilated arteries and aorta, hypermobility.
Specific characteristics: tortuosity of aorta and large arteries.
Cutis Laxa (Loeys B, 2011 ; Callewaert et al., 2012)
Autosomal recessive inheritance (mutations FBNL4/EFEMP2), autosomal dominant 
inheritance (mutaties ELN)
Overlapping features: aorta aneurysms, hypermoblity, retrognatia, arachnodactyly, pectus 
deformity, malar hypoplasia, high arched palate.
Specific characteristics: skin phenotype, arterial tortuosity, lung emphysema.
Recommendation
Consider other diagnoses, if a feature not matching Marfan syndrome is present (as in Table 5.1)
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Section 6  Treatment of Skeletal Abnormalities 
Introduction
Abnormalities of the musculoskeletal system are often present in patients with 
Marfan syndrome. The most common problems are:
- Scoliosis;
- Spondylolisthesis; 
- Pectus excavatum/pectus carinatum; 
- Instability (multidirectional) of the shoulder; 
- Instability carpometacarpal (CMC) joint 1; 
- Protrusio Acetabuli; 
- Patellar instability; 
- Pes planovalgus; 
- Hammer-/claw toes.
The question is whether the treatment of skeletal abnormalities in Marfan patients is 
different from that in patients without Marfan syndrome.
Summary of the literature 
Scoliosis
Scoliosis is a common orthopaedic problem in patients with Marfan syndrome. A scoliosis 
is present in approximately 62% of patients, where a curve greater than 40° suggests a 
high probability of progression following skeletal maturation (Sponseller et al., 1995). The 
curves are noticeably more rigid in comparison with idiopathic scoliosis, which may mean 
that the probability of success of brace treatment is lower.
A brace is the only non-invasive method available to counter the progression of scoliosis. 
Because the use of a brace has a significant impact on the life of a patient, it is important 
to be able to reach a judgement on the effect of the treatment.
In idiopathic scoliosis, brace treatment is known to be more favourable than the natural 
course in patients with a curve of between 20 and 45 degrees whose skeleton is still 
immature (Risserstadium less than or equal to 2). In 60-80% of cases the curve increases by 
less than 5 degrees during the treatment, which often allows an operation to be avoided 
(Emans et al., 1986; Nachemson & Peterson, 1995; Rowe et al., 1997).




















Only 2 retrospective studies describe the treatment of scoliosis in Marfan patients. 
Sponseller et al. (2000) have show that the effect of a Boston brace is limited. Of the 24 
patients (demonstrated Marfan syndrome, curve of 20-45°, Risser 0-2 at the beginning 
of brace treatment), 22 could persist with the brace program, the remaining two being 
unable to tolerate wearing the brace. The patients were followed for at least two years 
(until skeletal maturation or surgery), and during follow-up 4 of the 24 patients (17%) were 
found to have a curve increase of less than 5 degrees and a curve of less than 45 degrees. 
Fifteen patients underwent a surgical intervention and the remaining 5 were indicated for 
surgery but an operation had not yet been carried out.
Birch & Herring (1987) treated eight Marfan patients (diagnosis based on clinical signs, 
no DNA test) with a Boston or Milwaukee brace and saw a stabilisation of the curve in 
1 patient. She was already three months postmenarcheal, however. Six were surgically 
treated following curve progression, and one patient refused surgery (Birch & Herring, 
1987).
Spondylolisthesis
There is evidence that the incidence of spondylolisthesis occurrence and the severity of 
the slip are slightly higher than in patients without Marfan syndrome (Sponseller et al., 
1995). There is no evidence that treatment differs from that of patients without Marfan 
syndrome.
Pectus excavatum
There is no evidence in the literature that there are grounds to treat Marfan patients with 
pectus excavatum differently from non-Marfan patients, nor regarding the indication for 
surgery, nor regarding the timing of any surgical correction.
Other abnormalities
No literature was found to indicate that treatment should depart from the standard 
treatment applicable to the abnormalities mentioned in the introduction in patients 
without Marfan syndrome.
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Studies on the effects of wearing a brace do not clarify the issue of whether, without the 
brace, the scoliosis would have progressed to the extent to make surgery unavoidable. 
In other words, whether the brace affects the natural course of the disease. Adequate 
consideration of the advantages and disadvantages of both wearing a brace and of surgery 
should therefore always include the patient and possibly also the parents.
In cases of pectus excavatum, an indication for surgery is based on the psychological 
problems of a patient with this deformity. These problems usually start around adolescence, 
and do not differ between Marfan patients and non-Marfan patients.
There is no evidence in the literature for grounds to treat Marfan patients with pectus 
excavatum differently to non-Marfan patients, neither regarding the indication for surgery, 
nor regarding the timing of a possible surgical correction (Scherer et al., 1988; Jaroszewski 
et al., 2011).
Although improvements in cardiac and pulmonary function are mentioned in the literature, 
this phenomenon long remained difficult to objectify (Morshuis et al., 1994). This effect 
There are indications that, in Marfan patients with a still immature skeleton (Risser 2 
or less) and scoliosis curves of between 20 and 45 degrees, wearing a brace can avoid 
the need for surgery in a small proportion of patients.
C Sponseller et al., 2000; Birch & Herring, 1987
Level 3
There is insufficient available literature to justify treating other skeletal 
abnormalities in Marfan syndrome differently to those in patients without Marfan 
syndrome.
D Opinion of the working group
Level 4
There are indications that the percentage of patients in whom a brace can prevent 
surgery is lower in Marfan than in non-Marfan patients. 
C Sponseller et al. 2000; Birch & Herring, 1987
Level 3




















was attributed to an improved confidence and thus greater participation in gymnastics, 
sports, etc. post-correction. More recently, there are some indications for a measurable 
improvement in exercise capacity following surgical correction of severe pectus excavatum 
(Malek et al., 2006). There also seems to be no difference between patients with Marfan 
syndrome and patients with other diseases on this specific issue.
There are also no differences between Marfan syndrome and non-Marfan patients with 
regard to the use of surgical techniques.
Publications on combined correction of the chest wall deformity and cardiac surgery (e.g. 
aortic root replacement) are limited to case reports.
 
It is important to realise that cardiac surgery is no longer possible following  insertion of a 
Nuss bar. Prior to insertion of a Nuss bar, evaluation by a (child) cardiologist is recommended 
to evaluate the risk of cardiac surgery during the period the Nuss bar is in situ.
The working group is of the opinion that the musculoskeletal abnormalities found in 
Marfan patients should be treated in the same manner as in patients without Marfan 
syndrome. The treatment must be performed by a surgeon with specific experience in the 
area in question.
Recommendations
In general, treat abnormalities of the musculoskeletal system in patients with Marfan syndrome in 
the same manner as for patients without Marfan syndrome. 
In Marfan patients with scoliosis of between 20 and 45 degrees and a still immature skeleton, 
the (low) expected success rate of a brace should be weighed against the discomfort and the 
advantages and disadvantages of an operation.
Consult a (child) cardiologist before insertion of a Nuss bar.
Problems with the musculoskeletal system in patients with Marfan syndrome should be treated by 
a specialist with experience in the field of the specific musculoskeletal problem. It is not necessary 
that this occur within a Marfan team. 
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Section 7  Drug Treatment 
Introduction
Current drug treatment in Marfan syndrome is focused on slowing aortic root dilatation 
through a reduction in the haemodynamic stress in the aorta, mainly by means of beta-
blockers. However, there is increasing evidence that the renin-angiotensin system (RAAS) 
plays a role in the development of aneurysms. Blockade of the RAAS system not only 
lowers blood pressure, but also intervenes in the molecular mechanisms underlying the 
development of aneurysms, such as the TGFb cascade and the so-called extracellular-
signal-regulated kinases (ERKs).
Summary of the literature
The first open-label, randomised study of the effect of drug treatment in Marfan patients 
was published in 1994 (Shores et al., 1994), in which 70 Marfan patients aged between 12 
and 50 years were treated with the beta blocker, propranolol. After 4 years of follow-up, 
the treatment group had a 73% lower rate of aortic root dilatation and a lower mortality. 
Mechanical effects of beta-blockade were considered to be the cause of the beneficial 
effect of beta blockers. Lowering of blood pressure and a decreased contractility of the 
left ventricle lead to a reduction in haemodynamic stress in the aorta. Although the utility 
of beta blockers was never conclusively proven in a prospective double-blind, randomised 
study, the use of beta-blockade is currently the standard treatment in patients with Marfan 
syndrome and is recommended in all guidelines (Baumgartner et al., 2010; Hiratzka, 2010; 
Silversides et al., 2010; Regitz-Zagrosek et al., 2011). 
The cystic medial degeneration in the aortic wall seen in aneurysms is accompanied by 
apoptosis and loss of smooth muscle cells, degeneration of elastic fibres and build-up of 
proteoglycan, a major constituent of the extracellular matrix. Angiotensin II contributes 
to this process via angiotensin II type 1 or 2 (AT1- en/of AT2-) receptors. In recent years, a 
number of studies have been published on the effect of various antihypertensive drugs, 
and two small studies have compared the effect of ACE inhibitors and beta-blockers. ACE 
inhibitors were more effective in reducing arterial stiffness, improving aortic distensibility 
and delaying the growth of the aorta, compared to beta blockers (Ahimastos, 2007; 
Yetman, 2005).
In 2006, the AT1 receptor blocker Losartan was shown to have a beneficial effect on the 
structure of the aortic wall and on aortic growth in mice with a FBN1 mutation (Habashi 
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There are indications for an inhibitory effect of beta blockers on the growth of the 
aortic diameter in Marfan patients over the age of 12. 
B  Shores et al., 1994
D Baumgartner et al., 2010; Hiratzka, 2010; Silversides et al., 2010; Regitz-Zagrosek et 
al., 2011
Level 3
Results regarding the effect of beta-blockers on aortic growth in children are 
contradictory. 
B  Selamet Tierney, 2007; Ladouceur et al., 2007
Level 2
There are indications that Losartan slows aortic root growth in children with Marfan 
syndrome. 
C  Brooke et al., 2008 
Level 3
& Loeys, 2006). In a small retrospective cohort study in 18 children with a severe form of 
Marfan syndrome and rapid aortic growth, an AT1 blocker was added to existing medication 
and the growth of the aorta was followed for 12-47 months. A significant slowing of aortic 
growth was seen following treatment with Losartan, after adjusting for age and BSA 
(Brooke et al., 2008).
The prophylactic use of beta blockers in children with Marfan syndrome is still a subject of 
discussion. Most published studies persist in enrolling only a small number of children, thus 
preventing a conclusive appraisal of the effect of beta-blockers in children with Marfan 
syndrome. In a retrospective study by Selamet Tierney (2007) of 63 children with Marfan 
syndrome, up to 18 years old, the beneficial effect of beta-blockers on the speed of aortic 
root dilatation could not be demonstrated after 6 years of follow-up (Selamet Tierney, 
2007). The retrospective design, with a possible selection bias, and the small numbers 
make it impossible to draw definitive conclusions. In contrast, a similar retrospective study 
by Ladouceur et al. (2007) of 115 children younger than 12 years, including 77 treated with 
beta blockade, could show a decrease in the rate of aortic root dilatation of 0.16 mm/
year in the treated group compared to the non-treated group (Ladouceur et al., 2007). The 
authors concluded that it is advisable to start beta blockade at the moment of diagnosis, 
but because the treated group had greater aortic root dilatation than the non-treated 
group, a selection bias seems plausible.
Conclusions




















Prophylactic use of beta blockers should be continued in adult patients with Marfan syndrome, for 
the time being. 
Do not routinely prescribe beta blockers to children with Marfan syndrome, but carefully weigh the 
advantages and disadvantages on an individual basis. It is customary to prescribe beta-blockers in 
children with evident aortic root dilatation. 
Be conservative in the prescription of Losartan to children at present.
Considerations
Although the study by Brooke suggests that Losartan may have a beneficial effect on 
aorta growth, this beneficial effect should be confirmed through prospective randomised 
trials before definitive conclusions are drawn. Several trials, with a number of variations 
in the design, are currently underway worldwide. Until evidence regarding the effects of 
Losartan on the course of Marfan syndrome becomes available, a conservative approach 
to the administation of Losartan is appropriate.
Other potentially beneficial drugs, such as doxycycline (Chung, 2008) and pravastatin, are 
currently being investigated in mouse models.
Beta-blockers may have side-effects such as bronchospasm, fatigue, depression, insomnia 
and behavioural problems. These side-effects are especially unacceptable in children 
considering that the efficacy of these drugs on the inhibition of aortic growth is not 
conclusively proven.
Because a recommendation regarding the prophylactic use of beta-blockers in children 
with Marfan syndrome is lacking in current international guidelines, it seems sensible 
to carefully weigh the advantages and disadvantages of the use of beta-blockers for 
individual patients, and not to routinely prescribe these drugs. It is common practice in 
the Netherlands to prescribe beta blockers for children with evident aortic root dilatation.
The use of Losartan in children with Marfan syndrome is uncommon in the Netherlands. 
Furthermore, Losartan is not registered in the Netherlands as a hypotensive agent in 
children <6 years. Because the effect of Losartan on the course of Marfan syndrome is 
unproven, caution should be exercised when considering prescribing Losartan to children.
Recommendations
Section 7  Drug Treatment 
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Section 8  Timing of Aortic Surgery in Adults 
Introduction
An aortic dissection or symptomatic aortic aneurysm is a potentially life-threatening 
condition. The risk of rupture is strongly dependent on the diameter, and an aneurysm with 
a diameter of >60 mm has a 25 times higher chance of rupture than when the diameter 
of the aneurysm is between 40 and 49 mm (Davies et al., 2002). A decision to operate is 
always a trade-off between the risk of rupture and the surgical risk. Elective surgery of the 
descending aorta carries a high risk of morbidity and a somewhat lesser risk of mortality 
(10.9%) (Davies et al., 2002), but it is still much lower than under emergency conditions. In 
contrast, elective surgery of the ascending aorta (and arch) has low mortality (2.5%) and 
morbidity, especially in centers with extensive experience in this area (Davies et al., 2002). 
This surgical risk is accepted in the light of a greatly improved life expectancy after surgery.
The diameter of the aorta is measured in various ways (see also text on diagnostic imaging). 
The surgical literature generally describes a CT examination that uses the internal diameter 
(inside wall to inside wall), while the cardiological literature often describes ultrasound, 
with the so-called ‘leading edge to leading edge’ method (front wall to front wall; thus 
including measurement of a single wall thickness). Unless otherwise expressly stated, the 
diameters of the aorta given below refer to the internal diameters.
Summary of the literature
Most articles focus on small groups of patients and do not focus specifically on the Marfan 
population. Randomised studies are generally lacking, and prospective studies are rare and 
usually contain small numbers of patients. The recommendations of the working group are 
largely based on U.S. (Hiratzka 2010) and European (Baumgartner et al., 2010) guidelines, 
which include the most relevant literature.
Asymptomatic aortic root and/or ascending aorta dilatation:
The most recently published American guidelines for the diagnosis and treatment of 
patients with thoracic aortic pathology propose referral of Marfan patients for elective 
surgical replacement of the aortic root and/or ascending aorta when the internal diameter 
is >45 mm (corresponding with an external diameter of ≥50 mm) (Hiratzka et al., 2010; 
Pearson et al., 2008).
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A surgical correction is also considered indicated when the aortic root and/or ascending 
aorta has an internal diameter of <45 mm, in combination with:
- A rapid increase in the diameter (defined as >5 mm per year), and/or;
- A family history of aortic dissections and/or;
- A serious aortic regurgitation;
- Desire for pregnancy.
The European guideline (Baumgartner et al., 2010) also cites an upper limit of 50 mm 
(leading edge to leading edge) as an absolute indication and 45 mm when combined with 
the above mentioned risk factors.
The cited values are approximately 5 mm lower than in the non-Marfan patients.
Asymptomatic dilatation of the aortic arch, descending aorta or thoraco-abdominal aorta: 
In the case of these patients, a diameter of 55 mm or larger is an indication for surgical 
intervention. In the case of rapid growth (>5 mm per year), a family history of dissections 
or a wish to become pregnant, an indication for surgical correction is usually given for a 
diameter of 50 mm or even for 45 mm (Hiratzka et al., 2010). This was supported by a recent 
study, specifically of Marfan patients, which showed a significant increase in the risk of 
rupture or dissection with a diameter 50 mm or more (Jondeau et al., 2012).
Symptomatic aortic dilatation:
As is the case with non-Marfan syndrome patients, a surgical correction with optimal 
medical treatment is always indicated for symptomatic aortic dilatation (Hiratzka et al., 
2010), especially if a slow response to intravenous antihypertensive treatment is seen. 
If dilatation of the aorta is not clearly established, a plausible connection between the 
symptoms and aortic pathology should be confirmed.
Acute dissection type A:
All patients with an acute type A dissection (Stanford classification type A, DeBakey 
classification type I and II) have an absolute indication for emergency surgery (Hiratzka, 
2010), whether or not he or she has Marfan syndrome.
N.B. An intramural haematoma should be treated as an acute dissection (Hiratzka et al., 
2010).
Acute dissection type B:
The literature on the management of patients with acute type B dissection (Stanford 
classification type B; DeBakey classification types I and III) was inconclusive for some years. 
Experience with the placement of an endoprosthesis during the acute phase has remained 




















limited, due to an apparent association with high morbidity and mortality. Partly based on 
these experiences, and in accordance with current opinion, the generally recommended 
policies are:
A conservative policy, together with optimal drug treatment (including intravenous 
antihypertensive treatment), is recommended for uncomplicated dissections (i.e. without 
ischemia of the end organs, without leakage from the false lumen and without uncontrolled 
hypertension or persistent pain). The morbidity and mortality of surgical correction (open 
or endovascular) is high in the acute phase of the dissection, and is therefore only justified 
in the case of complications (Hiratzka et al., 2010).
Chronic dissection:
Indications for a patient with a chronic dissection are as applied for dilatation of the aorta 
(q.v.) (Hiratzka et al., 2010).
Considerations
The increased risk of rupture or dissection at larger aortic diameters and associated risks 
(including death), versus the risks of elective surgery, mean that the above recommendations 
from international guidelines are taken as standard despite the low level of evidence.
Individuals with a smaller body surface area (BSA) usually have a smaller aortic diameter. In 
general, the aortic root diameter in women is 5 mm smaller than in men (in part due to a 
smaller BSA). Recommendations should be applied using common sense. This means that 
the indication for surgery may be somewhat more aggressive in patients with a smaller 
BSA and more conservative in patients with an extremely high BSA.
Some remarks concerning surgical procedures:
In experienced centers, a valve-sparing procedure for the surgical correction of aortic root 
aneurysm or a type A dissection is usually possible, and this procedure should always be 
given preference. Referral to a center with experience in valve-sparing surgery is therefore 
recommended in cases of elective surgery. Due to an ongoing risk of  annular dilatation 
in patients with Marfan syndrome, this procedure should not employ the remodelling 
technique (as Yacoub) but a modified reimplantation technique (as David) (Hiratzka et al., 
2010; Kallenbach et al., 2007) .
The use of an endoprosthesis for aneurysms of the descending aorta is not yet 
recommended in patients with Marfan syndrome (Nordon et al., 2009). This is related to 
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an expectation of further aortic dilatation and the possibility of a type I or type V endoleak, 
an indication for a secondary procedure.
If a patient is scheduled to undergo cardiac surgery for another reason, for example, mitral 
regurgitation, a replacement may be considered even in cases with a less strongly dilated 
ascending aorta. An additional argument is the fact that damage to the aorta (aortic 
cannula, aortic root cannula and aortic clamp) could be a trigger for a dissection in cases 
with poor tissue quality.
Recommendations
Indications for elective surgical replacement of the aortic root and/or ascending aorta in 
asymptomatic Marfan patients occur at diameters of >45 mm on CT (internal diameter) or > 50 mm 
on ultrasound or MRI (leading edge to leading edge). Indications for surgery (some mm’s) are earlier 
in case of: 
- a rapid increase in the diameter (>5 mm per year), and/or; 
- a family history of aortic dissection and/or; 
- a major aortic regurgitation; 
- desire for pregnancy.
Proceed with replacement if a patient has to undergo heart surgery for any other reason, even in 
cases with a lesser dilatation of the aortic root and/or ascending aorta.
Consider a diameter of 55 mm or larger as an indication for surgical intervention in asymptomatic 
Marfan patients with dilatation of the aortic arch, descending or thoracoabdominal aorta. Indicate 
surgical correction at a diameter of 50 mm or even 45 mm in case of rapid growth (> 5 mm per year), 
family history of dissections or a wish to become pregnant.   
 
A surgical correction with optimal medication is indicated for all patients with symptomatic aortic 
dilatation, especially if a slow response to intravenous antihypertensive treatment is seen.
An acute type A dissection is an absolute indication for emergency surgery. Uncomplicated acute 
type B dissections are handled conservatively using optimal drug treatment. Surgical correction 
during the acute phase of a dissection carries a high risk and it is therefore only justified in the case 
of complications.
Apply indications for a patient with a chronic dissection as for dilatation of the aorta. 
For surveillance following cardiac surgery, see section 10.
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Section 9  Timing of Aortic Surgery in Children 
Introduction
While in adults the discussion on the optimal moment for aortic surgery centers around 
the question of at what absolute aortic root diameter is the probability of dissection or 
rupture so high that preventive aortic root replacement is justified, in the case of a growing 
child criteria are sought that can be related to physical proportions (weight, height, body 
surface area).
Aortic dissection is extremely rare under the age of 10 (Gillinov et al., 1997) or 12 (Zanotti 
et al., 2008). This means that preventive aortic root replacement is not indicated in young 
children. Because dissection is rare in children younger than 12 years, regardless of the 
degree of aortic root dilatation, Zanotti et al. (2008) are of the opinion that the use of 
z-scores as an indicator for surgery is unnecessary. This view is also expressed in a recent 
article (Everitt et al., 2009). (This approach contrasts with that for children with Loeys-
Dietz syndrome, in which a z-score of greater than or equal to 3.5 is used as an indication 
for surgery.)
Summary of the literature
The natural course of aortic root dilatation in a growing child with Marfan syndrome has 
been described in several publications. Westaby (1999) describe how the aortic root already 
begins to dilate in early childhood, with a maximum increase in diameter between the 
ages of 6 and 14 years, followed by a decline in the pace of dilatation. In women, dilatation 
averaged 0.38 mm/year, and in males 0.42 mm/year (Meyboom et al., 2005). Karnebeek et 
al. (2001) followed 52 children and adolescents with Marfan syndrome for an average of 7.9 
years. In the study group, 83% developed aortic root dilatation and 25% also showed aortic 
regurgitation. Eight patients underwent aortic root replacement, including two for acute 
dissection. 
The majority of publications (Gillinov et al., 1997; Carrel et al., 2003) are from cardiac 
surgery groups and describe the results of aortic root surgery in relatively small numbers 
of children with Marfan syndrome (21 and 13 patients, respectively), without comparing 
outcomes with those of unoperated patients. The group of 45 Marfan patients described by 
Cattaneo et al. (2004) partly overlaps with the population described by Gillinov (Cattaneo 




















et al., 2004). The most recent study, by Everitt and colleagues, described a group of 204 
children younger than 18 years, of whom 30 underwent aortic root surgery during follow-
up (Everitt et al., 2009).
In the above publications, the indication for aortic root surgery was already determined 
in advance and primarily defined on the basis of experience (expert opinion). Indications 
actually differ little between the different surgical groups, effectively creating a ‘common 
practice’ (Zanotti et al., 2008).
The indication for preventive aortic root surgery in children can therefore be formulated 
as follows:
1)  The presence of a ‘giant aneurysm’, which fulfills the criteria for intervention for 
adults, or;
2) A rapid increase in aortic root diameter (8-10 mm/year) and/or;
3) Rapidly progressive aortic regurgitation.
Based on database data from 410 patients (adults and children with and without Marfan 
syndrome) with aneurysms of the thoracic aorta, Davies (2006) introduced an “aortic-
size index” (measured absolute aneurysm diameter in cm, divided by body surface area 
expressed in m2) and defined three levels of risk for complications (rupture, dissection, 
death). An aortic diameter of less than 2.75 cm/mm2 BSA equalled low risk, a diameter from 
2.75 to 4.25 cm/mm2 BSA represented a moderate risk, and an indexed aortic diameter 
greater than 4.25 cm/mm2 BSA, a high risk of complications. Only 23 patients had proven 
Marfan syndrome and they were significantly younger, but the number of children included 
is not mentioned. This index does not seem to apply to young children with Marfan 
syndrome, in whom aortic root diameters greater than 2.75 cm/mm2 BSA are normal.
Conclusions
Preventive aortic root replacement is indicated in a child with Marfan syndrome if 
a ‘giant aneurysm’ is present that fulfills the criteria for intervention in adults or in 
the event of a rapid increase in the aortic root diameter (8-10 mm/jaar) or rapidly 
progressive aortic regurgitation.
D Gillinov et , 1997; Carrel et al., 2003; Zanotti et al., 2008; Everitt et al., 2009
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Considerations
There is only level 4 evidence for establishing the indication for aortic root replacement in 
a child with Marfan syndrome. This assessment is uniformly applied by several child heart 
surgery groups and therefore carries more weight.
Based on literature, it is not possible to indicate a z-score above which an indication for 
surgery in children becomes absolute.
In severely affected children with Marfan syndrome, mitral regurgitation is often prominent 
and this can be a reason for surgical intervention, even at a young age. Simultaneous aortic 
root surgery may then be considered. The risk of a second cardiac intervention is greatest 
when the first operation occurs at a young age and when significant mitral regurgitation 
is present (Gillinov et al., 1997; Everitt et al., 2009).
Valve-sparing aortic root replacement techniques require a functional and unaffected 
or little affected aortic valve. This may be a reason to chose aortic surgery, before aortic 
regurgitation arises due to a further increase in aortic root diameter.
The choice of surgical technique is determined by multiple factors. To what extent 
anticipated growth should role a play in this choice is unclear. In a study by Cattaneo et 
al. (2004), 26 children underwent a Bentall operation and during follow-up none of the 
survivors developed outflow obstruction as a result of the aortic prosthetic valve being 
too small.
Operated children with Marfan syndrome have a higher incidence of reoperation than 
adult patients (Gillinov et al., 1997). More than half will have to undergo reoperation within 
10 years.
Recommendations 
Perform preventive aortic surgery in Marfan syndrome children with a widely dilated aortic root.  
Criteria to be used, in addition to the Z-score, are an increase in aortic root diameter of greater than 
8-10 mm/year and/or the emergence of aortic regurgitation. As evidence is lacking, the decision 
should be made by the responsible treatment team.
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Section 10  Clinical Follow-up 
Introduction
There is no scientific literature on the need for and the frequency of medical follow-up in 
children or adults with Marfan syndrome.
Children
Throughout their childhood, children with Marfan syndrome are seen periodically by a 
variety of medical specialists, all preferably attached to and within the framework of a 
multidisciplinary clinic specifically designed for these children.
Frequency of assessment (see Table 10-1): these are usually determined by paediatric 
cardiology factors:
In case of a stable non-dilated aortic root: every 2 years.
In case of a dilated aortic root (Z < +3): every year.
In case of a dilated aortic root (Z > +3): every six months.
When determining beta blocker medication: every 3-6 months.
A paediatrician, paediatric endocrinologist or coordinating doctor sees the child at each 
check-up, at which a complete general physical examination takes place. In the case of 
extreme height increase and once a height of 150 cm has been reached, a height prediction 
is made by the paediatrician or paediatric endocrinologist based on bone age.
If more frequent follow-up by a paediatrician is needed than determined by the paediatric 
cardiologist, part of the care could be situated in a regional hospital after consultation wit 
the local paediatrician.
Paediatric cardiologist: sees the child at every check-up. Echocardiography at each check-
up. ECG and aortic MRI, if indicated.
Paediatric orthopaedic surgeon: sees the child by indication, based on musculoskeletal 
complaints or at the instigation of the paediatrician/coordinator.
Geneticist: sees the child at the time of diagnosis, for the results of DNA diagnostics and 
then by indication.




















Paediatric ophthalmologist: sees the child at first examination, then if no important 
ophthalmological abnormalities, every two years. In the case of significant abnormalities 
(usually lens (sub)luxation), frequency of inspection dependent on eye abnormalities. If the 
initial examination takes place during the first year of life, then repeat within one year.
Surveillance after cardiac surgery: in children, ultrasound examination is generally 
sufficient.
Table 10.1 Follow-up scheme for children with Marfan syndrome
Specialist Type of follow-up Frequency
paediatric cardiologist echocardiography, ECG Stable non-dilated aortic root every 
2 years; dilated aortic root but Z 
<+3 every year; dilated aortic root Z 
>+3 every 6 months
coordinating doctor1 physical examination; height 
prediction (at 150 cm or in case 
of extreme height increase); 
signalling of psychosocial problems; 
coordination of care




refraction test, slit lamp examination 
in maximum mydriasis
no important ophthalmologic 
abnormalities every 2 years; in case 
of ophthalmologic abnormalities, 




physical examination, X-ray if indicated
clinical geneticist at diagnosis, for results DNA-analysis if indicated
1this can be a paediatrician or clinical geneticist 
2 if more frequent follow-up by a paediatrician is needed, part of the care could be situated in a 
regional hospital after consultation wit the local paediatrician
Table 10.1 Follow-up scheme for children with Marfan syndrome
Adults
Life-long and regular clinical assessment is carried out in a Marfan center, with the 
involvement of specialists with extensive expertise in this area. Annual check-ups by a 
cardiologist are usually sufficient. In patients who have undergone surgery of the thoracic 
aorta, it is important that the cardiologist and cardio-thoracic surgeon agree on which of 
them will continue to monitor the patient on specific issues related to the aorta. Referral 
to other  specialties occurs as indicated, and specific examinations will be dictated by 
symptoms.
Section 10  Clinical Follow-up 
hoofdstuk 2.indd   87 19-04-13   09:27
Chapter 2  |  Practical clinical guidelines for the diagnosis and management of Marfan syndrome
88
Ophthalmologist:
There are indications that primary open-angle glaucoma is more common in patients 
with Marfan syndrome (Izquierdo et al,  1992; Nahum & Spierer 2008). Therefore, periodic 
examination of eye pressure and the aspect of the optic nerve should be considered.  In 
most cases, an ophthalmologist local to the patient may become involved.
Echocardiography:
In stable patients, an annual outpatient check-up involving echocardiography of the aortic 
root is recommended. Valve regurgitation and ventricular function can also be effectively 
monitored using echocardiography.
MRI:
Baseline MRI imaging of the entire aorta is performed at first check-up and repeated at 
least every 5 years as long as the dimensions beyond the aortic root are normal. In cases 
of aneurysm formation in the distal aorta, a repeat MRI is indicated at least annually. CT 
scintigraphy can replace MRI if there is a contraindication for MRI, such as claustrophobia 
or a pacemaker, and CT can sometimes be more suitable than MRI for the early detection of 
complications following aortic surgery. See Considerations in the section Imaging.
A patient should be assessed annually by CT (or MRI) in the event of a chronic aortic 
dissection, in order to allow timely detection of aneurysm formation (Hiratzka et al., 2010).
The elasticity of the aorta can also be measured with MRI, and elasticity of the thoracic 
descending aorta may have predictive value for the occurrence of progressive local growth 
(Nollen et al., 2004).
If there is an indication for elective surgery, the probability of coronary artery disease can 
be assessed using a CT scan, as catheter interventions entail a certain risk in patients with 
a dilated and weakened aortic wall. If the CT scan shows indications for coronary artery 
disease, the catheterisation will, however, still be required.
For optimal comparison, repeated measurements of the aortic diameter should be 
performed using the same technique.
Follow-up after aortic surgery:
In adults, a baseline CT/MRI should be made prior to discharge and repeated after 6 
months, 1 , 2 and 3 years. In case of stable diameters, a frequency of once every 2 years is 
sufficient, but surveillance should be increased as soon as growth is observed.






















Follow-up of children with Marfan syndrome should take place within a multidisciplinary Marfan 
clinic team.
If more frequent paediatric follow-up is needed than the cardiologic follow-up, part of the 
paediatric care can be performed by a regional paedriatrician after consultation.
Ophthalmologic follow-up should take place at least every two years.
Ultrasound  follow-up of the aorta after cardiac surgery is generally sufficient.
Adults
Adult Marfan patients should receive life-long check-ups, provided by a cardiologist attached to a 
Marfan clinic or alternately by a cardiologist attached to a Marfan clinic and a regional cardiologist.
Assessments by an ophthalmologist or orthopaedic surgeon take place as indicated.
Consider periodic follow-up for eye pressure and the optic nerve.
Folowing aortic surgery, perform a baseline CT/MRI before discharge. Repeat after 6 months, 1, 2, 3 
years and then every 2 years. Intensify surveillance as soon as growth is observed.
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Section 11  Family Studies
Introduction
Due to the dominant mode of inheritance, family studies are important in Marfan 
syndrome, and the intra-familial variability of the disorder means that it is not always clear 
which family members may or may not be affected. Family studies in Marfan syndrome 
are no different to those in other inherited disorders, especially if the mutation in the FBN1 
gene is known. The question is how studies will be conducted, in which family members, 
and where the research will take place.
Summary of the literature
Using the original ‘Ghent criteria’ (De Paepe A. et al, 1996), 91% of individuals conforming 
to a diagnosis of Marfan syndrome showed an FBN1 mutation, which confirmed the 
diagnosis at the genetic level (Loeys et al, 2004). In a recent publication by Sheikhzadeh, 
an FBN1 mutation was detected in 80% of the patients who met the original, the new, or 
both Ghent criteria (Sheikhzadeh et al, 2011). There is no specific literature that focuses on 
methodologies for family studies in Marfan syndrome.
Conclusions
Considerations
When a pathogenic mutation in the FBN1 gene is detected in an index patient, use 
is made of the ‘cascade-screening’ customary in clinical genetics. This involves the 
examination of (vertical) first-degree relatives in first instance, followed by wider 
screening depending on the position of the family members that tested positive. 
Brothers and sisters of the affected person will be examined if a parent has Marfan 
A mutation in the FBN1 gene can be demonstrated in most patients with Marfan 
syndrome.
C  Loeys et al, 2004; Sheikhzadeh et al, 2011 
Level 3




















syndrome or if anamnestic evidence points to Marfan syndrome in the siblings. 
Prior to blood withdrawal, the implications of possible DNA test results should be explained 
and discussed with family members by a clinical geneticist or genetic counsellor, especially 
where relatives are apparently healthy (presymptomatic DNA diagnostics). Depending on 
the time required for a DNA diagnostic test, in the case of a new index patient, and where 
appropriate, one can consider echocardiography in first-degree relatives of the index 
patient if there is strong suspicion of Marfan syndrome in a family member or high levels 
of anxiety.
If no pathogenic mutation of FBN1 is found in the index patient, a diagnostic examination 
is conducted as described in the section Diagnostics. This includes physical, cardiological 
and ophthalmological examination in all cases.
In practice, it is strongly recommended that the relatives of a Marfan syndrome patient be 
referred to a specialised Dutch Marfan clinic for diagnostics (where a clinical geneticist is 
involved).
Recommendations
Perform DNA analysis in the relatives of Marfan patients where possible, and otherwise by clinical 
diagnosis. Apply so called ‘cascade screening‘: vertical (at risk) first-degree relatives are the first to 
be screened.
DNA diagnostics in relatives must take place in a clinical genetic centre, and clinical diagnosis - 
where appropriate - in a multidisciplinary Marfan clinic. 
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Section 12  Pregnancy and Delivery 
Introduction
Literature and hard data related to pregnancy, childbirth and Marfan syndrome are 
relatively scarce. The questions central to this section are: “What are the risks of pregnancy 
and childbirth for mother and child?”, and “What are the recommendations for the 
guidance of pregnancy and childbirth?”.
Large randomised trials are lacking, as most literature consists of case reports. This leaves 
considerable room for expert opinion in the treatment recommendations for pregnant 
women with Marfan syndrome. Progress has been made in treatment and there is now 
a better understanding of the genetics and natural history. In this regard, studies of the 
effects of beta-blockers during pregnancy are promising but have yet to be completed.
Multidisciplinary teamwork and  a clear treatment plan, are important in pregnant women 
with Marfan syndrome.
The section is divided into two subsections. The first subsection concerns the risks of 
pregnancy and childbirth for mother and child. The second subsection concerns the 
supervision of pregnancy and childbirth. At the end a checklist is included.
1. Risks of pregnancy and delivery for mother and child 
Summary of the literature
Most literature consisted of case reports, with only a few of reviews and studies in patient 
groups.
The main complications for pregnant women with Marfan syndrome are cardiovascular 
events, aortic dissections in particular. The physiological changes during pregnancy 
(increased cardiac output (30-50%) and increased blood volume) constitute an extra 
burden on the heart and major blood vessels. Cardiac output increases by a further 20% 
during the contractions of labour, and an extra burden is also present immediately after 
delivery (Hytten & Paitin, 1963; Wallenburg, 1990; Silversides et al., 2010). In addition, the 
hormonal changes during pregnancy have a negative influence on the strength of the 
aortic wall (Manola-Estrella & Barker, 1967).
1.1  Aortic dissections
The incidence of aortic dissection in the general population is about 2.9-3.5/100,000 




















person-years (Ramanath et al, 2009). The risk in pregnant Marfan patients is estimated 
to be 1-5% (Pacini et al., 2009; Lind & Wallburg, 2001; Canadas, 2010). This seems to be 
related to aortic diameter, aortic diameter growth, family history and previous surgery on 
the aorta. (Preconceptional) counselling is therefore an important component of care for 
pregnant women with Marfan syndrome.
The likelihood of an aortic dissection during pregnancy
The average age at which a dissection occurs in Marfan patients is around 30-32 years 
(Murdoch et al., 1972; Silverman, 1995). A dissection can occur in any trimester in pregnant 
women, but the greatest risk is in the last trimester and in the postpartum period. From 
two cases series including 57 (Husebeye et al., 1958) and 51 patients (Konishi et al., 1980) 
and a literature review by Lind (2000), it appears that around 5% of dissections occur in the 
first trimester, 10% in the second trimester, 50% in the third trimester, 15% during delivery 
and 20% in the postpartum period. Only a relatively small number of dissections have been 
described in the literature (500-600).
Meijboom (2005) followed changes in aortic diameter for an average of 6.4 years in a group 
of 127 female Marfan patients. Within this group, changes in aortic root diameter could be 
followed in 31 (22 females) pregnancies, and were compared with 22 matched patients who 
did not become pregnant during the follow-up period. In the pregnant group, no significant 
change was found in the aortic root diameter prior to, during and following pregnancy. 
There were also no significant differences in diameters between women who were or were 
not pregnant. However, within the ‘pregnant’ group a significant difference was seen in 
increases in aortic root diameter in those women with an initial aortic root diameter ≥40 
mm, compared to women with a diameter <40 mm. There was also a significant difference 
in the long-term increase in aortic root diameter of ‘pregnant’ women with an initial 
aortic root diameter ≥40 mm and matched controls. In the group of pregnant women 
with an aortic root diameter of 40-45 mm and no haemodynamic abnormalities (n = 9; 11 
pregnancies), no aortic dissections or aorta-related complications were found.
An aortic root diameter <40 mm is considered a relatively safe limit for women with 
Marfan syndrome who wish to become pregnant.
The European guideline (Regitz-Zagrosek et al., 2011)) also adheres to a limit of 40 mm. 
Furthermore, the guideline states:
a. An aortic root diameter of >40 mm and an increase in diameter of the aortic root 
during pregnancy are risk factors for dissection in pregnant women with Marfan 
syndrome; 
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b. Pregnancy is not recommended at aortic root diameters greater than 45 mm;
c. During the counselling of women with Marfan syndrome with an aortic root diameter 
of 40-45 mm, risk factors such as aortic growth and family history of dissection should 
be taken into account. 
The Canadian guideline (Silversides et al., 2010) extends the threshold above which a 
pregnancy is not recommended to 44 mm.
Almost all literature indicates that even when the aortic root diameter is <40 mm, there is 
no guarantee that a dissection will not occur.
Pregnancy is discouraged in patients who have experienced a type A or B dissection (Regitz-
Zagrosek et al, 2011).
Possibilities for prevention of aortic dissection
Beta blockers could potentially reduce the risk of aortic dilatation (Regitz-Zagrosek et al, 
2011). It is recommended that prophylactic treatment with beta blockers be either continued 
or initiated, regardless of aortic diameter or length of pregnancy (Regitz-Zagrosek et al, 
2011; Goland et al., 2009; Canadas, 2010; Pacini et al., 2009). Beta-blockers have been linked 
to foetal growth retardation and neonatal bradycardia, hypoglycemia, hyperbilirubinemia 
and apnea but these complications are generally rare. The maternal clinical benefits far 
outweigh these risks (Magee & Dukey, 2003).
In practice, metoprolol is most widely prescribed; atenolol has been more frequently linked 
to foetal growth retardation (Hogstedt et al., 1985).
The detection and treatment of high blood pressure is important. Beta blockers are not 
indicated for the treatment of gestational hypertension, with the exception of labetolol, 
which has postsynaptic α1- en non-selective b-sympatholytic properties (NVOG 2005). 
Other agents which may be used for the treatment of gestational hypertension/pre-
eclampsia include nifedipine, nicardipine and aldomet.
ACE-inhibitors and AT1-receptor blockers are contraindicated in pregnancy due to 
teratogenic effects (Cooper et al., 2006; Alwan et al., 2005).
In cases of planned pregnancy, both the ESC guideline 2011 and the Canadian guideline 
advise preconceptional preventive surgery at aortic root diameters above 45 mm (leading 
edge to leading edge).




















Treatment of aortic dissection during pregnancy
Most acute situations involve a type A dissection (ascending aorta), and immediate surgery 
is required.
The length of gestation is of importance when considering whether a pregnancy should be 
terminated in cases of a type A dissection. At a gestational age of more than 30 weeks, a 
caesarean section is usually carried out and immediately followed by surgery of the aorta. 
The period between 24-30 weeks is still under debate. An emergency caesarean followed 
by surgery is common practice but in cases of extreme prematurity, one can elect to 
continue the pregnancy and to perform the operation under foetal monitoring, and with 
adjustments in anaesthesia and hypothermia. The risk of severe neonatal morbidity is 
about 3-6% and foetal mortality is high (Chambers, 1994). When a  dissection occurs at a 
gestational age of less than 24 weeks, the same dilemmas have to be faced.
Type B dissections (no involvement of ascending aorta) are generally treated by 
conservative drug treatment with frequent monitoring by MRI. Surgery may be indicated 
in symptomatic dilatation of the descending aorta. If a foetus is viable, the European 
guideline recommends a caesarean section first, immediately followed by treatment of 
the aorta (Regitz-Zagrosek et al, 2011).
1.2 Other complications of pregnancy and delivery
The rate of spontaneous abortion in women with Marfan syndrome may be slightly 
increased (15-20%; normal 10-15%) (Meijboom et al., 2006; Lind, 2000; Lind et al., 2001; 
Rossiter et al., 1995) .
Premature birth and dysmaturity are also somewhat more frequent (5-30% and 10-15%, 
respectively, normally about 8% and 10%) (Lind et al., 2001; Rossiter et al., 1995; Lipscomb 
et al., 1997).
Little information is available on the incidence of postpartum bleeding, manual placental 
removal and total rupture in Marfan syndrome compared with the normal population, but 
it does not seem to greatly deviate from that of the normal population (Lind, 2000; Lind 
et al., 2001).
Published data specifically focused on pregnant women with Marfan syndrome and 
scoliosis is lacking. The percentage of caesarean sections in non-Marfan patients with 
scoliosis is no higher than in the normal population(Betz et al., 1987; Orvomaa et al., 1997).
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Neonatal outcome is correlated with maternal health. If no cardiac or vascular surgery/
complications occur during pregnancy, neonatal outcome is comparable to that of a 
normal population (Regitz-Zagrosek et al, 2011).
Conclusions
Aortic dissection is a major complication of pregnancy in women with Marfan 
syndrome, and occurs in 1-5% of cases. 
B Lind et al., 2001; Pacini et al., 2009
D Canadas, 2010
Level 2
Most aortic dissections occur in the 3rd trimester, during delivery and postpartum.
C Husebeye et al., 1958; Konishi et al., 1980
Level 3
The probability of an aortic dissection during pregnancy is small, where the aortic 
diameter is stable and less than 40-45 mm. 
B Meijboom et al., 2005
Level 3
A type A dissection is an indication for emergency surgery. A type B dissection is 
usually treated conservatively. Depending on the findings and symptoms, a type B 
dissection may be treated surgically or by placing a stent.
D Regitz-Zagrosek et al, 2011
Level 4
A type A dissection is an indication for emergency surgery. A type B
dissection is usually treated conservatively. Depending on the findings and
symptoms, a type B dissection may be treated surgically or by placing a
stent.
D European Society of Cardiology 2011
Level 4





















The probability of an aortic dissection in pregnancy is lower with elective aortic surgery 
in the anamnesis than with a history of surgery for acute aortic dissection. Although 
no studies or literature are known, it is generally believed that the risk of dissection in 
pregnancy following elective aorta surgery is acceptable. In cases with a history of surgery 
for acute aortic dissection, the aorta is known to be poor and to carry an increased risk of a 
new dissection. In this case, a pregnancy is discouraged.
Recommendations
The risk of spontaneous abortion or preterm birth in women with Marfan syndrome 
may be slightly elevated. 
C  Meijboom et al., 2006; Lind et al., 2001; Rossiter et al., 1995; Lipscomb et al., 1997
Level 4
Do not discourage women with Marfan syndrome and an aortic root diameter of less than 40 mm 
from becoming pregnant.
 
When making decisions on pregnancy, in cases of aortic root diameters of 40-45 mm, individual risk 
factors should be taken into account. 
 
Encourage patients with an aortic root >45 mm to undergo elective aortic root replacement before 
becoming pregnant.
 
Advise against pregnancy in patients who have experienced an aortic dissection.
Diagnose high blood pressure actively and treat it.
 
Continue or begin prophylactic treatment with beta blockers during pregnancy. 
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2. Guidance during pregnancy and delivery
Summary of the literature
2.1 Pregnancy
There is little to no scientific literature on pregnancy guidance in Marfan patients. The 
recommendations therefore predominantly reflect the opinion of the working group.
 
2.2 Anticoagulants during pregnancy
Anticoagulants are indicated for a proportion of female Marfan patients, due to valve 
defects or following cardiovascular surgery.
There is no evidence that the use of anticoagulants in a pregnant patient with Marfan 
syndrome entails specific increased risks, but oral anticoagulants do cause an increased 
risk of miscarriage and haemorrhagic complications in pregnant women (Schaefer, 2006).
Patients taking anticoagulants should receive counselling appropriate to their situation. 
Congenital anomalies have been described following the use of coumarin derivatives, but 
not following the use of heparin and low molecular weight heparin (LMWH) derivatives 
(these substances do not cross the placenta). If oral anticoagulants (Marcoumar/
Sintromitis) were already in use before pregnancy, it is preferable to use Heparin/LMWH 
in the first and at the end of the 3e trimester, and to prescribe coumarin derivatives in 
the intervening period. In general, a daily dose of <2 mg Sintromitis dfoes not result in 
teratogenic effects and can therefore be considered for use throughout pregnancy. The use 
of LMWH throughout pregnancy has been linked to a slightly increased risk of thrombosis 
in patients with non-biological prosthetic valves (Yinon, 2009). Concentrations of LMWH 
may fluctuate during pregnancy, potentially resulting in a fall of anti-Xa-activity below the 
therapeutic value (Friedreich, 2010; Barbour, 2004).
Prolonged use of unfractioned heparin can result in complications such as osteoporosis 
and “heparin-induced thrombocytopenia”. The use of ascal is acceptable, if indicated (NICE 
2010).
2.2 Delivery
No scientific studies were found in which the risk of vaginal birth was compared with 
caesarean sections in women with Marfan syndrome. Reviews and guidelines do provide 
recommendations, but they are mainly based on expert opinion.
The European Society of Cardiology (Regitz-Zagrosek et al, 2011) provides recommendations 
and advice on parturition, based on the WHO risk classification. See Tables 12.1, 12.2 and 12.3.




















Table 12.1 Modified WHO classification of maternal cardiovascular risk: principles
Risk class Pregnancy-related risk with this condition 
I No detectable increased risk of maternal mortality and no/mild increase in 
morbidity.
II Small increased risk of maternal mortality or moderate increase in 
morbidity.
III
Significantly increased risk of maternal mortality or severe morbidity. 
Expert counselling is required. If pregnancy is decided upon, intensive 
specialist cardiac and obstetric monitoring is needed throughout 
pregnancy, childbirth and puerperium.
IV
Extremely high risk of maternal mortality or severe morbidity: pregnancy 
is contraindicated. If pregnancy occurs, termination should be discussed. If 
pregnancy continues, care as for class III.
Table 12.1 Modified WHO classification of maternal cardiovascular risk: principles
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Table 12.2: Risk classification of the various cardiovascular abnormalities 
that may occur in Marfan syndrome 
 Risk class Condition
WHO II-III Mild left ventricular dysfunction. 
Marfan syndrome without aortic dilatation. 
WHO III Mechanical valve. 
Marfan syndrome and aorta between 40-45 mm.
WHO IV Marfan syndrome and aorta >45 mm.
Table 12.2: Risk classification of the various cardiovascular abnormalities that may occur in 
Marfan syndrome 
Table 12.3 : Recommendations based on risk classification 




Marfan and aorta >45 mm: surgery before pregnancy I C
Ascending aorta <40 mm: vaginal delivery is favoured I C
In cases of severe hypertension: vaginal delivery with epidural and 
possibly elective assisted delivery 
IIa C
Marfan and aorta between 40-45 mm: vaginal delivery with 
epidural anaesthesia and expedited second stage should be 
considered
IIa C
Marfan and aorta between 40-45 mm: caesarean delivery may be 
considered
IIb C
Aorta >45 mm and Marfan syndrome: caesarean delivery should be 
considered
I C
Type B dissection or history of type B dissection: should be advised 
against pregnancy*
III* C
If delivery starts while on oral anticoagulants, caesarean delivery is 
indicated 
I C
alevel of recommendation blevel of evidence
I      :  recommended/indicated A: Data from clinical trials
II A :  must be considered B: Data from a randomised trial or
II B :  can be considered  from large non-randomised studies
III   :  not recommended  C: Expert consensus and/or small
*    : adviced against pregancy studies, retrospective studies, registrie
Table 12.3 : Recommendations based on risk classification 
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Two non-systematic reviews have suggested that women at low risk can undergo vaginal 
birth, provided there are no obstetric or other contraindications (Canadas, 2010(II), Goland 
et al., 2009).
Both Goland et al. (2009) and Canadas et al. (2010) recommend the liberal use of epidural 
anaesthesia and forceps or vacuum pump during vaginal delivery, in order to reduce effects 
on blood pressure and to accelerate the second stage of labour.
A position on the left side or half sitting places the least stress on the aorta during labour 
(Regitz-Zagrosek et al, 2011).
In cases with a high risk, a controlled setting is usually chosen and a primary caesarean 
section performed, together with intensive maternal monitoring and, if possible, 
fractionated administered epidural anaesthesia with haemodynamic monitoring (Canadas, 
2010; Goland et al., 2009).
The ability to administer epidural or spinal anaesthesia can sometimes be limited by dural 
ectasia (Goland et al., 2009; Canadas, 2010), previous back surgery, scoliosis or prolonged 
bleeding (anticoagulants). Dural ectasia cause the spinal block to fail through the dilution 
of the local anaesthetic agent and are responsible for a higher chance of a “dural tap” at 
the epidural punction.
A caesarean section is recommended in patients who enter labour while using oral 
anticoagulants (OAC), to prevent intracranial haemorrhage in the foetus. The OAC can 
cross the placenta and affect coagulation in the foetus (Regitz-Zagrosek et al, 2011).
Conclusions
As a consequence of fluctuating concentrations of LMWH, anti-Xa activity may fall 
below the therapeutic concentration and should be monitored.
C Friedreich, 2010; Barbour, 2004
Level 3





















A preconceptional consultation is important and should include: a gynaecologist, a 
clinical geneticist, a cardiologist and a paediatrician. During this consultation, the dangers, 
the strategy and plan of treatment can be determined in advance and discussed. An 
anaesthesiologist can be consulted preconceptionally, but should always be consulted 
before delivery.
If no preconceptional consultation has taken place, the above consultation should take 
place as early as possible in pregnancy and a written treatment plan should still be prepared.
The antenatal check-ups can, in principle, take place at regular intervals as described in 
the NVOG protocols. On theoretical grounds, frequent monitoring from 28 weeks appears 
logical.
Besides the routine 1e trimester foetal ultrasound (period; 11-14 weeks scan), a so-called 
advanced ultrasound examination of the foetus around 20 weeks gestation may be 
considered, with a repetition at 30-34 weeks. Although the chance of a foetus being 
The advice in literature is for liberal use of epidural anaesthesia and forceps or 
vacuum pump during vaginal delivery, in order to reduce the cardiovascular burden 
during the second stage of labour. 
D Goland et al., 2009; Canadas, 2010
Level 4
Vaginal delivery is safe in patients at low risk (aortic diameter <40 mm and no 
haemodynamic abnormalities).
According to the ESC guideline, both vaginal and caesarean delivery should be 
considered in cases with a moderately increased risk, depending on individual 
circumstances.
High risk cases (aortic diameter >45 mm, history of acute aortic dissection, 
haemodynamic limitations) usually undergo a primary caesarean section performed 
with intensive maternal monitoring and, if possible, fractionated administered 
epidural anaesthesia with haemodynamic monitoring.
 
D Canadas, 2010 II; Goland et al., 2009; Regitz-Zagrosek et al, 2011
Level 4
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affected by congenital abnormalities visible on ultrasound is very small, there are case 
reports and personal communications that report large aortic diameters antenatally. 
Moreover, it is undesirable to overlook a foetal abnormality in a pregnancy that is already 
hazardous.
Periodic monitoring of aortic dimensions is clearly required. In the literature, no clear 
indications are given for the frequency of monitoring, but a general scheme is: before 
pregnancy, at 20-24 weeks, 36 weeks, 2 days postpartum and 6 weeks postpartum. 
Depending on the history and clinical findings, more frequent monitoring may possibly 
be indicated. In high-risk patients, the abdominal aorta should also be properly examined.
The choice of the mode of delivery depends not only on the risk, but also on individual 
circumstances and patient preference. The patient should be well-informed about the risks 
of the various options. 
The safety of the mother and the child should take priority when making any choice.
Parturition should take place at the secondary or tertiary level, depending on the 
cardiovascular status of the patient and treatment capabilities of the hospital.
Low-risk patients (aortic diameter <40 mm) can receive check-ups and undergo childbirth 
at the secondary level, as long as clear agreement is reached with a cardiosurgical centre 
on check-ups, treatment and measures around parturition, and that the circumstances 
requiring referral are clearly discussed. A treatment plan for possible emergencies is 
important. Patients with moderate or high risk must give birth in a tertiary center with 
capabilities in cardiovascular surgery and an experienced team should be present.
Depending on general health and the results of cardiological investigations, in a medium-
risk situation (aortic diameter 40-45 mm or 1x elective aortic surgery or heart valve 
replacement with a stable haemodynamic result) it is possible to opt for a vaginal delivery 
with progressive epidural anaesthesia, basal maternal monitoring and possibly a primary 
assisted vaginal delivery (forceps/vacuum extraction).
If medication is used by a mother during pregnancy, a consultation with a paediatrician is 
indicated following childbirth.




















Both a (multidisciplinary) preconceptional consultation and a multidisciplinary treatment plan are 
important in Marfan patients planning pregnancy.
Consider a so-called advanced ultrasound examination of the foetus, in addition to routine foetal 
ultrasound, at around 20 weeks and around 30-34 weeks of pregnancy.
Pregnant Marfan patients should receive check-ups at the secondary or tertiary level, and these 
should include periodic monitoring of aortic diameter (before pregnancy, at 20-24 weeks, 36 weeks, 
2 days postpartum and 6 weeks postpartum). Depending on history and clinical findings, more 
frequent monitoring may possibly be indicated and monitoring of high-risk patients should also 
include the entire abdominal aorta.
Patients on anticoagulants should receive appropriate counselling. Check coagulation using 
the indicator of anti-Xa activity during therapeutic use of LMWH. If delivery occurs while oral 
anticoagulants are still being used, a caesarean section is indicated.
Advise a vaginal birth in a secondary centre for patients at low risk (aortic diameter < 40 mm and no 
haemodynamic abnormalities), provided that arrangements with a tertiary centre are made in case 
of problems or complications. Use epidural anaesthesia and forceps or vacuum pump liberally, in 
order to reduce effects on blood pressure and to accelerate the second stage of labour.
Consider a primary progressive epidural and primary assisted delivery (vacuum/forceps extraction) 
at parturition, with fractionated administered epidural anesthesia and haemodynamic monitoring 
in patients at moderate risk (aortic diameter 40-45 mm or 1x elective aortic surgery or heart valve 
replacement with a stable haemodynamic result). Consider a caesarean section depending on 
individual circumstances.
Perform elective caesarean section with intensive maternal monitoring and with fractionated 
administered epidural anaesthesia and haemodynamic monitoring, if possible, in high-risk cases 
(aortic diameter >45 mm or acute aortic dissection or haemodynamic limitations) in the presence of 
an experienced team.
Patients at moderate or high risk should give birth in a tertiary care centre with options for 
cardiovascular surgery
The choice of the mode of delivery should be made in consultation with the patient.
If medication is used during pregnancy, a consultation with a paediatrician is indicated following 
childbirth.
Recommendations
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Checklist: pregnancy and Marfan syndrome
Preconceptional consultation:
- Cardiovascular evaluation;
- Adjustments to medication: anticoagulants, ACE inhibitors, beta-blockers;
- R/ folic acid;
- Consultation with cardiologist and possibly other specialists as needed;
- Pregnancy preferably at a younger age;
- Prenatal diagnosis, consultation with clinical geneticist;
- General physical examination;
- Explanations of chance of aortic dissection, prevention, treatment, complications;
- Possible adjustments to lifestyle;
- Pregnancy check-ups at secondary/tertiary level, depending on health.
Pregnancy:
- Cardiovascular evaluation;
- Explanations of chance of aortic dissection, prevention, treatment, complications;
- Monitoring of aorta (at 20-24 and 36 weeks);
- Possible lifestyle guidelines;
- Consultation with cardiologist, anaesthesiologist and possibly other specialistss 
as needed;
- Consultation at a cardiosurgical centre;
- Prenatal diagnosis;
- Ultrasound: 11-13 weeks scan, 20 weeks ultrasound/advanced ultrasound 
examination type 1, 30-34 weeks scan, growth monitoring;
- Prepare a birth plan;
- Consultation with a paediatrician;
- Medication (anticoagulants, beta blockers, etc.);
- General physical examination;
- From approximately 28 weeks, more frequent check-ups in order to monitor 
blood pressure. 
Childbirth:
- If risk is low and aortic diameter <40 mm: secondary/tertiary level, vaginal 
delivery;
- If risk is moderately increased (decided at multidisciplinary consultation): vaginal 
delivery, tertiary level, maternal monitoring, epidural anaesthesia and primary 




















assisted vaginal delivery or caesarean section; 
- If high risk: tertiary level, intensive maternal monitoring, epidural anaesthesia, a 
primary caesarean section if possible. 
Postpartum:
- Contraception;
- Evaluation of neonate;
- Ultrasound of aorta (2 days and 6 weeks postpartum).
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Section 13  Prenatal and Preimplantation Diagnosis 
Introduction
Many patients with Marfan syndrome reach reproductive age in good health, thanks 
to the effective treatment options. Patients often have questions concerning fertility, 
pregnancy-related complications and the consequences for the child. Since Marfan 
syndrome is an autosomal dominant disorder, the chance that a Marfan parent will have 
a child with Marfan syndrome is 50%. As a molecular cause is currently found in a large 
percentage of Marfan patients, opportunities are available for prenatal diagnosis (PND) or 
preimplantation genetic diagnosis (PGD).
Brief explanation of procedure prenatal/preimplantation genetic diagnosis
Prenatal diagnosis of an existing pregnancy allows foetal material to be examined for a 
specific condition by chorionic villus sampling or amniocentesis. Chorionic villus sampling 
takes place via either the abdomen or vagina, around the 11th week of pregnancy. 
Amniocentesis can be performed from the 16th week onwards. PND involves certain risks: 
in general, the risk of miscarriage as a result of a chorionic villus sampling/amniocentesis 
is approximately 0.3-0.4%.
Preimplantation genetic diagnosis involves an IVF procedure whereby genetic diagnosis 
takes place prior to transfer of the embryo, and only embryos lacking a  mutation will 
be returned. If a couple chooses PGD, the laboratory must conduct preliminary genetic 
research of the parents themselves, any children and any relatives. The duration of the 
preliminary investigation can vary from several weeks to one year. Since the FBN1 gene 
is not prone to hot spot mutations and each family carries a specific mutation, marker 
analysis is usually chosen (Spits et al., 2006; Kilpatrick et al., 1996).
A gynaecologist, a clinical geneticist and a social worker will discuss the course of these 
studies (preparation, sampling, results, psychosocial aspects) with the prospective parents.
Summary of the literature
A literature search was carried out with the aim of identifying whether PND and PGD carry 
specific risks in the context of Marfan syndrome. If the father has Marfan syndrome, PND/
PGD is not expected to entail a higher risk than for any other indication for PND/PGD, 
as the expectant mother is healthy. However, in the event that the woman herself has 




















Marfan syndrome and wishes to become pregnant, there are theoretical additional risks 
to consider, including those of the tests (chorionic villus sampling/amniocentesis/follicular 
puncture), the hormonal stimulation in PGD, the multiple pregnancy risk with PGD and the 
use of anticoagulants.
The specific cardiac-related risks for a woman with Marfan syndrome during pregnancy are 
discussed in section 12.
The literature related to prenatal/preimplantation genetic diagnosis and Marfan 
syndrome is limited to individual case reports (Blaszczyk et al., 1998, Godfrey et al., 1993; 
Harton et al., 1996, Kilpatrick et al., 1996, Smith et al., 2010) and a few small series (Loeys 
et al., 2002; Toudjarska et al., 2001; Spits et al., 2006). These articles report that prenatal/
preimplantation diagnosis is possible, but do not discuss possible risks.
Whether amniocentesis/chorionic villus sampling/follicular puncture in an expectant 
mother with Marfan syndrome carries a higher risk of abortion than in the general 
population has not been studied. No complications associated with these procedures were 
found in the literature.
Adverse effects in female Marfan patients due to ovarian stimulation during an IVF 
procedure have not been described in the literature.
No report of a multiple pregnancy entailing additional risks for a Marfan patient could be 
found in the literature. The PGD guideline for Marfan syndrome includes no comment on 
the number of embryos that should be transferred. In general, the cardiac condition of a 
patient is taken into account (even for indications other than Marfan syndrome), and in 
consultation with the clinical geneticist, cardiologist and gynaecologist, 1 or 2 embryos will 
be transferred.
If a biopsy is to be performed on a woman using anticoagulant medication, this should be 
discussed with the cardiologist. Complications resulting from the use of anticoagulants in 
a pregnant patient with Marfan syndrome have not been described.
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Conclusions
Prenatal diagnosis for pregnancies that carry an increased risk of Marfan syndrome 
is possible if the familial mutation is known (or if there is linkage). A choice can be 
made between chorionic villus sampling (10-12 weeks gestation) or amniocentesis (15 
- 18 weeks gestation). 
C  Loeys  et al, 2002; Toudjarska et al, 2001; Spits et al, 2006
Level 3
No information is available from literature on whether invasive diagnosis (chorionic 
villus sampling/amniocentesis/follicular puncture) entails greater risks in a couple 
with Marfan syndrome than in the general population. 
No literature
Level
Pre-implantation genetic diagnosis for pregnancies that carry an increased risk of 
Marfan syndrome is possible if the familial mutation is known.
C  Loeys et al, 2002; Toudjarska et al, 2001
Level 3





There is no scientific literature to support the conclusion that PND or IVF for PGD is 
contraindicated for Marfan female patients. Conversely, it can also not be concluded that 
there is no additional risk. On the basis of small series and personal experience, PND and 
PGD does not seem to present a major risk to pregnant Marfan patients.
The clinical variability of Marfan syndrome leads to complex reproductive choices, since a 
molecular diagnosis does not predict the severity of symptoms.
Theoretically, a twin pregnancy is less desirable because of the additional cardiovascular 





















Prenatal or preimplantation genetic diagnosis is possible when the familial mutation of a parent 
with Marfan syndrome is known. 
 
Offer (or re-offer) genetic counselling to young adults (male or female) with Marfan syndrome. 
Recurrence risk, cardiac condition before and during pregnancy and reproductive options should be 
discussed during this preconception counselling. 
 
Do not transfer more than a single embryo during IVF. 
 
The risks of PND and PGD for IVF should be studied in larger series
stress. This is particularly important in cases where ovulation induction or IVF (with or 
without pre-implantation diagnosis) is applied, with the related increased risk of multiple 
births.
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Section 14  Lifestyle Recommendations
Introduction
The international guidelines on Marfan syndrome (Maron et al, 2004; Pelliccia et al, 2005; 
Maron et al, 2005a) advise patients to change their lifestyle. These recommendations 
mainly concern sport; advice related to daily activities and career choice is more limited. 
The motivation for lifestyle advice is to reduce the haemodynamic stress on the aortic wall. 
The increases in heart rate, blood pressure and stroke volume during intense activity may 
promote the development of aortic aneurysms and increase the rate of aortic dilatation. 
Distensibility declines and wall stress increases during progressive aortic dilatation, 
resulting in an aortic wall that is even less capable of compensating for the effects of 
haemodynamic stress during exercise and is thus at greater risk of aortic dissection or 
rupture (Elefteriades, 2008). Besides physical exertion, strong emotions also seem to play 
a role in the occurrence of aortic dissection (Hatzaras et al, 2007).
Limiting normal sports activity in children and adolescents with Marfan syndrome can have 
a dramatic effect, and may well have a negative impact on the physical and psychosocial 
well-being of the child. Adult Marfan patients experience this obligatory adjustment of 
their activity pattern as negative for their quality of life (Peters et al, 2001).
Summary of the literature
A scientific statement from the American Heart Association in 2004 (Maron et al, 2004) 
included advice on physical activity and recreational sport for young people with 
genetic heart disease, including Marfan syndrome. These recommendations were based 
primarily on the experience and insights of the panellists (expert opinion). Quote: “There 
is a paucity of precise published evidence. Indeed, the panel encountered few absolute and 
truly quantitive data…”. When formulating their advice, the panellists attempted to strike 
a balance between the positive effects of sports activity and the inherent risks for this 
particular patient group.
Avoiding participation in sports that involve rapid accelerations and decelerations 
(e.g. basketball, squash and tennis) and those that demand intensive isometric 
(= static) exertion is advisable for all individuals with Marfan syndrome. 




















School gym classes deserve particular attention. Activities during school gym and outdoor 
play are acceptable at all times for junior school children, but competitive sports tests in 
high school are not suitable. The above recommendations are not applicable to Marfan 
patients who have already had surgery, as more stringent recommendations generally 
apply to this group.
In 2005, the European Society of Cardiology (ESC) published recommendations for 
participation in competitive sports, also at the level of expert opinion (Pelliccia et al, 2005).
Competitive sport is not recommended for Marfan patients, at any age. Low intensity, 
recreational sport is acceptable. Contact sports are not recommended because of the 
risk of damage to the aorta or eyes. Moderately intense, recreational sports are allowed 
in individuals with normal aortic root dimensions. Recommendations have also been 
formulated for individuals with clinically suspected Marfan syndrome, but without definite 
genetic confirmation.
Aortic root diameter is at the centre of the recommendations formulated in 2005 at the 36th 
Bethesda Conference (BC#36) of the American College of Cardiology (ACC). Participation 
in low and moderate intensity static and low dynamic competitive sports is allowed 
if the aortic root diameter is below 40 mm or below 2SD in children, in the absence of 
haemodynamically significant mitral regurgitation and a family history of aortic dissection 
or sudden death. It is advisable to measure aortic root diameter by echocardiography every 
six months.
Marfan patients with an aortic root diameter above 40 mm or above 2SD in children with 
previous aortic surgery, chronic aortic dissection, moderate to severe mitral regurgitation 
and/or a family history of dissection or sudden cardiac death, may only participate in 
low intensity competitive sports. Participation in contact sports is not recommended 
for anyone with aortic dilatation, and in particular, for patients taking anticoagulant 
medication (Maron and Zipes, 2005b).
There are several published lists that provide a classification of the intensity of exercise in 
sports. The scheme by Mitchell et al (2005) may be helpful but the advice regarding sports 
is largely dependent on the individual situation of the patient (Mitchell et al, 2005).
In 2008, Pelliccia et al. (2008) compared the advice of the ESC and that of the ACC: the 
differences centred on whether or not to allow participation in competitive sport at (still) 
normal aortic root dimensions.
Sports advice aimed at lowering the burden on the joints is at the level of “common sense” 
(“Although there have been no trials to investigate the effectiveness of sports limitation to 
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avoid joint damage, common sense suggest that activities likely to stress the joints should be 
avoided.”) (Dean, 2007).
In connection with an increased risk of pneumothorax, scuba diving is discouraged.
Conclusions
Considerations
The international literature contains clear advice regarding the sports participation of 
patients with Marfan syndrome. On the one hand, these recommendations are based on 
theoretical considerations and the partly investigated effects of haemodynamic stress on 
the aortic wall, especially when dilatation and decreased distensibility is already present, 
and on the other, on retrospective observations concerning the circumstances under which 
patients developed aortic dissection or rupture. The advice of the ESC and ACC expert 
panels differ in the details regarding Marfan patients without aortic root dilatation. Advice 
should be tailored to fit individual needs and with as few restrictions as possible, especially 
with regards to children. The same sports exercise advice should be followed for non-sports 
related (daily) activities. In the opinion of the working group, there is no reason to dissuade 
Marfan patients from participation in normal daily activities (including sexual activity).
National Marfan organisations have an important supporting role to play in disseminating 
this lifestyle advice.
Most guidelines discourage participation in sports involving rapid accelerations 
and decelerations, sports requiring intensive static exertion and contact sports. 
Participation in recreational low-to-moderate intensity sports is permitted in most 
guidelines. Guidelines recommend that children participate as much as possible in 
normal school gym and outdoor play activities. Participation in intensive sports tests 
such as the Cooper Test or the Shuttle Run Test is not recommended.
D  Maron et al, 2004; Maron & Zipes, 2005b; Pelliccia et al, 2005; Pelliccia et al, 2008
Level 4





















Advice regarding participation in sports should be tailored to fit individual needs, for example, 
taking into account the condition of the aorta and the use of anticoagulants. 
 
Caution should be exercised with regard to competitive sports, major peaks of exertion and 
intensive static exertion. 
Participation in recreational low-to-moderate intensity exercise can usually be allowed. 
 
Children should participate as much as possible in normal school gym classes and outdoor play 
activities. Advice against participation in intensive sports tests such as the Cooper Test or Shuttle 
Run. 
 
There is no reason to dissuade Marfan patients from participating in normal daily activities 
(including sexual activities).
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Section 15  Organisation of Care 
Introduction
Marfan patient care is organised around Marfan clinics. These centres provide a team 
of medical specialists with expertise in the area of Marfan syndrome. This section aims 
to provide an illustration of the requirements that must be met by a Marfan clinic and 
recommendations for the organisation of diagnosis, monitoring and treatment.
Literature
There is no scientific literature to prove that the care for Marfan patients in a center of 
expertise is better than elsewhere. Nevertheless, the working group considers that a 
relatively rare multisystem disorder such as Marfan syndrome requires a multidisciplinary 
approach by specialists with expertise in the field of Marfan syndrome. A multidisciplinary 
approach is in line with recommendations in the literature: “The diagnosis and management 
of Marfan syndrome requires a multidisciplinary team approach, in view of its multisystem 
effects and phenotypic variability”(Dean, 2007). This is endorsed by the patientgroup 
“Contactgroup Marfan Netherlands”.
Out-patient clinics
Each clinic has at least one coordinator. This can be a doctor, but may also be a genetic 
counsellor or specialist nurse. The care coordinator is responsible for the organisational 
aspects of the Marfan out-patient clinic and may play a role in providing the patient with 
information. A Marfan team consists of at least a cardiologist, paediatric cardiologist, 
cardio-thoracic surgeon, paediatrician, clinical geneticist and an ophthalmologist. A 
paediatric endocrinologist, orthopaedic surgeon, gynaecologist and one physiotherapist 
can be part of the team or make contributions on a consultative basis. It is recommended 
that each Marfan team has a link via the website of the relevant University Medical Centre 
that clearly shows to whom and how a patient referral should occur and provides details of 
the coordinator or contact person.






















A patient consults the (family) physician with features reminiscent of Marfan syndrome. 
See also section “Diagnostics”. It is recommended that in cases with a strong suspicion of 
Marfan syndrome (e.g. dilatation or dissection of the aortic root without obvious cause, 
lens (sub)luxation or a first-degree relative with Marfan syndrome), the patient should 
be referred to a Marfan clinic. Patients with less specific features of Marfan syndrome 
are reviewed by the coordinator following referral, who then prepares a treatment plan. 
The referring physician should have a clear idea of how and to whom a patient should be 
referred.
The first appointment should take place within 4-8 weeks of referral. If this deadline is not 
feasible, it is recommended that the patient undergo an ultrasound examination of the 
heart in a local hospital to exclude serious pathology.
If serious pathology is suspected on the basis of the assessment of the referring physician, 
then the patient should obviously be referred to either an emergency department or 
directly to an appropriately qualified specialist.
Diagnosis
In a Marfan clinic, all diagnostic studies necessary for determining a diagnosis are 
performed in a single day (or part of). In practice, this means: (family)history and physical 
examination by the clinical geneticist, and examination by a (paediatric)cardiologist 
and ophthalmologist. Upon adequate suspicion, a blood sample is taken by the clinical 
geneticist for DNA testing. Although in most cases the results of the DNA tests can be 
slow (months or longer), at the end of this first visit it is usually possible to provide a 
statement of the probability that the referred patient has Marfan syndrome. Preferably, 
this preliminary result is discussed with the patient by the coordinating physician at the 
end of the day of diagnosis, and confirmed by a letter within 2-4 weeks, with copies to the 
relevant specialists, referring doctor and GP.
The Marfan team coordinator/clinical geneticist draws definitive conclusions following 
receipt of the result of the DNA test. The patient is notified in a final interview and 
the check-up schedule at the Marfan clinic modified, if necessary. This is followed by 
confirmation in writing to the patient, GP and specialists involved.
If, based on clinical investigations, insufficient evidence is found for a diagnosis of Marfan 
syndrome, then alternative diagnoses should be considered; see “Differential Diagnosis”.
Section 15  Organisation of Care 
hoofdstuk 2.indd   117 19-04-13   09:27
Chapter 2  |  Practical clinical guidelines for the diagnosis and management of Marfan syndrome
118
Clinical assessment
See the section “Clinical assessment”. The frequency of clinical assessment is determined 
by the clinical findings. Clinical assessment of children preferably takes place on a single 
day, in a multidisciplinary setting, with specialists from the Marfan team. In practice, 
adults only see a cardiologist and, after cardiovascular surgery, a cardio-thoracic surgeon. 
Assessment by other specialists takes place only on indication. Clear local arrangements 
are needed for the transfer of a patient from a paediatric cardiologist to a cardiologist. It 
should be clear at what moment the cardiologist should call in a young person for the first 
check-up and there should be a clear, written handover. The transition from a paediatric 
cardiologist to a regular cardiologist is an appropriate moment to offer a young person 
an appointment with the genetic counsellor/coordinator. The genetic aspects can be 
discussed and the patient can be informed of the possibility of making an appointment 
with the clinical geneticist should there ever be a wish to start a family.
Treatment
See sections 6 to 8, in which special attention is devoted to drug treatment, aortic surgery 
and the treatment of musculoskeletal disorders. Treatment is the responsibility of the 
treating specialist.
Pregnancy and childbirth
See the section 12 “Pregnancy and Childbirth”. The clinical geneticist or coordinator of the 
Marfan team must tell patients that they should contact the coordinator should they wish 
to start a family, allowing a multidisciplinary treatment plan to be prepared in the case 
that the prospective mother has Marfan syndrome. With an already pregnant patient, this 
treatment plan should be prepared at the earliest possible stage of the pregnancy. The 
factors included are also listed in the checklist “Pregnancy and Marfan syndrome.” During 
pregnancy, the gynaecologist and the cardiologist are the primary responsible physicians.





















Dean, J.C. (2007). Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet 15, 724-
733.
Each Marfan team has a coordinator who may be contacted by Marfan patients and referring 
physicians. The coordinator’s contact details are known to patients and referring physicians.
Effort should be made to reach a clinical diagnosis of Marfan syndrome within 3 months of referral 
by the general practitioner.
It must be clear to referring physicians how and to whom the referral should be made; a clear link 
on the website of the University Hospital is recommended.
Check-ups are dictated by the abnormalities found.
During the transition from paediatric cardiologist to regular cardiologist, an appointment should be 
made with the clinical geneticist.
Pregnancy in a Marfan patient requires multidisciplinary care, coordinated by a gynaecologist and 
cardiologist.
Recommendations
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Section 16  Patient Information 
Introduction
In many cases, the first confrontation with a (possible) diagnosis of “Marfan syndrome” 
will provoke considerable uncertainty in a patient and/or in his or her immediate family. It 
is common that those familiar with the Internet almost immediately launch on a veritable 
treasure hunt using “Marfan” and “Marfan syndrome” as search terms. Fortunately, there 
is now so much useful and readily available information that this initial information 
hunger can be partly satisfied. However, translation of the general information found 
on the Internet to their personal situation still appears to be difficult for many patients, 
and brings with it uncertainty and an unclear picture of the status and future of life with 
Marfan syndrome.
The website of the Contactgroup Marfan Netherlands (www.marfansyndroom.nl) offers 
a wealth of accessible information on a wide range of subjects. The Contactgroup can be 
easily reached for all questions arising from the first confrontation with Marfan syndrome, 
using a variety of channels. When a patient requires “peer support”, the treating physician 
may refer him/her to the Contactgroup.
Diagnosis
It is clear that provision of information by the medical team regarding the process leading 
up to a final diagnosis can be of great importance to a patient. In addition to examination 
of the patient, examination of relatives may also be essential. Any advice is usually 
insufficient to remove (all) uncertainty in the patient and relatives, but it is usually possible 
to provide a more acceptable perspective.
It is important that patient information clearly explains the agreements between the 
medical team and the patient and/or family. This concerns both agreements on the 
specific roles of medical team members and the family doctor, and on the coordination 
of care. It is also important that the patient is aware of the length of time required to 
make the diagnosis. What can be expected from the medical team during the course of the 
diagnostic process, in terms of treatment and counselling, should also be clear. 





















During the course of the monitoring and treatment of a patient with Marfan syndrome, 
a phased, timely and targeted provision of advice, in everyday language, to the patient 
and/or the immediate family must remain a central priority of practitioners in the medical 
team.
The transition from “diagnosis” to “monitoring and treatment”
Just as in the diagnosis phase, the patient and/or relatives should be informed of 
agreements with the medical team practitioners. This is especially true if the team is 
different to that during the diagnosis phase. This concerns agreements on the specific 
roles of medical team members and the family doctor, and on the coordination of care. The 
patient must receive clear information on who the care coordinator is and who to approach 
during a specific course of treatment. What can be expected of the medical team during 
further stages, in terms of treatment and counselling, should also be clear. 
Regular check-ups
Due to cardiac problems, Marfan patients should receive regular check-ups (every six 
months to once every few years). It is desirable that patients and families, through targeted 
and timely information, remain aware of the need for regular assessment. Being able to 
rely on one coordinating individual in a research institute medical team or Marfan clinic is 
not only a clear desire of individual Marfan patients, but can also represent an important 
stimulus to medically appropriate monitoring and compliance. This contact person can 
also play a coordinating role in informing the patient of results of examinations.
Coordinating information on medical consequences
Marfan patients express a clear need for practical advice and information. Besides the 
obvious need for information on the implications of cardiac and eye diseases, there is 
certainly a need for information on the implications with respect to muscle problems, 
orthopaedic abnormalities, dural ectasia, lung defect(s) and impact on daily life. Practical 
advice on everyday life is especially important.
The above-mentioned coordinating contact individual in the medical team can play an 
essential role in providing information.
Advice on lifestyle 
In connection with cardiac and lung problems in Marfan patients, issues such as 
hypertension and smoking are important and require attention. The treating specialist can 
play a role by, for example, giving advice on lifestyle, by referral for help with stopping 
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smoking and/or treatment for hypertension. Advice on lifestyle is also possible with regard 
to ophthalmic and orthopaedic problems.
Sports advice (also see section 14)
The treating specialist may refer a patient to a sports physician if there is a desire for 
(intensive) sports participation. The sports physician can advise the patient on which 
branch of sport is suitable, based on an individual situation. It is recommended that the 
patient always seek the advice of a cardiologist before he/she actively participates in sport.
Psychosocial aspects
General
It can not be stressed enough that caregivers should pay special attention, in the form 
of advice, to the psychosocial aspects of Marfan syndrome. Due to the complexity of the 
symptoms, those aspects are often difficult for the patient to distinguish. An additional 
aggravation of the situation is represented by the incurable nature of Marfan syndrome. 
Despite the psychosocial burden of disease, the experience of the Dutch patient 
organisation suggests that Marfan patients are often very positive about life. 
Signals that may indicate excessive physical and/or psychological stress on the patient, his 
or her partner and/or family should be noted by the care coordinator. The care coordinator 
can help a patient by offering a listening ear and more practically, by referring the patient 
to a psychologist or social worker.
Incidentally, the family doctor also has an important to role play in identifying excessive 
psychosocial stress.
Young children, their parents and the family
The psychosocial care of young children with Marfan syndrome, their parents and the 
family receives considerable attention at out-patient clinics for Marfan children. In other 
situations, there is an urgent need to provide the parents with the necessary information. 
Regular feedback should be sought from the young Marfan patient and possibly from 
other children in the family.
Adolescence
Psychosocial problems, especially in (pre)adolescents, may result from the sometimes 
extreme height growth and the physical appearance, but may also be caused by the 
impact of treatments such as hormonal or surgical length reduction or cardiac surgery. 
Adolescents may become socially isolated, and adolescent rebellion can also lead to denial 




















of the importance of regular check-ups. The care coordinator should be aware that during 
contact with the patient in this particular life phase (approaching autonomy), special 
attention should be paid to providing information on and stressing the importance of 
check-ups and compliance, on providing lifestyle advice and confronting any psychosocial 
problems. Any problems that may arise in school (introduction of necessary adaptations to 
furniture and/or classroom aids, changes to gym lessons, necessary additional educational 
support) can be (partly) overcome by targeted advice by the treating physician. 
The transition from adolescence to adulthood requires that the care coordinator be 
prepared to provide extra attention and advice. 
The older Marfan patient (50+)
Information on the consequences of specific symptoms that the older patient with Marfan 
syndrome may face is desirable. This information should preferably be available at the 
regular (annual) check-ups, and should be provided by the care coordinator.
The partner of a Marfan patient
The partner of a Marfan patient can play an important role in the process of aftercare. 
It is desirable that a patient’s partner is involved in the provision of any advice. This is 
particularly the case if it appears that the partner exhibits a (great) need for psychosocial 
support and advice. 
Psychosocial support
A patient with Marfan syndrome will have adapt to circumstances, given the physical 
constraints that the disease entails. This can be expressed in the choice of further 
education, career or the distribution of a limited energy reserve over (daily) activities. Some 
patients also have problems with their appearance or may encounter misconceptions 
amongst those around them. Due to chronic fatigue and other symptoms caused by 
Marfan syndrome, the patient will have to regularly call on those around them.
The working environment
The working environment can reveal the limitations of Marfan patients (e.g. endurance, 
joint strength). To what extent the (working) environment should be informed of these 
limitations and their cause can be a serious dilemma for Marfan patients. In such situations, 
the specialist treating the patient can recommend consulting the family or company doctor 
for help and advice.
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Insurance
The specialist(s) treating a patient can provide further information to the insurance 
company doctor when a patient experiences problems taking out insurance.
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Providing Marfan patients with good advice during diagnosis, monitoring and treatment is 
essential to both the success of the medical care and well-being of patients. In the field of advice 
provision, the following recommendations can be made.
After diagnosis
-  Ask how the patient and/or family experienced the medical team’s approach in the phase prior to 
the diagnosis. 
- Assess to what extent the patient and relatives have processed and accepted the diagnosis. 
-  Ascertain whether the need for further investigations in the family is understood by the patient 
and relatives and whether sufficient explanation was given. 
During control and treatment:
- Introduce a single care coordinator to act as a contact for the patient and his/her parents. 
-  Make the patient aware of how responsibilities are divided amongst the treating specialists.  
In the event that a Marfan patient has a prosthetic valve or a valve abnormality, the patient 
should be made aware of the increased risk of endocarditis and that profylaxis for endocarditis 
is indicated. It is of great importance that paradontitis and caries be prevented. The dentist and/
or dental hygienist play an important role in providing advice. The NHG Endocarditis Profylaxis 
Guideline clarifies other circumstances under which profylaxis for endocarditis is indicated.
- Provide advice on lifestyle and sports advice, if relevant. 
- Pay special attention to psychosocial issues including: 
o Specific issues in relation to age; 
o Family and friends; 
o Employment and insurance.
Recommendations




















Appendix 1  Clinical Questions
Diagnostics
– What are the symptoms that indicate Marfan syndrome and which diagnostic test is 
appropriate? 
– What is the policy in relation to a newborn with a 50% risk of Marfan syndrome?
 
Differential Diagnosis 
– What alternative diagnoses should be considered and what are the criteria?
Family studies
– How should family studies be conducted, where, in which family member and at what 
moment? 
Pregnancy and childbirth
– What are the risks of pregnancy and childbirth in a patient with Marfan syndrome? 
– Type and frequency clinical assessment during pregnancy. 
– When and how should a birth take place?
Prenatal diagnosis/preimplantation diagnosis 




– Frequency and nature of clinical assessment, as applicable to both adults and children.
Treatment
– What is the effect of drug treatment on the dilatation of the aortic root? 
– What is optimal moment for preventive aortic surgery in adults/children?
– Can brace treatment, compared with the natural disease course, prevent surgical 
intervention? 
Lifestyle
– Does participation in (top)sport and certain other activities lead to greater complications? 
Patient information
– Which information is important for patients with Marfan syndrome?
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Appendix 2  Characteristics of Marfan Syndrome
    
       Gent II criteria             Gent I criteria
                         (Loeys et al, 2010)  (De Paepe A. et al, 1996)
Facial features     +    +
dolichocephaly     +    +
enophthlamos      +    +
downward slanting palpebral fissures   +    +
malar hypoplasia     +    +
retrognathia     +    +
high and narrow palate  −   -    +
dental crowding  −    -    +
long face  −  −    -    -
 
Skeletal features  
arachnodactyly (positive thumb and  wrist sign)  +    +
pectus carinatum     +    +
pectus excavatum      +    +
chest wall asymmetry    +    -
hindfoot deformity      +    +
pes planus     +    +
protrusio acetabuli     +    +
long arms and legs     +    +
reduced elbow extension    +    +
scoliosis       +    +
thoracolumbar kyphosis    +    +
joint hypermobility      -    +
umbilical sign     -    -
  
Cardiovascular features  
aortic root dilatation or dissection   +    +
mitral valve prolapse     +    +
tricuspid valve prolapse    -    -
pulmonary artery dilatation    -    -
aortic dilatation or dissection distally from 
the aortic root     -    -
Ophthalmologic features  
lens(sub)luxation      +    +
myopia      +    +
increased globe length    +    -
Hypoplasia of the  iris or ciliary muscle   +    -
corneal flattening      +    -
cataract      -    -
retinal tears     -    -
  
Family history  
first degree family member with 
Marfan syndrome     +    +
  
Other features  
pneumothorax     +    +
apical blebs     -    +
emphysema     -    -
dural ectasia     +    +
striae      +    +
Recurrent inguinal herniae    -    +
recurrent umbilical herniae    -    +
recurrent incisional herniae    -    +
reduced body muscle and fat    -    -
tall stature     -    -
+ feature is part of the criteria
- feature is not part of the criteria





















De Paepe, A., Devereux, R.B., Dietz, H.C., Hennekam, R.C., Pyeritz, R.E. (1996). Revised diagnostic 
criteria for the Marfan syndrome. Am J Med Genet 62, 417-426.
Loeys, B.L., Dietz, H.C., Braverman, A.C., Callewaert, B.L., De, .B.J, Devereux, R.B., Hilhorst-Hofstee, Y., 
Jondeau, G., Faivre, L., Milewicz, D.M., Pyeritz, R.E., Sponseller, P.D., Wordsworth, P., De Paepe, A.M. 
(2010). The revised Ghent nosology for the Marfan syndrome. J Med Genet 47, 476-485.
hoofdstuk 2.indd   127 19-04-13   09:27
Chapter 2  |  Practical clinical guidelines for the diagnosis and management of Marfan syndrome
128
Appendix 3  Summary of Focus Group Meeting
Five people participated in the Marfan guideline focus group, three of whom themselves 
have Marfan syndrome, two have a child with Marfan syndrome, and one Marfan 
patient also has a child with Marfan syndrome. Three patients provided a report of their 
experiences, based on a set of prepared questions. The age at which Marfan syndrome was 
discovered ranged from 3 to 60 years. Several patients lost immediate family members 
prior to diagnosis, probably due to the symptoms of Marfan syndrome. The rapidity of 
diagnosis varied widely, and seemed to particularly depend on the familiarity with Marfan 
syndrome of the attending physician. There is room for improvement regarding the 
familiarity of the medical profession with Marfan syndrome. 
The following points were discussed:
Communication and Marfan syndrome – have all the implications been clearly explained?
All participants expressed dissatisfaction with this aspect. The consequences for 
cardiology were clearly explained, and eye defects were explained briefly. However, the 
other abnormalities such as joint/muscle complaints, dural ectasia, lung disorders and 
implications for daily life received little or no explanation. The bulk of their knowledge was 
derived from the patient group website and from conversations with others with Marfan 
syndrome.
Have you heard about the do’s and don’ts of Marfan syndrome?
Some patients received no advice, others were told that they should avoid strenuous 
exercise and endurance sports. They all indicated that they have received some information 
regarding the theoretical risks, but feel that the translation into practical advice for 
everyday life is lacking. However, the individual circumstances of the patient should not be 
overlooked, and individual limitations will vary from person to person.
 
What is your experience of the organisation of care and the collaboration between 
disciplines? 
The patients were satisfied with the Marfan clinics in the Netherlands, and also preferred to 
be treated there. They did feel the lack of one central individual. Specialists give conflicting 
advice on what to do or what not to do.
How was the transition from paediatrician to several specialists in adulthood experienced? 
The transition from the safe environment of a children’s clinic to the anonymous, 




















impersonal environment of the adult clinic is a huge step. In the children’s clinic, you are 
called in as necessary, but as an adult you have to suddenly do everything yourself. They 
feel the lack of a transitional period in which children are guided towards independence 
as a patient, and they would like to see transition nurses integrated into the Marfan clinic.
What are the typical symptoms in an older Marfan patient?
The distinction between age-related and Marfan-related ailments is currently unclear to 
both doctors and patients. This is an issue that they would like to see researched.
What are the good points of care?
Everyone is very satisfied with the children’s clinics.
What are the main areas for improvement?
(Parents of) patients would also like to receive a copy of the letter sent to the GP following 
a visit to a specialist.
The cooperation between the specialists would be improved by appointing a single 
coordinator, generating the impression that there is an overview of all problems.
Some patients see a different ophthalmologist and cardiologist each time. Why can’t this 
just be the same each time?
Greater attention should be paid to complaints relating to body regions/organs other than 
the heart, so that the patient can be referred to another specialist, if necessary. Complaints 
are discussed but do not lead to sufficient action or are not taken seriously.
There is too little preparation prior to a consultation, even by interns. Perhaps doctors 
could prepare a summary of all important information from the medical files.
Just as in the children’s clinic, adults also prefer that all investigations take place on the 
same day, as much as possible. 
Are there any questions/points that have not been addressed?
The partners of Marfan patients play an important role in the aftercare, but now are not 
sufficiently involved. If the partner is present during a consultation, he or she can also help 
ensure that all necessary information is available, both during and after the consultation.
Improvements at a glance:
♦	 Improved information on what Marfan syndrome entails; the do’s and don’ts are not 
communicated consistently.
♦	 One central coordinator, above all specialists, is highly desirable.
♦	 Preferably - only treatment by doctors in a Marfan (outpatient) clinic.
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♦	 The transition from child to adult care is too abrupt. A transition nurse is necessary to 
smooth this transition. 
♦	 Patient’s partners should also be involved in the aftercare.
♦	 Improved syndrome recognition by ‘regular’ doctors; for example, via a magazine read 
by many doctors.
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Abstract
The diagnosis of Marfan syndrome (MFS) relies on defined clinical criteria (Ghent 
nosology), outlined by international expert opinion to facilitate accurate recognition of 
this genetic aneurysm syndrome and to improve patient management and counselling. 
These Ghent criteria, comprising a set of major and minor manifestations in different body 
systems, have proven to work well since with improving molecular techniques, confirmation 
of the diagnosis is possible in over 95% of patients. However, concerns with the current 
nosology are that some of the diagnostic criteria have not been sufficiently validated, or 
are not applicable in children or necessitate expensive and specialised investigations. The 
recognition of variable clinical expression and recently extended differential diagnosis are 
further confounding accurate diagnostic decision making. Moreover, the diagnosis of MFS 
- whether or not established correctly- can be stigmatising, hamper career aspirations, 
restrict life-insurance opportunities and cause psychosocial burden. 
An international expert panel has established a revised Ghent nosology, which puts 
more weight on the cardiovascular manifestations and in which aortic root aneurym 
and ectopia lentis are the cardinal clinical features. In absence of any family history, the 
presence of these two manifestations is sufficient for the unequivocal diagnosis of MFS. In 
absence of any of these two, the presence of a bonafide FBN1 mutation or a combination of 
systemic manifestations is required. For the latter a new scoring system has been designed. 
In this revised nosology, FBN1 testing, although not mandatory, has greater weight in the 
diagnostic assessment. Special considerations are given to the diagnosis of MFS in children 
and alternative diagnoses in adults.
We anticipate that these new guidelines may delay a definitive diagnosis of MFS but 
will decrease the risk of premature or misdiagnosis and facilitate worldwide discussion of 
risk and follow-up/management guidelines.





















Since Antoine-Bernard Marfan described the five-year-old Gabrielle with skeletal 
manifestations of the disease that now bears his name 1, important progress has been 
made in the delineation of the Marfan syndrome (MFS) and recognition of associated risks. 
The main features of this autosomal dominant disorder include disproportionate long 
bone overgrowth, ectopia lentis and aortic root aneurysm. In 1955, Victor McKusick first 
established a classification of connective tissue disorders, which resulted in the publication 
of his monograph ‘Heritable Connective Tissue Disorders’ 2, 3. In 1986, an international panel 
of experts defined a set of clinical criteria (Berlin nosology) for the diagnosis of Marfan 
syndrome (MFS) 4 with the aim of facilitating accurate communication about the condition 
between healthcare providers, researchers and patients. It was felt that this would improve 
proper patient management and effective patient counselling.
Following the identification of FBN1 (encoding fibrillin-1) as the causal gene for MFS 5 
it was recognised that the Berlin criteria falsely allowed a diagnosis of MFS in individuals 
with a positive family history of MFS, who had only nonspecific connective tissue findings 
themselves and who did not carry the mutation present in more typically affected 
family members. New diagnostic criteria were therefore put forth in 1996, referred to as 
the Ghent nosology 6. These Ghent criteria were more stringent than the Berlin criteria, 
mitigating over-diagnosis of MFS and providing better guidelines to differentiate MFS 
from related, ‘overlapping’ conditions such as the MASS phenotype (myopia, mitral valve 
prolapse, borderline and non-progressive aortic root dilatation, skeletal findings and striae) 
and mitral valve prolapse syndrome (MVPS). 
Since physicians associate the diagnosis of ‘Marfan syndrome’, above all else, with risk 
for aortic aneurysm/dissection, it can be detrimental to diagnose MFS in patients without 
tangible evidence of such risk. Avoidable consequences associated with misdiagnosis of 
MFS include: restriction of career aspirations or access to insurance benefits; additional 
financial burden associated with frequent medical care; anxiety or situational depression; 
unfounded marital or reproductive decisions; loss of health benefits or psychosocial 
stigmatisation associated with exercise restriction, a particularly important issue during 
childhood. The challenge is to balance such concerns with the paramount need to 
maintain good health through proper counselling and application of sound anticipatory 
medical practices. Toward this objective, it is also important to avoid the diagnosis of MFS 
when clinical or molecular observations could reveal alternative (and often more severe) 
diagnoses that mandate specialised counselling or management protocols.
The Ghent nosology employs a set of ‘major’ and ‘minor’ manifestations in numerous 
tissues including the skeletal, ocular, cardiovascular, and pulmonary systems and the dura, 
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skin and integument 6. Major manifestations include ectopia lentis, aortic root dilatation/
dissection, dural ectasia or a combination of ≥ 4 out of eight major skeletal criteria. The 
diagnosis of MFS in an index patient requires major involvement of at least two organ 
systems with minor involvement of a third organ system. In the presence of an mutation 
known to cause MFS or a first-degree relative who was unequivocally diagnosed based 
upon Ghent nosology, the presence of one major and one minor manifestation in different 
organ systems is sufficient to make the diagnosis. 
Current status of the Ghent nosology
The Ghent criteria have found worldwide application in helping physicians to diagnose 
MFS appropriately. New molecular techniques allow the detection of FBN1 mutations 
in up to 97% of Marfan patients who fulfill the Ghent criteria 7, 8. This suggests that the 
current Ghent criteria have excellent specificity to identify patients with FBN1 mutations. 
Consideration of sensitivity is highly complex due to varying definitions of the ‘target’ 
population and competing clinical priorities. For example, the current criteria have been 
criticised for taking insufficient account of the age-dependent nature of some clinical 
manifestations (making the diagnosis in children more difficult) 9 and for including some 
rather nonspecific physical manifestations or poorly validated diagnostic thresholds. 
Although the assignment of major and minor criteria within the Ghent nosology has 
contributed to its utility, several of those criteria are not intuitive when considered from 
the perspective of the differential diagnosis or patient management. Consideration of the 
diagnosis of familial ectopia lentis is particularly illustrative of the prevailing issues. This 
diagnostic category has been widely applied for individuals and families that show lens 
dislocation and skeletal features of MFS but do not show aortic enlargement or dissection. 
FBN1 mutations are seen in familial ectopia lentis and are not easily distinguished from 
those causing MFS on the basis of character or location within the gene – suggesting either 
occult phenotype-genotype correlations or the influence of modifiers. 
The Ghent nosology clearly attempted to accommodate the fact that some people with 
ectopia lentis, skeletal findings and even FBN1 mutation have less cardiovascular risk (i.e. 
risk to the aortic root) than seen in classic MFS, by allowing the diagnosis of familial ectopia 
lentis in the absence of a second major Marfan manifestation. However, inadequate 
data were available to evaluate the critical issue of whether cardiovascular risk could be 
predicted by the presence of non-cardiac features, such as dural ectasia or major versus 
minor skeletal involvement. At the other extreme, is it justified not to diagnose MFS in 
someone with typical lens dislocation and aortic root enlargement simply because they 
lack minor skeletal or skin findings? To address some of these issues, an international 
panel (see acknowledgement) of experts in the diagnosis and management of MFS was 




















convened in Brussels, Belgium by the National Marfan Foundation (USA) and charged 
with considering modifications to the Ghent criteria. Other factors under consideration 
included the specialised nature, availability and cost of diagnostic tests for selected 
manifestations (eg, dural ectasia), the need to better define certain diagnostic categories 
better (eg, familial ectopia lentis, MASS phenotype10 and MVPS), to define features that 
should trigger alternative diagnoses and a desire to complement diagnostic criteria with 
follow-up and management guidelines for various patient groups including children who 
do not yet fulfill the diagnostic criteria but may do so in the future.
Proposal for New Nosology
This proposal for a revised nosology (box 1) was based on critical review of clinical 
characteristics in large published patient cohorts 7, 8, 11, 12, and expert opinions of the panel 
members with extensive experience in applying the current criteria, the differential 
diagnosis of MFS and the strengths and limitations of molecular genetic testing. Several 
guiding principles were followed: maximal use of evidence-based decision making; 
attention to practical (patient centric) implications; a focus on features and criteria that 
distinguish MFS from other disorders and definition of purposeful thresholds for diagnosis. 
As a result, five major changes in the diagnostic guidelines are proposed. 
First, more weight is given to two cardinal features of MFS, aortic root aneurysm/
dissection and ectopia lentis. In the absence of findings that are not expected in MFS, the 
combination of ectopia lentis and aortic root enlargement/dissection should be sufficient 
to make the diagnosis. All other cardiovascular and ocular manifestations of MFS and 
findings in other organ systems, such as the skeleton, dura, skin and lungs, contribute to 
a ‘systemic score’ (box 2) that guides diagnosis when aortic disease is present but ectopia 
lentis is not. 
Second, a more prominent role is assigned to molecular genetic testing of FBN1 and 
other relevant genes (eg, TGFBR1 and 2), as well as other genes indicated in table 1. In 
practice, this does not make FBN1 testing a formal requirement (which imposes financial 
burden in some countries, and does not yet have 100% sensitivity and specificity), but 
allows its appropriate use when available. 
Third, some of the less specific manifestations of MFS were either removed or made 
less influential in the diagnostic evaluation of patients. This avoids the use of obligate 
thresholds that lack clear validation or general availability.
Fourth, the new criteria formalise the concept that additional diagnostic considerations 
and testing are required if a patient has sufficient findings to satisfy the criteria for MFS 
but also shows unexpected findings, particularly if they segregate with disease in the 
family or if they are suggestive of a specific alternative diagnosis. Particular emphasis 
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is placed on Sphrintzen-Goldberg syndrome (SGS), Loeys-Dietz syndrome (LDS) and the 
vascular form of Ehlers-Danlos syndrome (vEDS). SGS and LDS have substantial overlap 
with MFS, including the potential for similar involvement of the skeleton, aortic root, skin 
and dura (table 1). Occasionally, vEDS can show overlap in the vascular system, dura, skin 
and skeleton. It is essential to consider discriminating features (table 1) because each of 
these conditions has a unique risk profile and management protocol.
Finally, this nosology should help to allay concerns regarding delayed or ambiguous 
diagnoses by providing context specific recommendations for patient counselling and 
follow-up.
In the absence of family history:
(1) Ao (Z≥2) AND EL = MFS*
(2) Ao (Z≥2) AND FBN1 = MFS
(3) Ao (Z≥2) AND Syst (≥7pts) = MFS*
(4) EL AND FBN1 with known Ao = MFS
EL with or without Syst AND with an FBN1 not known with Ao or no FBN1 = ELS
Ao (Z< 2) AND Syst (≥5 with at least one skeletal feature)without EL = MASS
MVP AND Ao (Z<2) AND Syst (<5) without EL = MVPS
In the presence of family history:
(5) EL AND FH of MFS (as defined above) = MFS
(6) Syst (≥7 pts) AND FH of MFS (as defined above) = MFS*
(7) Ao (Z≥2 above 20 yrs old, ≥3 below 20 yrs) + FH of MFS (as defined above) = MFS* 
*  Caveat: without discriminating features of SGS, LDS or vEDS (as defined in table 1) AND after 
TGFBR1/2, collagen biochemistry, COL3A1 testing if indicated. Other conditions/genes will emerge 
with time 
Ao, aortic diameter at the sinuses of valsalva above indicated Z-score or aortic root dissection; 
EL, ectopia lentis; ELS, ectopia lentis syndrome; FBN1, fibrillin-1 mutation (as defined in box 3); 
FBN1 not known with Ao, FBN1 mutation that has not previously been associated aortic root 
aneurysm/dissection; FBN1 with known Ao, FBN1 mutation that has been identified in an 
individual with aortic aneurysm; MASS,  
myopia, mitral valve prolapse, borderline (Z<2) aortic root dilatation, striae, skeletal findings 
phenotype; MFS, Marfan syndrome; MVPS = mitral valve prolapse syndrome; Syst, systemic score 
(see box 2); Z,  Z-score.
Box 1  Revised Ghent criteria for Diagnosis of Marfan syndrome and Related conditions




















In the revised nosology, new diagnostic criteria have been defined for a sporadic patient 
and for an index patient with a positive family history (box 1). In the absence of a conclusive 
family history of MFS, the diagnosis can be established in four distinct scenarios:
1.   The presence of aortic root dilatation (Z-score ≥2 when standardised to age and body size) 
or dissection 13 and ectopia lentis allows the unequivocal diagnosis of MFS, irrespective 
of the presence or absence of systemic features except where these are indicative of 
SGS, LDS or vEDS (table 1). 
2.   The presence of aortic root dilatation (Z≥2) or dissection and the identification of a bona 
fide FBN1 mutation (box 3) are sufficient to establish the diagnosis even when ectopia 
lentis is absent. An overview of criteria that enhance confidence in the pathogenetic 
potential for MFS of particular FBN1 mutations is provided in box 3. These include 
missense mutations that substitute or create cysteine residues, alter one of the 
conserved residues important for calcium binding in epidermal growth factor-like (EGF) 
domains, create a premature termination codon (nonsense mutations), delete or insert 
coding sequence, or disrupt the consensus sequence for pre-mRNA splicing. Evidence 
for pathogenicity of other types of missense mutations would include its absence in at 
least 400 ethnically-matched control chromosomes and co-segregation with disease 
in the family, or de novo occurrence in a sporadic case (with confirmation of paternity). 
}  Wrist AND thumb sign – 3 (Wrist OR thumb sign – 1)
}  Pectus carinatum deformity – 2 (pectus excavatum or chest asymmetry – 1)
}  Hindfoot deformity – 2 (plain pes planus – 1)
}  Pneumothorax – 2
}  Dural ectasia – 2
}  Protrusio acetabuli – 2
}  Reduced US/LS AND increased arm/height AND no severe scoliosis – 1
}  Scoliosis or thoracolumbar kyphosis – 1
}  Reduced elbow extension – 1
}   Facial features (3/5) – 1 (dolichocephaly, enophtalmos, downslanting palpebral fissures, malar  
hypoplasia, retrognathia)
}  Skin striae – 1
}  Myopia > 3 diopters – 1
}  Mitral valve prolapse (all types) – 1
Maximum total: 20 points; score ≥7 indicates systemic involvement; US/LS, upper segment/ 
lower segment ratio.
Box 2  Scoring of systemic features
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Definitive evidence of linkage to a predisposing FBN1 haplotype can substitute for an 
FBN1 mutation for diagnostic purposes but this linkage analysis requires at least six 
informative meioses in the patient’s family to confirm the MFS-associated FBN1 allele. 
The absence of a mutation in the  FBN1 gene despite complete screening is possible in 
MFS.
}  Mutation previously shown to segregate in Marfan family
}   De novo (with proven paternity and absence of disease in parents) mutation (one of the five  
following categories)
}  Nonsense mutation
}  Inframe and out of frame deletion/insertion
}   Splice site mutations affecting canonical splice sequence or shown to alter splicing on mRNA/
cDNA level
}  Missense affecting/creating cysteine residues
}   Missense affecting conserved residues of the EGF consensus sequence ((D/N)X(D/N)(E/Q)
Xm(D/N)Xn(Y/F) with m and n representing variable number of residues; D aspartic acid, N 
asparagine, E glutamic acid, Q glutamine, Y tyrosine, F phenylalanine)
}   Other missense mutations: segregation in family if possible + absence in 400 ethnically  
matched control chromosomes, if no family history absence in 400 ethnically matched  
control chromosomes
}  Linkage of haplotype for n≥6 meioses to the FBN1 locus
Box 3  Criteria for causal FBN1 mutation
3.   Where aortic root dilatation (Z≥2) or dissection is present but ectopia lentis is absent 
and the FBN1 status is either unknown or negative, a MFS diagnosis is confirmed by 
the presence of sufficient systemic findings (≥7 points, according to a new scoring 
system) (box 2) confirms the diagnosis. However, features suggestive of SGS, LDS or 
vEDS must be excluded and appropriate alternative genetic testing (TGFBR1/2, collagen 
biochemistry, COL3A1, and other relevant genetic testing when indicated and available 
upon the discovery of other genes) should be performed. 
4.   In the presence of ectopia lentis but absence of aortic root dilatation/dissection, the 
identification of an FBN1 mutation previously associated with aortic disease is required 
before making the diagnosis of MFS. If  the  FBN1 mutation is not unequivocally associated 
with cardiovascular disease in either a related or unrelated proband, the patient should 
be classified as ‘ectopia lentis syndrome’ (see differential diagnosis).




















In an individual with a positive family history of MFS (where a family member has been 
independently diagnosed using the above criteria), the diagnosis can be established in the 
presence of ectopia lentis, or a systemic score ≥7 points or aortic root dilatation with Z≥2 in 
adults (≥ 20 years old) or Z≥3 in individuals <20 years old.
Special consideration should be given to young individuals (<20 years old). In sporadic 
cases, these children may not fit in one of the four proposed scenarios. If insufficient 
systemic features (<7) and/or borderline aortic root measurements (Z<3) are present 
(without FBN1 mutation), we suggest to use the term ‘non-specific connective tissue 
disorder’ until follow-up echocardiographic evaluation shows aortic root dilation (Z≥3). If 
an FBN1 mutation is identified in sporadic or familial cases but aortic root measurements 
are still below Z=3, we propose to use the term ‘potential MFS’ until the aorta reaches 
threshold. Neonatal MFS is not considered as a separate category, but rather represents 
the severe end of the MFS spectrum.
In adults (>20 yrs), we define three main categories of alternative diagnoses: ectopia 
lentis syndrome (ELS), MASS phenotype (myopia, mitral valve prolapse, aorta, skin and 
skeletal findings), mitral valve prolapse syndrome (MVPS) (see differential diagnosis).
Finally, we recognise that some patients will remain difficult to classify due to overlap of 
phenotypes from different entities, the evolving nature of these connective tissue diseases, 
absence of mutation after screening of the appropriate genes or divergence between the 
phenotype and the genotype. However, these patients should be uncommon and will 
hopefully benefit from better definition of still unrecognised phenotypes in the future. 
Organ system specific considerations 
Cardiovascular Criteria
A key diagnostic criterion in the new nosology is aortic root aneurysm or dissection. Aortic 
root aneurysm is defined as enlargement of the aortic root at the level of the sinuses of 
Valsalva. Aortic root measurements should be done parallel to the plane of the aortic valve 
and perpendicular to the axis of blood flow. The largest correctly measured root diameter 
obtained from at least three transthoracic images should be corrected for age and body 
size and interpreted as a Z-score. There are varying practices regarding whether root 
measurements should be done in systole or diastole and whether the thickness of one 
aortic wall should be included (ie, the leading edge to leading edge method). The method 
employed must match that used to generate the normative data for Z-scores to be valid. 
For echocardiographic measurements made from inner wall to inner wall during systole in 
individuals ≤25 years, a convenient Z-score calculator can be found at www.marfan.org. 
For echocardiographic measurements made from leading edge to leading edge in diastole 
in all age groups, reference graphs and Z-score equations are available 13 . If transthoracic 
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echocardiographic evaluations do not allow precise visualisation of the proximal aorta, 
transoesophageal echocardiography or CT or MRI imaging should be applied, with special 
attention to using double-oblique images to obtain correct diameter measurements and 
use of the same nomograms 14.  
Mitral valve prolapse is also a common finding in MFS and is included as a feature in the 
systemic score. Mitral valve prolapse should be defined by echocardiography as protrusion 
of one or both of the mitral valve leaflets across the plane of the mitral annulus during 
systole. This is best detected in parasternal long axis or apical long axis three-chamber or 
two-chamber views. There are no special criteria for diagnosing MVP in MFS and standard 
practices should be applied 15.
Pulmonary artery (PA) dilation (eg, main PA diameter >23 mm in adults) 16 is often seen in 
MFS, but it is not specific to this diagnosis. In addition, complications of pulmonary artery 
disease occur rarely. PA dilation was not therefore included in the systemic score because 
further research is needed regarding thresholds and the diagnostic utility of this finding. 
Patients with MFS can develop aortic enlargement or dissection at segments distant 
from the aortic root. The frequency of this finding (particularly at the proximal descending 
thoracic aorta and in the abdomen) appears to be increasing with the prolonged survival 
due to improved management of disease at the aortic root. While descending aortic 
aneurysm or dissection in the absence of aortic root enlargement can occur in Marfan 
syndrome, 17, 18 this is rare and given the low specificity of this finding for MFS, this finding 
is not included in the diagnostic criteria. Intermittent imaging of the descending thoracic 
aorta is indicated in adult patients where there is a clinical suspicion of Marfan syndrome 
in the absence of aortic root enlargement. Widespread vascular disease is more common 
with other conditions in the differential diagnosis, such as vascular EDS and LDS. For 
example, systemic vascular imaging (head to pelvis) is recommended if there is a suspicion 
of LDS because of the high frequency of tortuosity, aneurysms and dissections throughout 
the vascular tree.
Ocular criteria
The most prominent ocular features of MFS are myopia and ectopia lentis. The diagnosis 
of ectopia lentis is based on slit-lamp examination after maximal dilatation of the pupil. 
Ectopia lentis reflects failure of supporting structures called ciliary zonules.  Dislocation of 
the lens in MFS is most typically upward and temporal but is not specific as deviation in 
any direction may occur. If lens subluxation is deemed equivocal or minimal, manifesting 
only as a scalloped or ruffled lens margin at extremes of gaze, the eye exam should be 
repeated later before a definitive diagnosis of ectopia lentis can be made (such findings 
can occur outside the context of MFS, eg, in individuals with high myopia).  Increased globe 




















length and corneal flattening are seen in MFS, but they have unclear specificity and are 
not routinely measured by ophthalmologists.  Given that myopia is very common in MFS, 
is routinely monitored, and tends to show early onset, high severity and rapid progression, 
myopia of > 3 diopters contributes to the systemic score for diagnosis. However, since 
myopia is quite common finding in the general population we have only attributed one 
point to it in the systemic score.
Systemic criteria
Clinical manifestations of MFS in other organ systems were critically evaluated for their 
specificity and diagnostic utility based on expert opinion and the available literature. 
Several of the ‘minor’ criteria from the old Ghent nosology were eliminated, but the most 
selective systemic features were included in the ‘systemic score’. 
Three points are assigned to the combination of wrist and thumb signs.  The thumb sign 
is positive when the entire distal phalanx of the adducted thumb extends beyond the ulnar 
border of the palm with or without the assistance of the patient or examiner to achieve 
maximal adduction. The wrist sign is positive when the tip of the thumb covers the entire 
fingernail of the fifth finger when wrapped around the contralateral wrist. If either of the 
two signs is absent, only one point is assigned.
Two points were assigned to each of five other specific systemic manifestations 
including anterior chest deformity, hindfoot deformity, spontaneous pneumothorax, dural 
ectasia and acetabular protrusion. Pectus carinatum is believed to be more specific for MFS 
than pectus excavatum and is assigned two points. Subjective qualifiers in the original 
Ghent criteria such as ‘requiring surgery’ have been eliminated but the examiner should 
be confident that a positive finding (pectus excavatum or chest wall asymmetry) extends 
beyond normal variation of chest contour in the general population before assigning 
one point.  Hindfoot valgus 19 (two points) in combination with forefoot abduction and 
lowering of the midfoot (previously referred to as medial rotation of the medial malleolus) 
should be evaluated from anterior and posterior view. The examiner should distinguish 
this from the more common ‘flat foot’ (one point) without significant hindfoot valgus. As 
in the past, any spontaneously-occurring pneumothorax remains a diagnostic feature. For 
the detection of lumbosacral dural ectasia, no preferred method (CT or MRI) or uniformly 
accepted cut-offs have emerged from the literature 20-23 and local standards should apply. 
Dural ectasia is a sensitive but not a specific sign of MFS and, as such, is no longer considered 
on equal footing with lens dislocation or aortic root enlargement.  It is commonly seen 
in Loeys-Dietz syndrome and has been described in mutation proven vEDS. Finally, an 
additional technical exam for detection of acetabular protrusion 24 can be helpful but is 
not mandatory: classical X-ray, CT or MRI can be used. On an X-ray anterior-posterior pelvis 
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angle, the medial protrusion of the acetabulum above 3 mm beyond the ilio-ischial (Kohler) 
line is diagnostic. Criteria on CT or MRI are not precisely defined but involve loss of the 
normal oval shape of the pelvic inlet at the level of the acetabulum. 
One point is assigned to eight other manifestations, one cardiovascular (mitral valve 
prolapse), one ocular (myopia, ≥3 diopters) and six features from other organ systems. 
These are considered less specific features for MFS and can be observed in other connective 
tissue disorders or as normal variation in the general population 18.
The combined presence of reduced upper segment to lower segment (US/LS) ratio 
(for white adults <0.85; <0.78 in black adults; no data have been assessed in Asians) and 
increased arm span to height ratio (for adults >1.05) in the absence of significant scoliosis 
contributes one point to the systemic score. In Asians the incidence of an enlarged armspan 
to height ratio in Marfan patients was noted to be lower 25 and prior studies of Asian (and 
also Afro-Caribbean) populations demonstrated different distributions of arm span and 
height, so one should consider these ethnic differences when using cut-off values 26. For the 
US/LS ratio in children, abnormal ratios are US/LS < 1 (for age 0-5 yrs), US/LS < 0.95 (for 6-7 
yrs), US/LS < 0.9 (8-9 yrs old) and < 0.85 (above age 10 yrs).The lower segment is defined as 
the distance from the top of the symphysis pubis to the floor in the standing position and 
the upper segment is the height minus the lower segment. Importantly, neither of these 
ratios provides an accurate measurement of bone overgrowth in the presence of severe 
scoliosis or kyphosis. Scoliosis 27 can be diagnosed either clinically if, upon bending forward, 
a vertical difference of least 1.5 cm between the ribs of the left and right hemithorax is 
observed or if a Cobb’s angle (angle between a line drawn along the superior end plate 
of the superior end vertebra and a second line drawn along the inferior end plate of the 
inferior end vertebra of the scoliosis measured on anterior-posterior view of the spine) of 
at least 20° is seen on radiographs. In the absence of scoliosis, one point can be contributed 
by the presence of an exaggerated thoracolumbar kyphosis. Elbow extension is considered 
reduced if the angle between the upper and lower arm measures 170° or less upon full 
extension. One point can be assigned based upon facial characteristics if the patient shows 
at least three of the five typical facial characteristics including dolichocephaly, downward 
slanting palpebral fissures, enophthalmos, retrognathia and malar hypoplasia. Striae 
atrophicae are considered significant as a diagnostic feature if they are not associated with 
marked weight changes (or pregnancy) and if they have an uncommon location such as the 
mid-back, lumbar region, the upper arm, axillary region or thigh. 
The following criteria were removed from the current nosology because of lack of 
perceived specificity: joint hypermobility, highly arched palate, and recurrent or incisional 
herniae 18.





















Several conditions have been recognised which present overlapping clinical manifestations 
with MFS in the cardiovascular, ocular or skeletal systems. These include conditions with 
aortic aneurysms (LDS, bicuspid aortic valve, familial thoracic aortic aneurysm, vEDS, 
arterial tortuosity syndrome), ectopia lentis (ectopia lentis syndrome, Weil-Marchesani 
syndrome, homocystinuria, Stickler syndrome) or systemic manifestations of MFS 
(Shprintzen-Goldberg syndrome, congenital contractural arachnodactyly, LDS, MASS 
phenotype (myopia, mitral valve prolapse, aorta, skin and skeletal findings) and MVPS 
(mitral valve prolapse syndrome) (table 1). 
Table 1.  Features of differential diagnosis
Table 1. Features of differential diagnosis.
Differential diagnosis Gene Discriminating features
Loeys-Dietz syndrome (LDS) TGFBR1/2 Bifid uvula/cleft palate, arterial tortuosity, hypertelorism, 
diffuse aortic and arterial aneurysms, craniosynostosis, club 
foot, cervical spine instability, thin and velvety skin, easy 
bruising 
Shprintzen-Goldberg syndrome (SGS) FBN1 and other Craniosynostosis, mental retardation
Congenital arachnodactyly syndrome (CCA) FBN2 Crumpled ears, scoliosis, contractures
Weill-Marchesani syndrome (WMS) FBN1 and ADAMTS10 Microspherophakia, brachydactyly, joint stiffness
Ectopia lentis syndrome (ELS) FBN1
LTBP2
ADAMTSL4
Lack of aortic root dilatation
Homocystinuria CBS Thrombosis, mental retardation
Familial thoracic aortic aneurysm syndrome (FTAA)
FTAA with bicupid aortic valve (BAV)
FTAA with patent ductus arteriosus (PDA)
TGFBR1/2, ACTA2
MYH11
Lack of marfanoid skeletal features, levido reticularis, iris 
flocculi
Arterial tortuosity syndrome (ATS) SLC2A10 Generalised arterial tortuosity, arterial stenosis, facial 
dysmorphism
Ehlers-Danlos syndromes (vascular, valvular, 
kyphoscoliotic type)
COL3A1, COL1A2, PLOD1 Middle sized artery aneurysm, valvular insufficiency, 
translucent skin, dystrophic scars, scoliosis, facial 
characteristics
Conditions with cardiovascular features of MFS 
Historically the terms MASS phenotype and MVPS (mitral valve prolapse syndrome) have 
been used but several issues about the use of these terms have arisen. First, the definition 
of the MASS phenotype is not unequivocally applicable as it required at least two, but 
preferably three of the following manifestations: myopia, mitral valve prolapse, borderline 
aortic root enlargement, skin and minor skeletal features (insufficient to fulfill the major 
skeletal criterion of the original Ghent nosology) 6. 
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This definition indirectly also assumes a non-progressive nature of the aortic root 
dilatation but it is currently unknown to what proportion of patients this applies. Third, 
FBN1 mutations have been found occasionally in MASS phenotype patients 18, 28 but the 
precise risk for the development of aortic aneurysm and progression for these patients 
is poorly studied. Analogous to the ectopia lentis syndrome, the spirit of the definition of 
MASS phenotype aims to avoid the diagnosis of MFS without documented risk for aortic 
root aneurysm development. The diagnosis of MASS is made in individuals with an aortic 
root size below Z=2, at least one skeletal feature and a systemic score ≥5. The presence of 
ectopia lentis precludes this diagnosis. If an FBN1 mutation is identified in a MASS patient, 
this patient has the potential to evolve into MFS but it is currently unknown how often and 
which factors predict this transition over time. 
Alternatively, when mitral valve prolapse is present in association with limited systemic 
features (score < 5), we suggest to use the term mitral valve prolapse syndrome (MVPS). 
MVPS is a common condition usually inherited in autosomal dominant mode 29 with several 
candidate gene loci 30 but with evidence for rare X-linked inheritance 31 which affects ~1.5% 
of the population. In addition to prolapse of the mitral leaflets, MVPS commonly includes 
pectus excavatum, scoliosis and mild arachnodactyly 32. However, aortic enlargement and 
ectopia lentis preclude this diagnosis.
Loeys-Dietz syndrome (LDS) is an autosomal dominant aortic aneurysm syndrome 
characterised by the triad of hypertelorism, bifid uvula/cleft palate, and/or arterial 
tortuosity with ascending aortic aneurysm/dissection. It is caused by heterozygous 
mutations in the genes encoding the type 1 or 2 subunit of the transforming growth factor-β 
receptor (TGFBR2 or TGFBR2) 33. Other more variable clinical features that distinguish LDS 
from MFS include craniosynostosis, Chiari malformation, club foot deformity, congenital 
heart disease, cervical spine instability, easy bruising, dystrophic scarring, translucent skin 
and, most importantly, a high risk of aneurysm and dissection throughout the arterial tree. 
Patients with LDS are not typically inappropriately tall and do not exhibit disproportionally 
long extremities, although arachnodactyly is observed. Some patients with TGFBR1/2 
mutations lack overt craniofacial features despite an equal or greater severity of vascular 
or systemic findings. Importantly, the natural history of patients with LDS tends to be 
more aggressive than those with MFS or vEDS. In LDS, aortic dissections often occur at a 
younger age or at smaller aortic dimensions (<40 mm) compared to MFS, and the incidence 
of pregnancy-related complications is particularly high 34. As with FBN1 mutations, the 
phenotype associated with TGFBR1/2 mutations can be variable, even within families, and 
can be associated with skeletal features of MFS leading to overlapping phenotypes in the 
old Ghent nosology 35-37. In order to avoid persistent ambiguity even under the proposed 
criteria, molecular testing should be strongly considered because it influences the clinical 




















management 34. It has been proposed that patients with TGFBR1/2 mutations that lack 
outward discriminating features of LDS should be designated LDS2, highlighting the 
potential for more aggressive vascular disease than seen in Marfan syndrome (MIM 190181 
and 190182).
With a population prevalence of up to 1% 38, 39, bicuspid aortic valve (BAV) is the most 
common congenital cardiac malformation. A subset of individuals with BAV present 
with ascending aortic aneurysm, however such patients usually lack ocular or other 
systemic findings that contribute strongly to MFS diagnosis. Skeletal findings such as 
pectus deformity and scoliosis can be observed in these families. Bicuspid aortic valve 
and aortic aneurysm can occur together in some family members but independently 
in others, indicating that they can be variably penetrant consequences of a common 
underlying genetic defect 40, 41. Unlike MFS this condition commonly shows maximal or 
exclusive dilatation in the ascending aorta above the sinotubular junction 42. Mutations 
have been identified in the NOTCH1 and KCNJ2 genes, but these account for only a small 
fraction of BAV patients, who may have prominent valve calcification or associated forms 
of congenital heart disease. Linkage analysis reveals genetic heterogeneity with putative 
loci on chromosomes 18q, 5q and 13q 43.
Familial thoracic aortic aneurysm syndrome dissection syndrome (FTAAD) is a 
clinically and genetically heterogeneous group of disorders where thoracic aortic 
disease predominates. The age of onset and rate of progression of aortic dilatation is 
highly variable and conditions that include variable or subtle systemic manifestations 
of a connective tissue disorder have been included in this designation. It is anticipated 
that future stratification of patients by genetic etiology will help to refine phenotypic 
descriptions and inform patient counselling and management. To date, there are five 
genes and two additional loci 44, 45 associated with FTAAD Mutations have been identified 
in FBN1, TGFBR1/2, MYH11, and ACTA2, the latter two encoding components in the smooth 
muscle cell contractile apparatus. Mutations in MYH11 associate aortic root aneurysms 
with patent ductus arteriosus (PDA) 46. Mutations in ACTA2, accounting for up to 16% of 
FTAAD, associate aortic aneurysm with other variable features including iris flocculi, livedo 
reticularis, cerebral aneurysm, bicuspid aortic valve and PDA 47. In addition to thoracic aortic 
aneurysms and dissections, patients with ACTA2 mutations can present with vascular 
disease in the cerebrovascular system (premature ischemic strokes, Moyamoya disease 
and cerebral aneurysms) or premature coronary artery disease 48
The vascular type of EDS (previously EDS IV), is caused by mutations in COL3A1, the gene 
encoding type III collagen; it is characterized by vascular and tissue fragility. Cardinal features 
distinguishing vEDS from MFS include translucent skin, easy bruising, dystrophic scarring 
and a tendency for intestinal or uterine rupture. Typically, dissection or rupture occurs in 
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medium sized arteries in vEDS although aortic involvement is sometimes observed. There 
is no particular predisposition at the aortic root. About half of the aneurysms/dissections 
occur in thoracic or abdominal branch arteries; arteries of the head, neck and limbs are less 
frequently involved 49. 
Three other rare types of Ehlers-Danlos syndrome have been associated with 
vascular problems. The kyphoscoliotic type (previously type VI EDS) is characterised by 
kyphoscoliosis, joint laxity, and muscle hypotonia. This autosomal recessive condition is 
caused by defects in the enzymatic activity of lysyl hydroxylase, encoded by the PLOD1 
gene. Aortic dilation/dissection and rupture of medium-sized arteries have been observed 
50. Patients with the so-called ‘cardiac valvular subtype of EDS’, which associates severe 
cardiac valvular problems and features of the classic type of EDS (atrophic scars, skin 
hyperelasticiy and joint hypermobility), were found to have a complete deficiency of the 
proα2-chain of type I collagen (COL1A2) 51. Most recently, patients with arginine to cysteine 
substitutions in the proα1-chain of type I collagen (COL1A1) displayed classic EDS but evolved 
to a vascular EDS-like phenotype later in life, with increased risk for spontaneous arterial 
rupture, most prominently affecting the femoral and iliac arteries 52.
Arterial tortuosity syndrome (ATS) is a rare autosomal recessive connective tissue 
disorder, characterised by severe tortuosity, stenosis, and aneurysms of the aorta and 
medium-sized arteries 53. Skeletal and skin involvement is common. The underlying genetic 
defect is homozygosity or compound heterozygosity for loss-of-function mutations in 
SLC2A10, the gene encoding the facilitative glucose transporter GLUT10 54. The condition is 
lethal in infancy in a subset of patients but some survive into adulthood and seem to do 
well 55.
Conditions with ectopia lentis 
Patients with familial ectopia lentis typically have some skeletal features of MFS and an 
FBN1 mutation. While lack of aortic disease is a defining feature of this condition, it may 
be difficult to distinguish from emerging MFS in the absence of other affected family 
members or at a young age. Even within extended pedigrees with familial ectopia lentis, 
later onset aortic aneurysm may be observed. In order to highlight the systemic nature of 
this condition better and to emphasise the need for assessment of features outside the 
ocular system, we propose the designation ectopia lentis syndrome (ELS). The presence of 
a personal or family history of aortic aneurysm or the identification of an FBN1 mutation 
previously associated with aortic aneurysm would be sufficient to transition the diagnosis 
to MFS, independently of the number or distribution of systemic features. To ensure that 
adequate vigilance of other organ systems is maintained, the diagnosis of ELS cannot be 
formally invoked before the age of 20 years. The disorder is genetically heterogeneous, 




















with autosomal dominant inheritance caused by FBN1 mutations 56 and recessive forms 
caused by LTBP2 and ADAMTSL4 mutations 57, 58. Importantly, in ELS patients with FBN1 
mutations, cardiovascular follow-up by imaging should be maintained throughout life.
Ectopia lentis can be present as a component of other rare conditions. Ectopia lentis et 
pupillae is an autosomal recessive condition in which remnants of the pupillary membrane 
are present. However, it is not associated with cardiovascular or skeletal features of MFS.
In contrast to Weill-Marchesani syndrome (WMS), the lens dislocation is typically 
associated with microspherophakia (small, rounded and thickened crystalline lens) and 
a shallow anterior eye chamber. WMS patients are short with brachydactyly and joint 
stiffness. Both autosomal dominant and recessive forms of WMS have been described and 
are caused by FBN1 mutations 59, 60 and mutations in the ADAMTS10 gene 61, respectively. 
Homocystinuria is often easily differentiated from MFS by the presence of mental 
retardation and thrombosis, and can be excluded by urine amino acid analysis in the 
absence of pyridoxine supplementation. In homocystinuria, the lens usually dislocates 
downward due to complete loss of support by ciliary zonules. In Stickler syndrome, patients 
can present with a Marfanoid habitus. Typical ocular signs include retinal detachment, 
myopia and open-angle glaucoma. Early cataracts are common, but lens subluxation is 
not. Other potential discriminating features from MFS include cleft palate, hearing loss 
and epiphyseal changes of the bones. 
Conditions with overlapping systemic features
Shprintzen-Goldberg syndrome (SGS) is a rare craniosynostosis syndrome characterised 
by some of the systemic features found in MFS (pectus abnormalities, scoliosis, 
arachnodactyly), craniofacial dysmorphism (exophtalmos, hypertelorism, downslanting 
palpebral fissures, maxillary and mandibular hypoplasia, high arched palate and low set 
ears) and developmental delay. So far, only two SGS patients have shown an FBN1 mutation 
62, 63. Another patient reported by Kosaki et al. 63 as SGS was felt to have LDS based on arterial 
tortuosity and the presence of a bifid uvula 64. Other important distinguishing features 
between SGS and either LDS or MFS are the high incidence of cognitive impairment and 
the low frequency of vascular disease in the former.
Congenital contractural arachnodactyly (CCA) is an autosomal dominant disorder 
characterised by a Marfan-like body habitus and arachnodactyly 65. Most affected 
individuals have ‘crumpled’ ears that present as a folded upper helix and contractures of 
major joints (knees and ankles) at birth. The proximal interphalangeal joints of the fingers 
and toes have flexion contractures (camptodactyly). Kyphosis/scoliosis is present in about 
half of affected individuals. Mild enlargement of the sinuses of Valsalva has been reported, 
but there is no evidence that the aortic dilatation progresses to dissection or rupture 66. 
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CCA is caused by mutations in the FBN2, gene encoding the extracellular matrix microfibril 
fibrillin-2 67.
Management
Management guidelines for MFS patients
Aortic root dilatation in MFS is usually progressive. Therefore absence of aortic root 
enlargement on initial clinical examination does not necessarily exclude the diagnosis, 
even in adulthood. 
All individuals who meet the criteria for MFS should initially have at least yearly 
echocardiograms. More frequent imaging should be performed if the aortic diameter 
is approaching a surgical threshold (≥4.5cm in adults; less well defined in children) or 
shows rapid change (≥0.5 cm/year) or with concerns regarding heart or valve function. 
Individuals under age 20 with systemic findings suggestive of MFS but no cardiovascular 
involvement should have annual echocardiograms due to the potential for rapid evolution 
of the phenotype. Adults with repeatedly normal aortic root measurements can be seen 
at intervals of 2-3 years.  
Although several alternative medical treatments have been proposed (angiotensin 
converting enzyme (ACE) inhibitors, calcium channel antagonists), the standard of care 
in most centers for the prevention of aortic complications in MFS remains β-blockade 68. 
More data are required before ACE inhibitor therapy can be considered standard treatment 
69. β-blockade should be considered in all patients with MFS, including children and those 
with aortic root diameters of < 4 cm, unless contraindicated. The β-blocker should be 
titrated to maximum effect, aimed at a heart rate after submaximal exercise (eg, running 
up and down two flights of stairs) < 100 beats/ min in individuals over 5 years of age. 
Angiotensin receptor blockers (ARBs) have shown the ability to prevent aortic enlargement 
in a mouse model of Marfan syndrome 70, and encouraging results were observed in a pilot 
experience in children with severe MFS 71. Several multicenter trials of losartan versus or on 
top of atenolol in MFS are currently underway 72. If β-blockers are contraindicated or not 
tolerated, other classes of antihypertensive agents can be used, but there is not definitive 
evidence that they will afford protection in people with MFS.
Management of acute dissection of the ascending aorta (type A dissection) is emergency 
surgery. Consideration of prophylactic surgery is recommended when the diameter at the 
sinuses of Valsalva approaches 5.0 cm. Other factors that inform the timing of surgery 
include a family history of early dissection, the rate of aortic root growth, the severity 
of aortic valve regurgitation, associated mitral valve disease, ventricular dysfunction, 
pregnancy planning in women, and the desire for a valve sparing operation. 
Type B dissection (originating in the thoracic descending aorta) accounts for about 10% 




















of all dissections in MFS. Possible indications for surgery include intractable pain, limb 
or organ ischemia, an aortic diameter exceeding 5.5 cm or a rapid increase in the aortic 
diameter. Open surgery is still preferred as experience with intravascular stenting in 
MFS is very limited, and the pressure endovascular stents need to apply against the wall 
of adjacent normal sized aortic segments to remain well seated may not be tolerated by 
weakened connective tissue, or the adjacent aorta may also be dilated. Regular imaging of 
the entire aorta is encouraged after root surgery and in adulthood.
Mitral valve repair or replacement is advised for severe mitral valve regurgitation with 
associated symptoms or progressive left ventricular dilatation or dysfunction. Repair should 
be considered, especially in patients undergoing aortic valve-sparing root replacement. If a 
mechanical aortic valve prosthesis is chosen, mitral valve replacement may be considered, 
although preservation of left ventricular function may be better with mitral valve repair. 
After isolated mitral valve repair, one should carefully monitor aortic root size as increased 
rates of enlargement have been observed.
Decisions regarding exercise restriction should always be made on an individual 
basis. Recommendations from the National Marfan Foundation (www.marfan.org) and 
guidelines from the American Heart Association/American College of Cardiology task 
forces 73 are useful templates. In general, patients with MFS should avoid contact sports, 
exercise to exhaustion and especially isometric activities involving a Valsalva manoeuver. 
Most patients can and should participate in aerobic activities performed in moderation.
Pregnancy in MFS women is associated with increased cardiovascular risk, with the 
majority of aortic complications (progressive dilatation and dissection) occurring in the 
third trimester or in the early postpartum period. The risk of aortic root complication is 
increased when the aortic root diameter is above 4.0 cm at the start of the pregnancy 74. 
Annual ophthalmological evaluation for the detection of ectopia lentis, cataract, 
glaucoma and retinal detachment is essential. Early monitoring and aggressive refraction 
is required for children with MFS to prevent amblyopia. Indications for surgical lens 
extraction include lens opacity with poor visual function, anisometropia or refractive error 
amenable to optical correction, impending complete luxation and lens-induced glaucoma 
or uveitis.
Skeletal manifestations such as scoliosis and pectus deformity should be treated 
according to standard orthopedic management rules.
Management guidelines for related conditions
Regular follow-up including annual cardiovascular imaging and ophthalmological 
evaluation is advised in MASS, MVPS and ELS to monitor aortic size, and the degree of 
mitral regurgitation, over time. Counselling for patients with either ELS or MASS phenotype 
hoofdstuk 3.indd   151 19-04-13   09:26
Chapter 3  |  The revised Ghent nosology for the Marfan syndrome
152
should include the risk of a more severe presentation in their offspring, including aortic 
enlargement.
Careful cardiovascular and ophthalmological follow-up is of course strongly indicated in 
children with potential MFS or non-specific connective tissue disorders.
Conclusion
The diagnostic evaluation for MFS is unavoidably complex due to the highly variable 
presentation of affected individuals, the age-dependent nature of many of its 
manifestations, the absence of gold standards and its extensive differential diagnosis. 
While diagnostic criteria should emphasise simplicity of use and the desire for early 
diagnosis, accuracy receives highest priority in order to avoid the deleterious and often 
irreversible consequences of ungrounded or erroneous assignment. While the increased 
focus on vascular disease for the diagnosis of MFS in this proposal will likely prove 
controversial, it is responsive to the practical burden faced both by patients and physicians 
and does not represent a true departure from the spirit of prior diagnostic guidelines. 
Ongoing concerns about delayed diagnosis and/or the use of diagnostic categories that 
may prove provisional should be offset by additional discussion of ongoing risk and the 
definition of follow-up and management principles. A comparative analysis on different 
retrospective datasets has shown ~90% concordance between the old and revised Ghent 
nosology. The 10% discordance was generally beneficial by facilitating earlier diagnosis in 
young children with a convincing clinical phenotype and delayed diagnosis in individuals 
without clear cardiovascular risk. The current proposal will benefit from a prospective 
analysis, leading to further refinement. A web based diagnostic tool for the application of 
these criteria can be accessed at http://www.marfan.org.
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Abstract
Marfan syndrome (MFS) is a dominant disorder with a recognizable phenotype. In most 
patients with the classical phenotype mutations are found in the fibrillin-1 gene (FBN1) on 
chromosome 15q21. It is thought that most mutations act in a dominant negative way or 
through haploinsufficiency. In 9 index cases referred for MFS we detected heterozygous 
missense mutations in FBN1 predicted to substitute the first aspartic acid of different 
calcium-binding Epidermal Growth Factor-like (cbEGF) fibrillin-1 domains. A similar mutation 
was found in homozygous state in 3 cases in a large consanguineous family. Heterozygous 
carriers of this mutation had no major skeletal, cardiovascular or ophthalmological features 
of MFS. In the literature 14 other heterozygous missense mutations are described leading 
to the substitution of the first aspartic acid of a cbEGF domain and resulting in a Marfan 
phenotype. Our data show that the phenotypic effect of aspartic acid substitutions in 
the first position of a cbEGF domain can range from asymptomatic to a severe neonatal 
phenotype. The recessive nature with reduced expression of FBN1 in one of the families 
suggests a threshold model combined with a mild functional defect of this specific 
mutation.   ©2010 Wiley-Liss, Inc.
KEY WORDS: Marfan syndrome, fibrillin-1, FBN1 gene, autosomal recessive inheritance, 
pathogenesis
Introduction
Human fibrillin-1 is a large protein of approximately 350 kD and member of a family 
of extracellular cysteine-rich glycoproteins. Since 1991 mutations in the fibrillin-1 (FBN1) 
gene have been found to be responsible for Marfan syndrome (MFS; MIM# 134797) 
(Kainulainen et al., 1990; Dietz et al., 1991). Fibrillin-1 is characterized by a highly conserved 
modular domain organization. The most prominent domain is the Epidermal Growth 
Factor-like (EGF) domain present 46 times and containing six highly conserved cysteine 
residues stabilizing the structure by three disulfide bonds. Of these EGF domains, 43 have a 
consensus sequence for calcium binding (cb) in the N-terminal pocket of the domain which 
may mediate protein-protein interactions. The EGF domains are interrupted by seven 
transforming growth factor (TGF)-binding protein domains characterized by 8 cysteine 
residues involved in intra-domain disulfide bonds (Pereira et al., 1993; Robinson et al., 2006). 
In the last update of the Universal Marfan Database – FBN1 (UMD-FBN; http://www.umd.
be) (Faivre et al., 2007) 803 different mutations are reported. Most of the mutations are 




















missense mutations (56%) mainly substituting or creating a cysteine in a cbEGF domain. 
Other mutations are frameshift mutations, splice mutations and nonsense mutations. 
About 14% of mutations are recurring.
All cbEGF domains start with a highly conserved aspartic acid, which is crucial for 
binding of a positively charged Ca2+ ion (Whiteman et al., 2007). We have identified 10 index 
cases with a substitution of the first aspartic acid substitution of a cbEGF domain and 
reviewed a further 14 published cases. Most of them exhibit a complete MFS phenotype. 
Surprisingly, in one family the substitution only led to MFS in homozygous state in three 
family members, whereas 13 family members carrying the heterozygous mutation do not 
have Marfan syndrome after thorough clinical examination. 
There is still a lot of debate how mutations in FBN1 result in the MFS phenotype, but 
increasing evidence for different models is emerging. Possible explanations for the 
observed extreme variation in expression of the substitution of the first aspartic acid of 
a cbEGF domain are discussed. The observation of recessive inheritance of an expected 
dominant mutation also underscores the fact that mutations which are predicted to have 
a pathogenic effect, may not always lead to clinical symptoms. 
Patients and methods
Patients
The patients were referred for DNA analysis of the fibrillin-1 gene to confirm the clinical 
diagnosis of MFS. Case 1, 2, 5, 7, 9 and 10 fulfilled the clinical Ghent criteria (De Paepe A. 
et al., 1996) for the diagnosis MFS. All index patients fulfilled the Ghent criteria when the 
finding of a pathogenic mutation in FBN1 was included. 
Case 9 belongs to a large Turkish pedigree (Figure 1, III-1). She was examined at the age 
of 22 years. At the age of 6 weeks she was operated on a right sided hernia inguinalis. She 
was diagnosed with bilateral subluxation of the lenses when she was 3 years old. From that 
time on she has been operated several times for retinal detachments and lens luxation. At 
the age of 14 years an aortic root replacement was performed for progressive aortic root 
dilatation and aortic valve regurgitation. A spontaneous pneumothorax occurred at the 
age of 16 years.
Clinical examination at the age of 18 years showed a marfanoid habitus, slight 
downslanting of palpebral fissures and a high and gothic palate. Despite long fingers, 
wrist and thumb signs were negative. She exhibited limited extension of her elbows, mild 
asymmetry of the chest, and bilateral flat feet. Her skin showed several striae on the chest, 
shoulders, hips and lower back. Her length was 179.5 cm (+3,7SD for Turkish descent) and an 
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arm span of 175 cm (within normal limits). The brother of case 9 (III-3) was a 13 year old boy 
with Marfan syndrome. He had mild skeletal manifestations of Marfan (pes planus), a mildly 
dilated aortic root, ectopia lentis and dural ectasia with an anterior sacral meningocele. 
Furthermore he suffered from recurrent episodes of intracranial hypertension treated by 
drainage of cerebrospinal fluid. He has been described in a case report (Hilhorst-Hofstee 
et al., 2008).
The third patient (II-15) died at the age of 22 years. His case history was obtained from 
the medical records. At the age of 2 years bilateral subluxation of lenses was diagnosed. He 
developed severe aortic and mitral valve regurgitation with an aneurysm of the aortic root. 
He had skeletal involvement and an anterior sacral meningocele. When he was 17 years of 
age an aortic root replacement was performed with reconstruction of the aortic and mitral 
valve. Due to progressive aortic regurgitation, a re-operation was performed a year later. 
He died at the age of 22 after a second episode of ventricular fibrillation. 
All heterozygous family members had a thorough skeletal, cardiologic and ophthal-
mologic examination including anthropometric measurements, echocardiography and slit 
lamp evaluation (Table 1). Only the mother and father of case 9 had an MRI evaluation for 
dural ectasia. The obtained clinical data of all family members are summarized in Table 
1. The father of case 9 (II-6) had no clinical signs of Marfan syndrome. The mother (II-7) 
was tall, with a height on +2.5 SD but with normal body proportions. She had no other 
skeletal, ocular or cardiovascular involvement, but had several striae on the lumbar region 
and around the knees. Furthermore she suffered from spontaneous pneumothorax at the 
age of 21 years. An MRI-scan showed a dural ectasia at S2 with otherwise a normal dural 
sac. The father and mother of II-15 did not exhibit any signs of Marfan syndrome. None 
of the nine other heterozygous family members had a major criterion in one of the organ 
systems. Some were found to have a non-specific or minor sign. Individual II-1 has an arm 
span to height ratio of 1.06 and a mild dilatation of the abdominal aorta. II-4 had recurrent 
inguinal hernias but this was during a period of performing heavy physical labor. II-8 had 
an arm span to height ratio of 1.07 and bilateral flat feet. II-9 had reduced extension of the 
elbows.
The clinical data of cases 1- 10 and published cases are summarized in Table 2 together 
with the molecular data.




















Figure 1. Pedigree of the family of case 9. Squares, male subjects; circles, female subjects. 
Affected subjects with a homozygous mutation (c.7454A>T) are represented by solid 
symbols. Presence or absence of the heterozygous mutation is represented by an open 
symbol with a black dot or a minus symbol respectively.
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22 10 42 43 9 57 56 61 44 41 37 35 33 55 48 37
Sex F M M F M M F M M M F M F M F F
height (cm) 180,9 150,5 167,1 174,4 135,0 164,0 157,5 166,0 167,5 174,5 167,0 188,5 161,0 181,0 164,7 161,0
height SDS (for 
Turkish descent)
3,7 1,6 -1,2 2,5 -0,2 -1,7 -0,6 -1,4 -1,1 0,1 1,1 2,5 0,8 1,2 0,7 0,2
arm span : height 
ratio
0,97 1,02 1,04 1,00 1,00 1,01 1,03 1,01 1,06 1,04 0,98 0,99 1,02 1,07 1,02 1,03
sitting height : 
height ratio
0,515 0,488 0,536 0,513 np 0,535 0,528 0,519 0,527 0,517 0,531 0,516 0,523 0,482 0,520 0,526
sitting height : 
height ratio SDS
-0,8 -2,0 1,6 -0,8 np 1,5 0,2 0,3 1,0 0,3 0,3 0,2 0,0 -1,8 -0,4 0,0








no no no no no no no no no no no no no no no no
sitting height : 
height ratio <2 
SD or armspan : 
height ratio >1.05
no yes no no np no no no yes no no no no yes no no
wrist and 
thumbsigns
no no no no no no no no no no no no no no no no
scoliosis 
of >200 or 
spondylolisthesis
no no no no np no no no no no no no no no no no
reduced 
extension at the 
elbow (<1700)
yes no no yes np no no no no no no no no no yes no
pes planus yes yes no no yes no no no no no no yes no yes no no
protrusio 
acetabulae






no no no no yes no no no no no no no no no no no
joint 
hypermobility




yes no no no yes no no no no no no no no no no no
facial appearance yes no no no yes no no no no no no no no no no no
Ocular system major major none none major none none none none none none none none none none none
major




np np np np np no no no no no no no no no no no
increased axial 
length of globe
np np np np np np np np np np np np no no no no
hypoplastic iris 
or ciliary muscle




III-3 II-6 II-7 II-15 I-5 I-6 I-1 II-1 II-2 II-3 II-4 II-5 II-8 II-9 II-12
Cardiovascular 
system









yes no no yes 
(arr)
no no no no no no no no no no no
dissection of 
ascending aorta








no no no no np no no no no no no no no no no no
calcification 
of the mitral 
annulus < 40 
years





no no np no np no no no yes no no no no no no no
Pulmonary 
system





yes no no yes no no no no no no no no no no no no
Skin and 
integument
involv none none involv np none none none none none involv involv none none none none
minor
striae atrophicae yes no no yes np no no no no no yes no no no no no
recurrent or 
incisional herniae
no no no no np no no no no no no yes3 no no no no




np yes no yes np np np np np np np np np np np np
Family or genetic 
history






no yes yes yes no yes yes no no no no no no no no no
pathogenic 
mutation in FBN1
hom hom het het hom het het het het het het het het het het het
F female; M male; involve involvement; np not performed; arr aortic root replacement; hom homozygous c.7454A>T FBN1 mutation; het heterozygous c.7454A>T FBN1 mutation; 
Z-score related to body surface area and age according to Roman et al. (Roman et al., 1989); 1) aortic root measurement at the age of 14 years just before aortic root replacement; 2) 
no exact measurement available; 3) recurrent inguinal hernias during a period of heavy duty; 4) major criterion on the basis of a first degree affected family member or the presence 
of a pathogenic FBN1 mutation.
Table 1. Summary of the clinical features in the family of case 9























III-3 II-6 II-7 II-15 I-5 I-6 I-1 II-1 II-2 II-3 II-4 II-5 II-8 II-9 II-12
Cardiovascular 
system









yes no no yes 
(arr)
no no no no no no no no no no no
dissection of 
ascending aorta








no no no no np no no no no no no no no no no no
calcification 
of the mitral 
annulus < 40 
years





no no np no np no no no yes no no no no no no no
Pulmonary 
system





yes no no yes no no no no no no no no no no no no
Skin and 
integument
involv none none involv np none none none none none involv involv none none none none
minor
striae atrophicae yes no no yes np no no no no no yes no no no no no
recurrent or 
incisional herniae
no no no no np no no no no no no yes3 no no no no




np yes no yes np np np np np np np np np np np np
Family or genetic 
history






no yes yes yes no yes yes no no no no no no no no no
pathogenic 
mutation in FBN1
hom hom het het hom het het het het het het het het het het het
F female; M male; involve involvement; np not performed; arr aortic root replacement; hom homozygous c.7454A>T FBN1 mutation; het heterozygous c.7454A>T FBN1 mutation; 
Z-score related to body surface area and age according to Roman et al. (Roman et al., 1989); 1) aortic root measurement at the age of 14 years just before aortic root replacement; 2) 
no exact measurement available; 3) recurrent inguinal hernias during a period of heavy duty; 4) major criterion on the basis of a first degree affected family member or the presence 
of a pathogenic FBN1 mutation.
Table 1. Continue
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Molecular studies
DNA was extracted from peripheral blood or paraffin embedded tissue, using standard 
techniques, analyzed by DHPLC and direct DNA sequencing as described previously (Matyas 
et al., 2002).
The reference sequence used to describe the mutations is the FBN1 cDNA GenBank 
reference sequence: NM_000138.3. Nucleotide numbering reflects cDNA numbering with 
+1 corresponding to the A of the ATG translation initiation codon in the reference sequence, 
according to journal guidelines (www.hgvs.org/mutnomen). 
Skin biopsies of case 1, 9 and her mother and case 10 were available. Fibroblasts were 
cultured and mRNA was isolated from confluent monolayers. For each individual two RNA 
isolations were performed: one cell culture of each was incubated with cycloheximide 
(0.25 mg/ml) for 4.5 hours prior to RNA isolation, to prevent possible nonsense mediated 
decay (NMD) of aberrantly spliced mRNA. 
RNA was isolated using the RNA isolation minikit (Qiagen) according to the manufacturers 
instructions. Full length single stranded cDNA was prepared with oligo-dT-primer and 
SuperscriptTMII RT reverse trancriptase (Invitrogen). To detect possible splice errors, the 
complete coding sequence of FBN1 was analyzed by direct sequencing in 24 overlapping 
PCR fragments. The primers for overlapping fragments were positioned in different exons, 
to avoid allele dropout in case of exon skipping. For analysis of the mutation in exon 60, 
primers in exon 55 (forward) and 63 (reverse) were used. 
Primer sequences are given in Supp. Table S1.
Results
Heterozygous mutations leading to a substitution of the first aspartic acid of a cbEGF 
domain were found in nine index cases and a homozygous mutation was found in 1 index 
case. These mutations and 14 comparable mutations described in the literature or in the 
UMD-FBN1 (UMD-FBN; http://www.umd.be) are listed in Table 2. The phenotypes were 
classical MFS in 15 cases, neonatal MFS in two cases, thoracic aortic aneurysm in one 
case and lens luxation with striae in one case. In four cases described in the literature the 
phenotype is not clear. 
The mutation was de novo in cases 2, 4, 5, and 8. In case 1, 3 and 6 parental DNA was not 
available. In case 1 five sibs were tested negative for the mutation. In case 6 the parents and 
seven sibs had no clinical symptoms of MFS. Case 7 has an affected sister with the same 
mutation. Their father died as a consequence of his third aortic dissection when he was 52 
years of age. He was thought to have MFS. The mother of case 10 is probably affected but 




















was not molecularly tested. Of the published mutations three were de novo, three were 
familial and in eight inheritance was unknown (Table 2).
Using DHPLC for mutation scanning of all 65 exons of FBN1, initially no mutation was 
found in case 9. As the parents are consanguineous, a recessive mutation was suspected. 
Testing one of the parents, a heterozygous mutation was detected in exon 60: c.7454A>T, 
leading to the amino acid substitution p.Asp2485Val. This mutation was found in a 
homozygous state in the patients III-1, III-3 and II-15. The parents (II-6 and II-7) of patients 
III-1 and III-3 are first cousins. The parents of patient II-15 are distantly related and both 
are related to II-6 and II-7 (Figure 1). In the parents of patients III-1, III-3 and II-15 and 9 
family members the mutation was heterozygous. The mutation was not detected in 1000 
Caucasian and 60 Turkish control chromosomes. 
Sequence analysis of cDNA, made from mRNA from cultured fibroblasts of case 1, 
case 9 and her mother, and case 10 showed no evidence of erroneous splicing of exon 
60. Treatment with cycloheximide, to prevent possible nonsense mediated decay of 
erroneously spliced mRNA, gave the same results. Fibrobasts of the other patients were 
not available.
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c.1468G>T p.Asp490Tyr 11 #3 Classical MFS ard, el, sk (Hayward and Brock, 
1997)
np yes Unknown
c.2168A>C p.Asp723Ala 18 #7 Severe classical MFS ard, mvp, el, 
myop, sk
(Dietz et al., 1993) np no De novo
c.2168A>T p.Asp723Val 18 #7 Classical MFS ard, mvp, el, sk, 
myop
(Katzke et al., 2002) np no De novo
c.2728G>A p.Asp910Asn 22 #10 Classical MFS unknown UMD np yes Unknown
c.3209A>G p.Asp1070Gly 26 #12 Neonatal MFS unknown UMD np no Unknown
c.3338A>G p.Asp1113Gly 27 #13 Phenotype 
unknown
unknown (Liu et al., 1997) np no Unknown
c.3463G>A p.Asp1155Asn 27 #14 Thoracic aortic 
aneurysm
ard, mvp, diss (Milewicz et al., 1996) no yes De novo
c.3464A>G p.Asp1155Gly 28 #14 Classical MFS ard, el Case 1 no no
Parents not 
available, 5 sibs neg 
for mutation
c.3712G>A p.Asp1238Asn 29 #16 Phenotype 
unknown
unknown (Yuan et al., 1999) np no Unknown
c.3713A>G p.Asp1238Gly 30 #16 Classical MFS ard, mvp, sk (Tiecke et al., 2001) np no Familial
c.3964G>A p.Asp1322Asn 31 #18 Neonatal MFS ard, mi, ti, myop, 
sk
Case 2 np yes De novo
c.4210G>T p.Asp1404Tyr 33 #20 Classical MFS ard, el, sk (Hayward et al., 1997) yes yes Familial
c.5422G>C p.Asp1808His 43 #26 Lens luxation and 
striae
el, str Case 3 np no Parents not 
available
c.5671G>A p.Asp1891His 45 #28 Classical MFS ard, sk Case 4 np no De novo
c.5788G>C p.Asp1930His 45 #29 Classical MFS ard, el, sk Case 5 np yes De novo
c.5788G>A p.Asp1930Asn 46 #29 Phenotype 
unknown
unknown (Liu et al., 1997) np yes Unknown
c.5788G>A p.Asp1930Asn 46 #29 Classical MFS ard, el, sk, de, str Case 6 np yes Parents not 
available
c.6037G>T p.Asp2013 Tyr 48 #31 Classical MFS ard, el, sk, de, str Case 7 np yes Familial
c.6379G>T p.Asp2127Tyr 51 #32 Classical MFS ard, el (Matsukawa et al., 
2001)
np yes Familial
c.6381T>A p.Asp2127Glu 52 #32 Classical MFS ard, sk (Kainulainen et al., 
1994)
np no Familial
c.7331A>G p.Asp2444Gly 59 #38 Classical MFS ard, sk Case 8 np no De novo
c.7454A>T p.Asp2485Val 60 #39 Classical MFS in 
homozygous state
ard, el, sk, str, 
her, pn
Case 9 no no Familial
c.7819G>A p.Asp2607Asn 62 #42 Classical MFS ard, mvp, sk Case 10 no no Mother suspect for 
MFS
c.7820A>G p.Asp2607Gly 63 #42 Phenotype 
unknown
unkown (Liu et al., 1997) np no Unknown
UMD Universal Marfan Database – FBN1 (UMD-FBN; http:/www.umd.be); cbEGF calcium binding Epidermal Growth Factor domain; bp basepair; np not performed; neg negative; 
pos positive; ard aortic root dilatation; diss aortic dissection; mvp mitral valve prolapse, mi mitral valve insuffi ciency; el ectopia lentis; pal high arched palate; ti tricuspid valve 
insuffi ciency; myop high myopia; ar arachnodactyly; hm hypermobility; contr contractures; str striae; her hernia; sk skeletal involvement; de dural ectasia; pn pneumothorax; 
unknown. The gray row represents the recessive mutation described in this article.
Mutation numbering refers to the FBN1 cDNA GenBank reference sequence: NM_000138.3, with the A of the ATG translation initiation codon as nucleotide +1 (www.hgvs.org/
mutnomen). a) Alamut mutation interpretation software version 1.5; Interactive Biosoftware, Rouen France.
Table 2. Published and observed missense mutations leading to the substitution of the first aspartic acid 
of a cbEGF domain





















We identified a heterozygous substitution of the first aspartic acid of a cbEGF domain 
in FBN1 in nine index patients and a homozygous substitution in one index patient with 
MFS. Reviewing the literature we found 12 reports of substitution of the first aspartic acid, 
and a further two unpublished cases are quoted in the UMD database (UMD-FBN; http://
www.umd.be) (Collod-Beroud et al., 2003) as summarized in Table 2. All 10 index patients 
found in our center fulfilled the Ghent criteria when the finding of a pathogenic mutation 
was included. Of the 14 published cases, eight were reported to have a classical Marfan 
phenotype, one was a neonatal Marfan and one had a thoracic aortic aneurysm. Of four 
cases the phenotype was not reported. In all cases the acidic amino acid aspartic acid is 
replaced by a nonpolar or noncharged polar amino acid, apart from one mutation where 
aspartic acid is replaced by another acidic amino acid (p.Asp2127Glu) (Kainulainen et al., 
1994). The codons of the first aspartic acids in the cbEGF domains always contain the last 
base of one exon and the first two bases of the next. Consequently, mutations of these 
codons may affect splicing. Aberrant splicing was excluded in cases 1, 9, and 10 and in 
one of the published cases (Milewicz et al., 1996). The mutation c.4210G>T was shown to 
destroy a donor splice site with abnormal splicing as a consequence (Hayward et al., 1997). 
Of the 19 cases in which no cDNA analysis was performed, prediction software predicted 
aberrant splicing in eight cases (Table 2). Exon skipping, as a result of these mutations, may 
have more severe effects than missense mutations, because the exons are all in frame and 
consequently, skipping will lead to a shorter protein that may exert a dominant negative 
effect (Robinson et al., 2002). 
There are several reasons to argue that a substitution of the first aspartic acid of a 
cbEGF domain will lead to a MFS phenotype in the heterozygous state. Calcium binding 
of cbEGF domains is necessary for stabilization of the secondary structure, prevention of 
proteolytic degradation and for protein-protein interaction (Dietz et al., 1993; Handford et 
al., 1991; Cooke et al., 1987). The first aspartic acid of a cbEGF domain is highly conserved in 
evolution and in the human fibrillin-1 gene all cbEGF domains start with an aspartic acid, 
which is crucial for binding of a positively charged Ca2+ ion (Figure 2) (Whiteman et al., 
2007). Furthermore mutations of the first amino acid of a cbEGF domain of coagulation 
factor IX in haemophilia B have been proven to reduce calcium binding even if the aspartic 
acid is replaced by the acidic amino acid glutamic acid (Handford et al., 1991; Winship and 
Dragon, 1991). The finding of 23 MFS or MFS-like cases with a heterozygous substitution of 
an aspartic acid in this position of the cbEGF domain underscores the crucial role of this 
amino acid. In this view the recessive nature of the mutation p.Asp2485Val in the family of 
case 9 came as a surprise. The family of case 9 (Figure 1) has been thoroughly investigated. 
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Patients III-1 (case 9), III-3 and II-15 have the classical type of Marfan syndrome according 
to the Ghent criteria (De Paepe A. et al., 1996). Based on the pedigree with three affected 
patients and healthy consanguineous parents recessive inheritance could be expected. This 
was confirmed by finding a homozygous missense mutation in all three affected patients. 
The four unaffected parents and nine other unaffected relatives were found to be carriers 
of the mutation. Unexpectedly in none of the investigated heterozygous carriers obvious 
signs of Marfan syndrome could be found. Only after thorough clinical examination one 
of them (II-7) was found to have a dural ectasia at S2, which as yet is considered a major 
symptom in the Ghent criteria. Together with the family history and some minor signs 
(pneumothorax, striae and reduced extension of the elbows) this classifies II-7 as having 
Marfan syndrome. However, compared to the homozygous cases, the cardinal Marfan 
features in the skeletal, cardiac and ophthalmological systems are absent.
Figure 2. Class I cbEGF domain showing the position of the first Asp in relation to the 
calcium molecule. (A) 3D picture of a cbEGF domain of fibrillin-1. The arrows point to 
the first Asp. Picture derived from the NCBI database (http://www.ncbi.nlm.nih.gov/) 
(Downing et al., 1996). (B) cbEGF like domain (Handford et al., 1991). The arrow points to 
the first aspartic acid residue. Solid lines are the disulphide bridges between cysteine 
residues.




















To our knowledge very little is known about recessive FBN1 mutations. Only one 
family has been reported in which Marfan syndrome was found in two affected cousins 
homozygous for a FBN1 mutation while the four normal parents were heterozygous carriers, 
indicating recessive inheritance of the syndrome (De Vries et al., 2007). The mutation is 
located in exon 11 and leads to an amino-acid substitution creating a cysteine. Like us the 
authors expected this mutation to have a dominant effect in the heterozygous state. 
Two of the parents were sibs and exhibited minor signs of Marfan syndrome (increased 
arm span to height ratio and a highly arched palate). No other family members have been 
investigated. Only one other probably recessively inherited form of Marfan syndrome has 
been described but could not be proven by molecular analysis as the gene was not yet 
known (Fried and Krakowsky, 1977).
Three families have been described in the literature in which both parents are affected 
with more severely affected children. The first is an Italian couple of first cousins, both 
affected with Marfan syndrome, who had 4 affected children. Two of the four affected 
children showed more severe manifestations than other affected family members, 
presumably due to homozygosity (Capotorti L. et al., 1959). In 1984, Chemke described a 
family with Marfan syndrome. Two sibs suffered from a severe phenotype reminiscent of 
neonatal Marfan syndrome. Their parents were cousins and had a much milder phenotype. 
Remarkable is that the probably homozygous sibs were the only patients in the family with 
ectopia lentis (Chemke et al., 1984). In 1988 a severely affected boy has been described 
(Schollin et al., 1988). Both parents were affected and were found to carry a missense 
mutation in FBN1. Compound heterozygosity was identified in the severely affected child 
(Karttunen et al., 1994). 
In the recessive family described here the heterozygous mutation does not exert an 
important effect on the phenotype. Only in the homozygous state the abnormal fibrillin 
causes the classical clinical phenotype of Marfan syndrome. This observation together 
with the few other described families with bi-allelic inheritance, may support both 
alternative pathogenetic models of Marfan syndrome. A dominant negative effect of FBN1 
mutations has been the leading hypothesis for the pathogenesis of Marfan syndrome for 
a long time. However, several manifestations of Marfan syndrome like bone overgrowth, 
craniofacial features, lung disease, and muscle and fat hypoplasia could not be explained 
by a structurally abnormal protein. The observation that fibrillin interacts with a variety 
of proteins, including the latent TGFβ binding proteins (LTBP’s) has lead to several 
investigations indicating that fibrillin-1 can interact with TGFβ signaling (Annes et al., 2003; 
Azhar et al., 2003; Isogai et al., 2003; Hubmacher et al., 2006; Kaartinen and Warburton, 
2003; Loeys et al., 2006; Neptune et al., 2003; Ng et al., 2004; Ten Dijke and Arthur, 2007).
According to splice site prediction software (Alamut mutation interpretation software 
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version 1.5; Interactive Biosoftware, Rouen, France) the c.7454A>T mutation, found in the 
family described here, is not predicted to cause erroneous splicing. This was confirmed by 
cDNA studies, showing no evidence of splice error. The position of the mutation (exon 60) 
may explain the lack of expression as mutations in the more C-terminal end of the gene are 
expected to give a milder phenotype (Faivre et al., 2007; Robinson et al., 2002). However 
the mutation in case 10 is even more terminal and still leads to a classical MFS phenotype.
Hutchinson et al. (Hutchinson et al., 2003) hypothesized that variable expression 
of the normal FBN1 allele could moderate the phenotypic effect of the mutant allele. A 
compensatory higher level of FBN1 expression from the normal allele would explain 
a milder phenotype. As the normal alleles are inherited from 5 different parents in our 
recessive family, this mechanism is highly unlikely. 
We hypothesize that the p.Asp2485Val mutation acts as a hypomorphic allele with a 
minimal dominant negative effect. Reduction of gene expression of both alleles could 
be the main determinant of the phenotype in homozygotes. The observation of only one 
major clinical sign in one of the heterozygotes (dural ectasia in II-7, Figure 1) and no major 
clinical signs in 12 other heterozygotes could be explained by sufficient gene expression 
with only a mild functional defect of the mutant allele product. This was also shown in 
a mouse model, however in this model the mutation had a severe dominant negative 
effect (Pereira et al., 1997). In this model with a deletion of 272 amino acids in the central 
part of fibrillin-1, a tenfold reduction in expression of the mutant allele was shown in 
heterozygous mice, resulting in a normal phenotype. Homozygous mutant mice however 
died shortly after birth due to severe vascular complications. The other mouse model of 
Pereira was a targeted FBN1 mutation leading to 15% expression of a normal product with 
no abnormal phenotype in heterozygous mice, while mice homozygous for this mutation 
have severe abnormalities comparable with the neonatal MFS phenotype. These mouse 
models suggests that there is a threshold of expression of the normal allele below which 
the abnormal phenotype will develop (Pereira et al., 1999; Dietz and Mecham, 2000).
To understand the exact pathogenetic mechanism expression studies and studies on 
protein synthesis, secretion and matrix incorporation of the Asp2486Val mutation are 
necessary For comprehensive studies of this type, a mouse model should be created.
The finding of a homozygous substitution of A>T, as described here, has implications 
for mutation screening in MFS. Homozygous substitutions will not have an effect 
on denaturation of double stranded DNA, because the basepair remains the same. 
Consequently, heteroduplex based testing, such as DHPLC, working with the principle 
of differential denaturation of double stranded heteroduplex DNA, cannot detect this 
mutation in homozygous state. Formerly, based on the presumed dominant inheritance 
mode, only heterozygous mutations were expected. Now it is clear that recessive 




















inheritance is also possible and mutations may have been missed in similar cases, because 
heteroduplex based testing has been used until recently in many large diagnostic centers. 
Most laboratories nowadays use direct sequencing, which avoids this problem.
In conclusion we have shown that the first aspartic acid of a cbEGF domain in FBN1 is 
important for the function of fibrillin-1, but may not always lead to a clinical effect in the 
heterozygous state. This underscores that missense mutations must be interpreted with 
care.
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Supp. Table S1. Primers for cDNA sequencing of FBN1: F=forward; R=reverse; numbers refer to 
position in cDNA sequence.
fragment primername Sequence 5’ > 3’ Length 
bp
1 FBN1F1 ATGCGTCGAGGGCGTCTGCT 384
FBN1R384 GCTACCTCCATTCATACAGCGA
2 FBN1F318 GATAGCTCCTTCCTGTGGCTCC 406
FBN1R728 CCGTGCGGATATTTGGAATG
3 FBN1F657 CCCCTGTGAGATGTGTCCTG 407
FBN1R1064 TTGGTTATGGACTGTGGCAGC
4 FBN1F1012 ACAGCTCTGACAAACGGGCG 384
FBN1R1396 TGCAGCGTCCATTTTGACAG
5 FBN1F1358 GCCAGTTGGTCCGCTATCTC 330
FBN1R1688 ACATGAAAGCCCGCATTACAC
6 FBN1F1609 AATGGCCGGATCTGCAATAA 398
FBN1R2007 CTGGCCTCTCTTGTATCCACCA
7 FBN1F1927 CTGGCTGTGGGTCTGGATGG 362
FBN1R2289 GCAGTTTTTCCCAGTTGAATCC
8 FBN1F2212 ATCTGTGAAAACCTTCGTGGGA 399
FBN1R2611 AGGTGGCTCCATTGATGTTGA
9 FBN1F2458 GTCTGCAAGAACAGCCCAGG 357
FBN1R2815 TGGGACACTGACACTTGAATGA
10 FBN1F2699 TACTCAAGAATTAAAGGAACA 525
FBN1R3224 CGGCATTCGTCAATGTCTGTGC
11 FBN1F3141 CATTGGCAGCTTTAAGTGCAGG 460
FBN1R3621 ACCACCATTCATTATGCTGCA
12 FBN1F3558 CCATTCAACTCCCGATAGGCT 335
FBN1R3893 TTTTCACAGGTCCCACTTAGGC
13 FBN1F3783 CAGGTGCTTGTGTTATGATG 392
FBN1R4173 GCACAGACAGCGGTAAGA
14 FBN1F4062 GATTGGAGATGGCATTAAGTGC 451
FBN1R4513 TGTTGACACAGTTCCCACTGA
15 FBN1F4425 CTACGAACTGGACAGAAGCGG 593
FBN1R5018 ATACAGGTGTAGTTGCCAACGG
16 FBN1F4910 ACTACCTGAATGAAGATACACG 626
FBN1R5536 GACCTGTGGAGGTGAAGCGGTAG
17 FBN1F5348 TCAACATGGTTGGCAGCTTCC 476
FBN1R5824 AAAGATTCCCATTTCCACTTGC
18 FBN1F5722 ACAATTGGTTCCTTCAACTG 356
FBN1R6074 GCACAAATTTCTGGCTCTT
19 FBN1F5973 CTTGGATGGGTCCTACAGATGC 579
FBN1R6552 CACATTCTTGCAGGTTCCATT
20 FBN1F6466 GGTTATACTCTAGCGGGAATG 450
FBN1R6937 TCCCACGGGTGTTGAGGCAGCG
21 FBN1F6842 AGCGGAGACCTGATGGAGAGG 645
FBN1R7487 CAGTTGTGTTGCTTGGTTGCA
22 FBN1F7429 CAAGAGGATGGAAGGAGCTGC 476
FBN1R7905 GAACTGTTCATACTGGAAGCCG
23 FBN1F7785 CTACCTCCAGCACTACCAGTGG 384
FBN1R8169 GTAGCCATTGATCTTACACTCG
24 FBN1F8024 CACCTGGTTACTTCCGCATAGG 672
FBN1R8696 ATGATTCTGATTGGGGGAAAA
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Abstract
The most common mutations found in FBN1 are missense mutations (56%) mainly 
substituting or creating a cysteine in a cbEGF domain. Other mutations are frameshift 
mutations, splice mutations and nonsense mutations. There are only a few reports of 
patients with marfanoid features and a molecularly proven complete deletion of a FBN1 
allele. We describe the clinical features of 10 patients with a complete FBN1 gene deletion. 
Seven patients fulfilled the Ghent criteria for Marfan syndrome (MFS). The other three 
patients were examined at a young age and did not (yet) present the full clinical picture 
of MFS yet. Ectopia lentis was present in at least two patients. Aortic root dilatation was 
present in six of the 10 patients. In three patients, the aortic root diameter was on the 
95th percentile and in one patient the diameter of the aortic root was normal, the cross-
section however had a clover-leaf appearance. Two patients underwent aortic root surgery 
at a relatively young age (27 and 34 years old). Mitral valve prolapse was present in four 
of 10 patients and billowing of the mitral valve in one. All patients had facial and skeletal 
features of MFS. Two patients with a large deletion extending beyond the FBN1 gene had 
an extended phenotype.
We conclude that complete loss of one FBN1 allele does not predict a mild phenotype, and 
these findings support the hypothesis that true haploinsufficiency can lead to the classical 
phenotype of Marfan syndrome.
Keywords: Marfan syndrome, FBN1, fibrillin-1, deletion, haploinsufficiency 





















Marfan syndrome (MFS) is a dominant disorder mainly caused by mutations in the fibrillin-1 
gene (FBN1) on chromosome 15. The estimated prevalence is about 1 in 10.000 1. The disorder 
has a very variable intra- and interfamilial expression. Different tissues and organs can be 
affected, with main features in the cardiovascular, skeletal, and ocular systems. Revised 
international criteria for the diagnosis were published in 1996 to facilitate the clinical 
diagnosis 2,3. 
FBN1 mutations are detected in the majority of patients fulfilling the clinical criteria, but 
also in incomplete phenotypes referred to as type 1 fibrillinopathies 4. Mutations in other 
genes have been reported to cause Marfan syndrome related disorders, such as TGFBR1 
and 2 in Marfan syndrome type 2 5,6 and Loeys-Dietz syndrome 7,8 and MYH11 and ACTA2 in 
familial thoracic aortic aneurysms and dissections 9,10. 
To date over 600 mutations have been published in the Universal Marfan Database (UMD-
FBN1; http:\www.umd.be), but only a minority are recurring mutations. Missense mutations 
substituting or creating a cysteine in one of the calcium binding EGF domains are most 
prevalent. Other mutations are frameshift, splice-site and nonsense mutations 11.
Deletions of single and multiple exons can be detected using appropriate methods like 
Multiplex Ligation-dependent Probe Amplification (MLPA), cDNA or Southern blot analyses. 
Most of these deletions are associated with a severe or classical Marfan phenotype12-17 . Only 
four reports are known of a molecularly proven whole gene deletion of FBN118-21. We describe 
10 patients including a family with five patients with whole gene deletions and show that 
complete loss of one FBN1 allele does not predict a mild phenotype. These findings support 




We screened DNA samples of 300 patients with clinical features of MFS or a related 
phenotype by MLPA. All samples had been previously screened by DHPLC and no mutations 
in FBN1 were found. In one patient, chromosome analysis and array CGH performed for 
mental retardation screening revealed a deletion including the FBN1 gene. In all patients 
the size of the deletion was determined by SNP array analysis.
The clinical features of the patients are listed in Table 1. A more detailed description can be 
found in the Supplementary Material.
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Multiplex ligation-dependent probe amplification
MLPA analysis was performed as described elsewhere22 with the SALSA MLPA kits P065 and 
P066 that contain probes for 53 of the 65 FBN1 exons (including exons 1 and 65) and all the 
7 TGFBR2 exons and reference probes widely spread over the genome (MRC-Holland, see 
http://www.mlpa.com). 
PCR products were analysed on a fluorescent capillary sequencer (ABI3130, Applied 
Biosystems, Torrence, CA, USA) using Genemarker software (Softgenetics Inc., State 
College, PA, USA). 
Cytogenetic analysis (patient 8 and 9)
Conventional chromosome analysis was performed on phytohemagglutinin stimulated 
lymphocytes from peripheral blood cultures using GTG-banding according to standard 
protocols.
High density microarray analyses, SNP Arrays
The Affymetrix GeneChip Human Mapping 262K NspI array (Affymetrix, CA, USA) contains 
262.000 25-mer oligonucleotides with an average spacing of approximately 12 kb. An 
amount of 250 ng DNA was processed according to the manufacturer’s instruction (www. 
Affymetrix.com). SNP copy number was assessed using the software program Copy 
Number Analyzer for Genechip (CNAG) Version 2.0 (see http://www.genome.umin.jp)23.
Fluorescence in situ hybridization (FISH) analysis 
Fluorescence in situ hybridization (FISH) analysis was performed following the 
manufacturer’s instructions using the BAC clone RP11-42K15 (Children Hospital Oakland 
Research Institute, Oakland, CA, USA).
Results
In nine patients, MLPA revealed reduced relative peak areas for all probes within the FBN1 
gene indicating a deletion of the entire FBN1 allele. 
Five patients (patients 1-5) are part of one family (Figure 1). The parents of patients 1, 2 and 5 
have no clinical features of MFS. However in the mother, both MLPA and SNP array analysis 
showed lower intensity signals for the probes in the deleted area but higher signals than in 
the patients, suggesting a mosaic deletion. 
Figure 2 shows the MLPA results in patient 2 and her mother. The other eight patients have 
MLPA results comparable to the results of patient 2. FISH analysis with a probe within the 
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Figure 1 Pedigree of the family 
with five members carrying a 
complete deletion of a FBN1 
allele, del – no deletion present; 
del + deletion present
Figure 2 MLPA results of FBN1 in mother and daughter (patient 2), compared to healthy 
control (MLPA kit P065, MRC Holland). The control probes are normalized to 2 copies. 
The probe signals for FBN1 relative to control probes and to TGFBR2 probes show a single 
copy for FBN1 in patient 2. All other patients discussed in this paper show MLPA results 
comparable to patient 2. The healthy mother of patient 2 has reduced probe signals for 
all FBN1 probes, indicative of somatic mosaicism for the deletion. The mean (±standard 
deviation) signals for all FBN1 probes were: 1.93±0.08 (control), 1.08±0.08 (case 2) and 
1.71±0.05 (mosaic mother; p<10-15 compared to control, according to a two tailed t-test).




















FBN1 gene confirmed the mosaic deletion in 21% of the totally 200 analyzed interphase 
nuclei. MLPA and FISH analysis in 200 interphase nuclei of the father showed a normal 
result (results not shown). 
In three patients (patients 6, 8 and 9) the deletion occurred de novo. In one patient (patient 
7), the parents were not tested for the deletion but appeared completely normal by clinical, 
ophthalmologic and cardiologic examination. The mother of patient 10 was not available 
for molecular testing.
In patient 8, the cytogenetic analysis revealed a de novo translocation between the 
long arms of chromosome 12 and chromosome 15. Additional array CGH analysis, with a 
resolution of 1 Mb, detected a 4,9 Mb interstitial deletion at the translocation breakpoint 
of the long arm of chromosome 15 between the bands q21.1 and q21.2 (results not shown). 
The FBN1 gene is located in this region. At the translocation breakpoint of chromosome 12 
no deletion was dectected by array CGH or SNP array analysis. Conventional karyotyping 
of case 9 was performed as part of the mental retardation screening showing a normal 
female karyotype. In the other patients no standard cytogenetic analysis was performed.
Figure 3 Position of the deletions on chromosome 15 (Ensemble release 53, March 2009) 
including the deletion described by Faivre et al.19. The bars underneath the chromosome 
depict the known protein coding genes according to Ensemble release 53, March 2009. 
The names of the genes are written below. The horizontal colored lines show the size of 
the different deletions and their overlap.
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For all probands the size of the deletion was characterized by SNP array analysis. The results 
are depicted in Figure 3 and Table 2.
The clinical features of the patients are summarized in Table 1. Except for patients 8, 9 and 
10, all patients fulfilled the Ghent criteria for Marfan syndrome. The young age of patients 
8, 9 and 10 could explain why they do not yet present the full clinical picture of MFS. 
Ectopia lentis was present in patient 1 and 7. Patient 4 had questionable lens subluxation, 
and patient 6 had very mild lens subluxation of her right eye. Aortic root dilatation was 
present in six of the 10 patients. In patients 8, 9 and 10 the aortic root diameter was on 
the 95th percentile. In patient 6 the diameter of the aortic root was on the 50th percentile. 
the cross-section however had a cloverleaf appearance. Patient 2 and patient 7 underwent 
aortic root surgery at a relative young age (27 and 34 years old). Mitral valve prolapse was 
present in four of ten patients and billowing of the mitral valve in one. All patients had 
facial or skeletal features of MFS. 
The two children with larger deletions (patients 8 and 9) had an extended phenotype 
with psychomotor retardation and additional features. Patient 8 was a 5-year old girl who 
presented at the age of 2.5 years with psychomotor retardation and hypotonia with severe 
motor delay. Patient 9 presented with psychomotor retardation with non-progressive 
ataxia. Apart from het marfanoid features she had a very pale skin and hair without other 
ectodermal manifestations. She had facial dysmorphisms consisting of a brachycephalic 
skull, long philtrum, broad nose and prognathism. 
Further details about the clinical manifestations of the 10 described patients are found in 
the Supplementary Information.
Table 2 Size of the deletions and number of genes deleted. The location of the SNP’s are derived from 
Ensemble release 53, March 2009
Patient Starting SNP Ending SNP SNPs Starting bp Ending bp Max. size (bp) Genes
2 SNP_A-1876769 SNP_A-1938857 44 46.434.718 46.742.196 307478 1
6 SNP_A-2169073 SNP_A-2251237 429 42.867.884 46.950.476 4082592 23
7 SNP_A-2099749 SNP_A-1871856 107 46.098.636 47.145.902 1047366 9
8 SNP_A-2055581 SNP_A-1811386 366 46.116.834 50.383.848 4267009 36
9 SNP_A-2127245 SNP_A-2283948 2007 44.000.164 53.427.159 9426995 46
10 SNP_A-1826755 SNP_A-1823624 141 45.715.212 46.963.495 1248283 9
Abbreviations: bp, basepair; SNP single nucleotide polymorphism
Table 2. Size of the deletions and number of genes deleted. The location of the SNP’s are 
derived from Ensemble release 53, March 2009





















There are several reports of deletions of the long arm of chromosome 15 involving 
chromosome band q21.1. However, in most of these reports the deletion of FBN1 or the 
presence of marfanoid features are not discussed24-29. In four reports the deletion of FBN1 
is confirmed by molecular techniques, with marfanoid features in three cases18,19,21 and 
absence of marfanoid features in one case which could be due to the young age of this 
patient20.
In this study we describe 10 patients with a deletion of an entire FBN1 allele. To our 
knowledge this is the first series of complete FBN1 allele deletions published so far. These 
patients and three previously described sporadic patients18,19,21 have a Marfan phenotype 
due to pure haploinsufficiency. The phenotype of the patients in our series varies from 
mild features of MFS to the classical MFS phenotype. One family (patients 1-5) has a 
deletion encompassing only the FBN1 gene, whereas patients 6, 7, 8, 9 and 10 have much 
larger deletions spanning 1 to 9.4 Mb, with 9 to 46 genes respectively (Figure 3 and 
Table 2). Patients 6, 7 and 10 have no other features than those which can be attributed 
to the deletion of FBN1. Patients 8 and 9 have psychomotor retardation and dysmorphic 
features. In addition, patient 9 has an extended phenotype with more severe neurological 
impairment and lack of skin and hair pigmentation. The deleted genes Myosin 5A (MYO5A, 
MIM 160777) and RAS associated protein (RAB27A, MIM 603868) could play a role in the 
phenotype of this girl. Mutations in MYO5A and RAB27A cause Griscelli syndrome type 1 and 
type 2 respectively. These rare autosomal recessive disorders are characterized by partial 
albinism, immunological problems and/or neurological impairment. Further studies of 
these genes on the normal allele are pending. The three previously published patients18,19,21, 
also have a deletion extending beyond the FBN1 gene. Faivre et al19 describes a teenage girl 
with a deletion of 2.97 Mb with some skeletal features of MFS and mitral valve prolapse, 
but absence of aortic root dilatation and ectopia lentis. Apart from language disabilities 
she was not mentally retarded. The size of the deletion was characterized by array CGH and 
13 genes were found to be deleted including FBN1. In Figure 3 the size and position of this 
deletion is compared with the deletions described in this study. The patients described by 
Adès et al18 and Hutchinson et al21 have psychomotor retardation with additional features, 
probably due to haploinsufficiency of other genes. The size of the published deletions is 
unknown but in the patient described by Hutchinson et al the MFAP1 locus was deleted. 
That means that this deletion is extending more centromeric than our deletions. No further 
information is available about the breakpoints in these patients. Hutchinson et al21 found 
that in the deletion patient the fibrillin-1 protein and mRNA levels were significantly higher 
than expected for a single FBN1 allele. They suggest that the clinical variability in MFS could 
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be due to variable FBN1 expression from the normal allele. They compared their results 
with three members of one family with a premature termination codon (PTC) mutation 
and showed that the variable expression in these individuals appeared to correlate with 
variability in FBN1 expression of the normal allele and not with variable rates of nonsense-
mediated decay (NMD).
Apart from the PTC mutations where the phenotype will be due to partial haploinsufficiency 
caused by NMD and a dominant negative effect of the fibrillin-1 molecules which escape 
NMD, few other mutations have been described leading to a haploinsufficiency state. 
Milewicz et al30 described a patient with only skeletal features of MFS and a missense 
mutation in the FBN1 gene. This mutation co-segregated with tall stature in the family. The 
mutation disrupted the normal processing of one-half of secreted profibrillin in fibrillin. Half 
the normal amount of fibrillin was shown to be deposited in structurally normal-appearing 
microfibrils. They hypothesized that this mutation mimics a null allele of FBN1 and leads to 
a milder phenotype, analogous to the null allele of COL1A1 which leads to the milder form 
of osteogenesis imperfecta 31,32. Our results, however, show that haploinsufficiency of FBN1 
is sufficient for the development of the full clinical expression of MFS with some carriers 
exhibiting severe features. For instance, two of our patients (patients 2 and 7) needed 
aortic surgery at a relatively young age (age 27 and 34, respectively). Additional evidence 
supporting the haploinsufficiency model are the two patients with classical MFS described 
by Mátyás et al 16 with a deletion of the putative regulatory and promoter region of FBN1, 
resulting in complete loss of transcription of the corresponding allele. Both patients 
fulfilled the Ghent criteria with major manifestations in the skeletal and cardiovascular 
systems, but no ectopia lentis. The authors conclude that these two patients represent 
true haploinsufficiency. 
Although no mouse model is known with a complete deletion of one FBN1 allele, the mouse 
model of Pereira suggests that there is a threshold of expression of the normal allele 
below which the abnormal phenotype will develop 33,34. Mice with a heterozygous targeted 
mutation leading to 15% expression of a normal product have no abnormal phenotype, 
while the mice with the same mutation on both alleles have severe abnormalities 
comparable with the neonatal MFS phenotype. 
Judge et al 35 used yeast artificial chromosome-based transgenesis to overexpress a disease-
associated mutant form of human fibillin-1 (C1663R) on a normal mouse background. These 
mice showed no abnormalities whereas a heterozygous comparable cysteine mutation in 
mice leads to the Marfan phenotype and histological changes as seen in heterozygous 
human. They showed that haploinsufficiency for the WT protein can be a significant factor 
in the pathogenesis of MFS when combined with an abnormal FBN1 allele. In keeping with 
the hypothesis of the critical contribution of haploinsufficiency, introduction of a wild-




















type transgene in the heterozygous mouse rescues the aortic phenotype.
How the lower production and deposition of fibrillin-1 will affect the TGFβ signaling 
pathway, and how it leads to the aortic and skeletal features is subject for debate. Recent 
evidence of the role of the TGFβ signaling pathway in the pathogenesis of MFS shows that 
fibrillin has a stabilizing effect on the latent TGFβ binding protein-1 (LTBP-1) in the extra 
cellular matrix (ECM) 34-37. LTBP1 plays a role in the release of TGFβ in the ECM. Mice with 
a Marfan phenotype and a centrally deleted FBN1 allele showed marked dysregulation of 
TGFβ activation and enhanced signaling 38. They hypothesize that deficiency of fibrillin-1 
causes excessive amounts of active TGFβ to be liberated from the matrix. This might as 
well be the case in the patients with a deletion of the FBN1 gene. Increased TGFβ signaling is 
also shown in aortic tissue of patients with Loeys-Dietz syndrome 8. The exact mechanism 
how changes in TGFβ signaling lead to such a specific phenotype has still to be elucidated. 
Ectopia lentis was present in at least two of our patients. The published patients with 
molecularly proven complete FBN1 allele deletions did not exhibit ectopia lentis18-21. None 
of the patients with a TGFBR2 or TGFBR1 mutation have ectopia lentis. We hypothesize that 
ectopia lentis in our patients is caused by the lower production of fibrillin-1 and not by 
perturbation of the TGFβ signaling. This is in keeping with the observation that mutations 
in LTBP2 (latent transforming growth factor beta binding protein 2) cause recessive eye 
abnormalities including ectopia lentis39,40. LTBP2 is the only member of the LTBP family not 
to bind to latent forms of TGFβ, and is thought to have an important structural role in the 
ciliary body together with fibrillin-141. 
In conclusion, our patients with a complete FBN1 allele deletion show that haploinsufficiency 
has a major contribution to the pathogenesis of MFS and can lead tot the whole spectrum 
of MFS. We hypothesize that the skeletal and aortic phenotype are caused by aberrant TGFβ 
signaling and the ocular phenotype by the lower production of the fibrillin-1 microfibrils.
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Family 1 (patients 1-5) (Figure 1)
Patient 1 was diagnosed with MFS at the age of 4 years, when bilateral ectopia lentis and 
mitral valve prolapse were detected. At the age of 36 years bilateral lensextraction was 
performed. At the age of 22 years she had a height of 175 cm (+0.7 SDS) with normal body 
porportions, arachnodactyly with bilateral positive wrist and thumb signs, general joint 
hypermobility, mild scoliosis and varicosis. She had a mild non-progressive aortic root 
dilatation.
Patient 2 is a younger sister of patient 1. She had progressive aortic root dilation, for which 
elective root replacement was performed at the age of 33 years. Prior to the aortic root 
surgery she delivered two children by caesarian section after uncomplicated pregnancies. 
She had high myopia, but no ectopia lentis. Physical examination revealed a normal height 
of 174.5 cm with normal body proportions. She had a long face, arachnodactyly with 
positive wrist and thumb signs, camptodactyly of the right fifth finger and mild scoliosis. 
As a child she was operated for recurrent inguinal hernias. She fulfilled the Ghent criteria 
for the diagnosis MFS when the mutation or a first affected family member is accounted 
for. Her first child (patient 3) was a boy with marfanoid build with a height of 179 cm 
(+1.4 SDS) at the age of 14, with an arm span/ length ratio of 1.04. He had a high arched 
palate with crowding of teeth, arachnodactyly, pectus carinatum, pes planus, and general 
joint hypermobility. No ectopia lentis was found. He had a dilated aortic root. His sister 
(patient 4) had a marfanoid build with a long and narrow face, high arched palate, pectus 
carinatum, mild scoliosis and long narrow feet with flat arches. At the age of 11 years she 
had a height of 185 cm with normal body proportions. Cardiologic examination showed 
aortic root dilatation with mitral valve prolapse. On ophthalmologic examination she had 
dubious ectopia lentis. 
Patient 5, the sister of patient 1 and 2, had a marfanoid build with typical facial 
appearance, high arched palate, blue sclera, arachnodactyly, bilateral flexion contractures 
of the elbows, scoliosis of 32 degrees, general joint hypermobility, permanent clavicula 
dislocation, mild pectus excavatum and varicosis. At the age of 18 years her height was 
174.6 cm (+0,8 SDS) with normal arm span and sitting height. Cardiovascular examinations 
showed a progressive aortic root dilatation. Apart from translucent irides she had a normal 
ophthalmologic examination.
The parents of patient 1, 2, and 5 had no clinical features of MFS but the mother was shown 
to be mosaic for the deletion.
All members of family 1 had normal intelligence.
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Patient 6
Patient 6 was a high school student. She was referred for a severe pectus excavatum. Her 
pectus deformity was corrected by a nuss bar at the age of 14 years. At examination at 
the age of 17 years her height was 179.5 cm (+1.5 SDS) with normal body proportions. She 
had a long narrow face with downslanting palpebral fissures, a high arched palate with 
crowded teeth and an asymmetric nose. She had no arachnodactyly, but a severe pectus 
deformity, general joint hypermobility, and bilateral flat feet. She had stretch marks on 
the lower lumbar region (normal finding for females of this age). She had normal aortic 
root dimensions, but the root has a cloverleaf appearance on ultrasound examination. 
Ophthalmologic examination revealed a minimal lens subluxation on the right. An MRI 
scan of the lower spine revealed lumbosacral dural ectasia. 
Patient 7
Patient 7 is a male patient presenting with hip dislocation at 3 months of age. He was treated 
with splints for a period of about 3 years. At the age of 8 years a severe pectus excavatum 
was corrected. At the age of 18 years he suffered from a pneumothorax, due to rupture of 
an apical bulla which had to be removed surgically. He had progressive aortic root dilation, 
and an elective aortic root replacement was performed at the age of 27 years. Furthermore, 
he had a dilatation of the pulmonary artery and the abdominal aorta. Ophthalmologic 
examination revealed bilateral superior lens dislocation. Physical examination showed an 
outspoken marfanoid habitus with a height of 201 cm (+2.4 SDS) with normal arm span and 
sitting height. He had a long face with high arched palate, dental crowding, general joint 
hypermobility, arachnodactyly with positive wrist and thumb signs, pectus excavatum and 
numerous striae.
Clinical examination of his parents revealed no clinical, ophthalmologic or cardiologic 
abnormalities.
Patient 8
This 4-year old girl presented at the age of 2.5 years with psychomotor retardation. On 
examination her height was 91.5 cm (-0.4 SDS) with an arm span of 91 cm (+2.6 SDS for height) 
and a sitting height of 52.5 cm (normal for height). She had mild facial dysmorphisms with 
downslanting palpebral fissures and hypertelorism. She had arachnodactyly with positive 
thumb and wrist signs and flat feet with long toes. Her thorax was asymmetric and she 
was hypotonic. Ultrasound of heart and aorta revealed billowing of the mitral valve and 
tricuspid valve with grade 1 regurgitation. The aortic root measurements were on the 95th 
percentile. Apart from translucent irides, eye examination showed no abnormalities.





















Patient 9 presented with psychomotor retardation with non-progressive ataxia. At the 
age of 4 years she had joint hyperlaxity, pectus excavatum, a very pale skin and hair 
without other ectodermal manifestations. She had facial dysmorphisms consisting of a 
brachycephalic skull, long philtrum, broad nose and prognathism. She had arachnodactyly 
and flat narrow feet. Her height is within normal limits. At the age of 13 years her height 
was 164,4 cm (+0,6 SDS) with a sitting height/height ratio of -1,1 SDS. She had a normal 
weight. Cardiac examination revealed a mitral valve prolapse but no aortic root dilatation. 
Ophthalmologic examination showed anisohypermetropia but no lens dislocation.
Patient 10
Patient 10 presented at the age of 4 years because his mother was diagnosed with MFS. 
Physical examination showed a tall stature, mild thoracic scoliosis, pectus carinatum, 
hypermobility and arachnodactyly. At the age of 8 years his height was 140.7 cm (+2 SDS) 
and he had an arm span of 149 cm. Cardiac examination showed an aortic root on the 95th 
percentile and mild mitral valve insufficiency. His mother had an normal height, an aortic 
root dilatation, but no ophthalmologic abnormalities. The mother was not tested for the 
deletion.
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Abstract
Several genes involved in the familial appearance of thoracic aortic aneurysms and 
dissections (FTAAD) have been characterized recently, one of which is SMAD3. Mutations 
of SMAD3 cause a new syndromic form of aortic aneurysms and dissections associated 
with skeletal abnormalities. We discovered a small interstitial deletion of chromosome 
15, leading to disruption of SMAD3, in a boy with mild mental retardation, behavioral 
problems and revealed features of the aneurysms-osteoartritis syndrome (AOS). Several 
family members carried the same deletion and showed features including aortic 
aneurysms and a dissection. This finding demonstrates that haploinsufficiency of SMAD3 
leads to development of both thoracic aortic aneurysms and dissections, and the skeletal 
abnormalities that form part of the aneurysms-osteoarthritis syndrome. Interestingly, the 
identification of this familial deletion is an example of an unanticipated result of a genomic 
microarray and led to the discovery of important but unrelated serious aortic disease in the 
proband and family members. 
Introduction
Several genes are known to cause syndromic and non-syndromic forms of aneurysms 
and dissections including FBN1, TGFBR1, TGFBR2, ACTA2, MYH11 and MYLK. These genes 
encode either structural proteins associated with connective tissue, members of the TGF-β 
pathway or components or regulators of the contractile unit of vascular smooth muscle 
cells (SMCs). Recently, mutations in SMAD3 were shown to cause a new syndromic form of 
aortic aneurysms and dissections associated with skeletal abnormalities (1). The authors 
proposed the name aneurysms-osteoarthritis syndrome (AOS). SMAD3 is another member 
of the TGF- β pathway and is essential for TGF- β signal transduction (2). 
We describe the molecular and clinical analysis of a three-generation family, including 
eight members with an interstitial deletion of the long arm of chromosome 15 containing 
SMAD3. Although the deletion was initially identified in the proband, who showed mild 
mental retardation, it was not related to this phenotype. Unforeseen findings resulting 
from untargeted diagnostic testing such as microarray analysis or whole genome 
sequencing will be encountered with increasing frequency and will soon represent a major 




















challenge for counselors. In the case of the family described here, we were able to identify 
additional at-risk family members and could offer them appropriate cardiovascular follow-
up and treatment options.
Patients and methods
Patients
The (simplified) pedigree of the family is depicted in Fig. 1. The proband (IV-1) was a boy 
with mild mental retardation and behavioral problems who was eligible for SNP-array 
analysis as part of mental retardation screening. Following the detection of two copy 
number variants (CNVs), family members were approached and asked to participate in 
SNP-array analysis. As one of the CNVs disrupted the gene SMAD3, which is associated 
with vascular and skeletal abnormalities, affected family members underwent a thorough 
physical and cardiologic examination, including transthoracic echocardiography (TTE) and 
magnetic resonance imaging (MRI), and a skeletal survey of the hands, elbows, spine, hips, 
knees and feet.
Figure 1. Pedigree of the family. Unaffected family members and family members who 
were not investigated are not shown.
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High density microarray analyses, SNP arrays
The Affymetrix GeneChip Human Mapping 250K NspI array (Affymetrix, California, USA) 
contains 262.000 25-mer oligonucleotides with an average spacing of approximately 12 
kb. Subject DNA (250 ng) was processed according to the manufacturer’s instructions 
(www.Affymetrix.com). SNP copy number was assessed using the software program Copy 
Number Analyzer for Genechip (CNAG) Version 2.0 (3).
Transthoracic echocardiography
The diameters of the thoracic aorta at the level of the sinus of Valsalva, sinotubular junction 
and ascending aorta were measured in the left parasternal long axis view from leading 
edge-to-leading edge at end diastole, according to the recommendations of the American 
Society of Echocardiography (4). Body surface area (BSA) was calculated according to the 
DuBois formula (BSA (m2) = 0.007184 × height (cm) 0.725 × weight (kg) 0.425). Measured 
values for adults were plotted against nomograms derived from individuals with normal 
cardiac findings and related to gender, age and body surface area (5). For children, Z-scores 
of the aortic root and ascending aorta were obtained from body surface area-related 
nomograms derived from normal children (6).
Magnetic resonance imaging
Imaging of the entire aorta and large arteries, including the cerebral arteries, was 
performed in the five adult family members (Fig. 1, II-4, II-5, III-1, III-6 and III-4).
Magnetic resonance (MR) imaging was performed on a 1.5 Tesla scanner (Philips Intera, 
Philips Medical Systems, Best, the Netherlands). Survey images were used for planning 
the scans. Body coil was used for MR angiography and 30 mL of a gadolinium-containing 
contrast agent (Dotarem; gadoteric acid 0.5 mmol/mL, Guerbet, Aulnay-sous-bois, France) 
was injected in an antecubital vein with an injection speed of 2 mL/sec. After bolus 
timing, MR angiography of the aorta was acquired during breath-hold. Scan parameters: 
3D high resolution T1-fast field echo sequence, 75 mm coverage, field of view (FOV) 500 
mm, repetition time (TR) 4.6 ms, echo time (TE) 1.3 ms, flip angle (FA) 40°, reconstructed 
voxel size 0.98 x 0.99 x 1.5 mm3. Imaging of the carotid arteries (from aortic arch to head 
including circle of Willis) was performed using a head-neck coil and a 3D time-of-flight 
sequence. Scan parameters: FOV 250 mm, TR 21 ms, TE 6.9 ms, FA 20°. Reconstructed voxel 
size 0.82 x 0.82 x 1.0 mm3. 
Skeletal survey
Six family members underwent a radiographic skeletal survey of the whole spine, 
hands, elbows, knees (in weight-bearing position), ankles and feet. Osteoarthritis was 




















scored as positive when intervertebral disc space or joint space narrowing, osteophytes 
or reactive sclerosis was present. Presence of osteochondritis dissecans, spondylolysis, 
spondylolisthesis and scoliosis were also scored. 
Results
SNP-array analysis of the proband (Fig. 1, IV-1) revealed two CNVs. The first variant was an 
interstitial duplication of the long arm of chromosome 22q11.2, of a maximum 3.2 Mb (130 
SNP probes), from 17.020.301 bp to 20.258.915 bp (Ensembl release 54). The second variant 
was an interstitial deletion of the long arm of chromosome 15q22.3q23, of a maximum 
194.8 kb (11 SNP probes), from 65.195.296 bp to 65.390.067 bp (Ensembl release 54) (Fig. 
2a, b). The deleted region contained the three protein-encoding genes, SMAD3, AC012568.7 
and IQCH (Fig. 2c), and the proximal breakpoint was in intron 1 of SMAD3, resulting in the 
deletion of the gene from exon 2 onwards.
The proband’s father (III-1) had the same copy number abnormalities as his son, and a 
further five family members (II-4, II-5 III-4, III-5 and IV-2) carried the interstitial deletion of 
chromosome 15q22.3q23 but not the interstitial duplication of chromosome 22q11.2 (Table 
1). 
The clinical features of the family are summarized in Table 1. Seven family members were 
investigated, including the proband and a 4-year-old child. Despite the fact that he could 
not be examined, the proband’s grandfather (II-2) is an obligate carrier of the chromosome 
15 deletion. The great-grandparents of the proband (I-1 and I-2) died at the age of 89 and 92 
of unrelated disorders. 
Of the five adults investigated, four experienced an aneurysm of the thoracic aorta. All four 
showed dilation of the aortic root, with three also showing dilation of the ascending aorta. 
MR imaging of patients II-4, II-5 and III-1 showed clear tortuosity (due to elongation) of the 
aorta, the carotid arteries and in III-1, of the superior mesenteric artery. The MR-angiography 
images of II-4 and II-5 (brother and sister) are depicted in Fig. 3a, b. No aneurysms or clear 
tortuosity of the cerebral arteries were detected. Although the 12-year-old proband and 
his 4-year-old cousin (IV-1 and IV-2) showed normal absolute aortic diameters, the Z-scores 
of the ascending aorta were higher compared to the Z-scores of the sinotubular junction. 
All five adult family members investigated for skeletal abnormalities showed scoliosis and 
four also exhibited intervertebral disc space narrowing. One family member (II-5) also had 
a grade one spondylolisthesis at lumbar level 2-3, secondary to facet artrosis. X-rays of the 
hands and spine (Fig. 3c-f) of a 68-year-old woman, II-4, showed both severe deforming 
osteoarthritis in the distal and proximal interphalangeal joints, without degeneration 
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of the scaphotrapezotrapezoidal (STT) and first carpometacarpal (CMC1), and severe 
degeneration of the whole spine. Neither spondylolysis nor ostechondritis dissecans was 
found in the investigated family members.
Apart from varicosis in III-1 and a soft skin in II-4, no skin abnormalities were found, and in 
particular, thread veins were absent. An abnormal uvula or a high narrow palate was found 
in four family members. Two family members showed inguinal hernias, including one that 
was recurrent (II-5) but possibly due to work-related physical exertion. Diaphragmatic 
hernias were detected by MRI in two patients (II-4 and II-5). 
Figure 2. SNP array results – proband. (a) Chromosome 15 plot obtained by SNP array 
analysis, with black arrows indicating the deletion. (b) Detailed view of the 15q22.3q23 
deletion. (c) Position of the deletion on chromosome 15 (Ensemble release 54, May 2009). 
The three known protein-encoding genes affected by the deletion, SMAD3, AC012568.7 
and IQCH , are represented by the bars beneath the chromosome.




















Figure 3. (a, b) Gadolinium contrast agent enhanced magnetic resonanceangiography (a, 
b) in a 69-year-old female patient (a, II-4)) and 64- year-old male patient (b, II-5); sister and 
brother. Both had severe elongation of the descending aorta with similar presentation 
of leftbackward bulging of the aorta (a, b). Both showed elongation of the carotid artery 
on the left side (not shown). (c–f) Conventional X-rays of the 69-year-old female patient 
(II-4) with osteoarthritic changes of the hands, showing osteoarthritic changes with 
narrowing of multiple interphalangeal joints and subluxation of distal interphalangeal 
joints 2–5 on left and 2, 3, 5 on right (c). No degenerative changes in first carpometacarpal 
or scaphotrapezotrapezoidal joints of wrists. Upper part of cervical spine showing 
narrowing of intervertebral disk spaces C3-4 and C4-5 and facetarthrosis (d, arrows). 
Thoracic (e) and lumbar (f) spine showing scoliosis convex to the left on thoracic level 
and to the right on lumbar level. Narrowing of intervertebral disk spaces and extensive 
degenerative spondylophytes on thoracic and lumbar levels (arrows).
hoofdstuk 6.indd   207 19-04-13   08:23
Chapter 6  |   An unanticipated copy number variant of chromosome 15 disrupting SMAD3
208
Table 1. Laboratory investigations and clinical features
Pedigree number II-2 III-1 IV-1 (proband) III-4 IV-2 III-5 II-4 II-5
sex M M M F F M F M
age at examination; d: age at 
death
d54 42 12 33 4 18 69 64
BSA u 2.2 1.9 1.9 0.8 2.3 1.9 1.9
Molecular results
dup22q ni Yes Yes No No No No No
del15q (including SMAD3) ni1 Yes Yes Yes Yes Yes Yes Yes
Cardiovascular
dilatation aortic root (cm)* >22 No (3.8) No (2.9) Yes (3.8) No (2.1) Yes (4.3) Yes (4.0) Yes (4.3)
dilatation ascending aorta (cm)* Yes2 No (3.5) No3 (2.9) No (2.9) No3 (2.0) Yes (3.4) Yes (4.7) Yes (4.2)
dissection ascending aorta Yes No No No No No No No
aneurysms of other arteries u No ni No ni No No No
arterial tortuosity u Yes ni No ni No Yes Yes
mitral valve abNormalities No No No No No No No No
other heart disease ihd No No No No No No No
Skeletal
pectus deformity u No No No No No No No
scoliosis u No4 Yes Yes No Yes Yes Yes
joint laxity u No No No No Yes No No
Joints
intervertebral disc degeneration u Yes No Yes ni No Yes Yes
osteoarthritis (location) u No No No ni No Yes (hand, knee, 
hip)
Yes (hand, ankle, 
elbow, hip)
osteochondritis dissecans u No No No ni No No No
Craniofacial
hypertelorism u Yes Yes No No No No No
abNormal palate or uvula u Broad uvula Mild cleft 
uvula
High and narrow 
palate
No No No Broad uvula
Skin/hernia’s
velvety skin u No No No No No Yes No
umbilical or inguinal hernia u No No No No No Yes Yes5
diaphragmatic hernia u No No No ni No Yes Yes
thread veins u No No No No No No No



























*) measurements obtained by TTE; 1) obligate carrier; 2) observation during operation; 3) the Z-score of the ascending aorta was wider than the Z-score of the aortic root; 4) mild 
deviation of the spine; 5) recurrent inguinal hernias associated with physical labor. Abbreviations: u, unknown; ni, not investigated; ihd, ischemic heart disease; ADHD, attention 
deficit hyperactivity disorder.





















In this report we describe an incidental finding from an unrelated microarray analysis that 
led to the discovery of a serious health risk for the family involved. Microarray analysis is 
widely used in the diagnostic work-up of patients with mental retardation, with or without 
congenital abnormalities, and while much emphasis is placed in the literature on the 
likelihood of a pathogenic role for a CNV in the context of the patient’s phenotype, the use 
of whole genome analysis in a diagnostic setting may detect variants unrelated to current 
clinical findings (7, 8). The identification of the family described here was due to a SNP-array 
analysis carried out as a component of mental retardation screening. The duplication of 
chromosome 22q11.2, found in both the proband and his father, is a frequently encountered 
CNV and has been associated with an extremely variable phenotype ranging from 
completely normal to mental retardation and congenital abnormalities. The duplication is 
often encountered in a parent with no or a mild phenotype (9, 10) and it is thus probable 
that the learning and behavioral problems of the proband are, at least in part, due to this 
duplication.
The interstitial deletion of chromosome 15q22.3q23 disrupts SMAD3, and excepting exon 
1, leads to deletion of the whole coding region of SMAD3 and haploinsufficiency. As 
recent reports demonstrated the role of mutations in SMAD3 in an autosomal dominant 
syndromic form of aneurysms and dissections (1, 11, 12), it was decided to inform the family 
of the possible risk for aortic disease and to initiate a family study. In addition to the 
proband, seven other family members carried the deletion, including one obligate carrier. 
In addition to SMAD3, the deletion encompasses the genes AC012568.7 and IQCH and has 
not been previously described in the normal population. All carriers showed vascular 
involvement and the majority also showed skeletal involvement. It is not clear whether the 
diaphragmatic hernia found in two carriers is due to the SMAD3 deletion (Table 2). 
Our findings are in accordance with those of previously described SMAD3 families (1, 11, 12), 
including features of AOS with highly variable expression ranging from very mild features 
to dissection of the thoracic aorta. Thirteen SMAD3 mutations have been described to date 
and are summarized in Table 2 (1, 11, 12, 13). Three reports have described 12 mutations in 
11 families, with all cases recruited from TAAD families, implying a bias towards an aortic 
phenotype (1, 11, 12). This is further emphasized by the patient group described by van de 
Laar et al. (12), of which  89% showed cardiovascular anomalies, predominantly thoracic 
aortic aneurysms but also including high percentages of aneurysms of the abdominal 
aorta, large arteries and cerebral arteries. Though not ascertained due to aortic disease, 
the family described here shows aortic involvement in five of the six adults carrying the 
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SMAD3 deletion. In the 12-year-old proband (Fig. 1, IV-1) and a 4-year-old cousin (Fig. 1, IV-
2), the abnormal feature of an ascending aorta wider than the sinotubular junction was 
seen and could be the first sign of future dilatation. All five adult carriers investigated 
showed remarkable scoliosis, including four with radiologically proven intervertebral disc 
degeneration. The 68-year-old woman (II-4) with severe distal osteoarthritis of the hands 
showed normal STT and CMC1 joints, in contrast to cases described in the literature (1). This 
might well be the classic form of osteoarthritis and not linked to the disruption of SMAD3.
Table 2. Summary of SMAD3 mutations described in the literature

















1 0 Knee OA no 
investigations for 
other features of AOS
Yao 2003
         
c.859C>T p.Arg287Trp 6 MH2 domain Family 1 25 5 TAAD, AAA, ICA, IAA, 
OA, aortic and arterial 
tortuosity
van der Laar 
2011; van de 
Laar 2012c.741–742delAT p.Thr247ProfsX61 6 MH2 domain: premature stop in 
exon 7; proven NMD; removes nearly 
complete MH2 domain, TGFBR1 target 
site and residues involved in homo 
and heterodimer formation
Family 2 2 1
c.782C>T p.Thr261Ile 6 MH2 domain Family 3 2 0
c.313delG p.Ala105ProfsX11 2 MH1 domain; probable NMD Family 7 1 0
c.539_540insC p.Pro180ThrfsX7 4 proline rich linker region; probable 
NMD
Family 8 1 0
c.788C>T p.Pro263Leu 6 MH2 domain Family 6 1 0
c.1045G/C p.Ala349Pro 8 MH2 domain Family 4 1 0
c.1080dupT p.Glu361X 8 MH2 domain Family 5 1 0
         
c.652delA p. Asn218fs 5 premature stop TAA549 7 6 TAAD, AAA, ICA, IAA, 
OA, aortic tortuosity
Regaldo 2011
c.836G>A p.Arg279Lys 6 MH2 domain, predicted to affect 
hydrogen bond formations and XPO4 
interaction (promotion of SMAD3 
nuclear transport)
TAA071 7 2
c.836G>A p.Arg279Lys 6 MH2 domain, predicted to affect 
hydrogen bond formations and XPO4 
interaction (promotion of SMAD3 
nuclear transport)
TAA072 2 0
c.715G>A p.Glu239Lys 6 MH2 domain, predicted to affect 
hydrogen bond formations
TAA365 3 1
c.235C>T p.Ala112Val 2 not conserved in fruitfly, possibly 
damaging
TAA115 4 1
Abbreviations: AAA, abdominal aortic aneurysms; AOS, aneurysms-osteoarthritis syndrome; IAA, iliac arterial aneurysms; ICA, intracranial aneurysms; OA, 
osteoarthritis; TAAD, thoracic aortic aneurysms and dissections




















As little is yet known of the two other genes in the deleted region, a possible role in the 
phenotype cannot be entirely ruled out. AC012568.7 encodes a protein of unknown function 
and the IQCH gene is thought to be associated with tall stature (14). 
We conclude that the similarities of the vascular and skeletal phenotype in the family 
described here to those of other families with mutations in SMAD3 is the result of the 
disruption and resulting haploinsufficiency of SMAD3. The discovery of a serious health 
risk unrelated to the phenotype of the proband is a telling example of the potential impact 
of whole genome analysis on family members. Although current literature contains few 
articles describing unexpected results, this family underlines the importance of precise 
genetic interpretation of a CNV and the genes involved in order to provide appropriate 
information to the patient and family. The identification of at-risk members of this 
particular family allowed early detection of vascular disease, appropriate counseling and 
facilitated possibly life-saving follow-up and treatment.
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Introduction
Marfan syndrome (OMIM 154700) is a connective tissue disorder with multisystemic 
involvement and autosomal dominant inheritance due to mutations in the fibrillin-1 
gene (FBN1).1 Here we report two unrelated children with Marfan syndrome and recurrent 
intracranial hypertension. To our knowledge, intracranial hypertension (IH) has never been 
associated with Marfan syndrome.
Case report
The first case is an 11-year-old boy with Marfan syndrome who presented with headache, 
nausea and vomiting on several occasions. The intracranial pressure at these events was 
measured to be above 20 cm H2O. His symptoms disappeared after drainage of at least 15 
cc of cerebrospinal fluid (CSF). Extensive investigations revealed only mild iron deficiency 
anemia. Treatment of the anemia did not prevent a new episode of high intracranial 
pressure. Magnetic resonance imaging (MRI) of the brain showed bilateral choroid plexus 
cysts, slightly dilated ventricles, and a small arachnoid cyst of 1.5 cm in the cisterna magna 
(Figure 1A). The spinal cord MRI showed sacral dural ectasia with radicular cysts and an 
anterior sacral meningocele (Figure 1B and 1C). The diagnosis Marfan syndrome was made 
in the first year of life because of lens subluxation and a positive family history. At age 11 
he has mild skeletal manifestations of Marfan (pes planus) and a mildly dilated aortic root. 
His length is on the 84th centile, his weight on the 80th centile and his head circumference 
on the 50th centile. He has had several ophthalmological operations for lens luxations and 
strabismus. He fulfills the international criteria for Marfan syndrome.2 A homozygous 
missense mutation in exon 60 of the fibrillin-1 gene was found, leading to the amino acid 
substitution p.Asp2485Val. Both parents carry one copy of the mutation and exhibit very 
minor signs of Marfan syndrome. His affected sister also has a homozygous mutation. 
She has the classical manifestations of Marfan syndrome but does not have signs of high 
intracranial pressure.
The second case was a 7.5 year old girl who was evaluated for complaints of headache, 
vomiting, diplopia and a tonic clonic epileptic seizure. Apart from papil edema there 
were no neurological signs. After excluding intracranial mass lesions or vascular lesions, 
a lumbar puncture was done revealing a CSF pressure of 50 cm H2O. Repeated lumbar 
punctures were necessary to alleviate her symptoms. Medical treatment was started 
with acetazolamide that relieved her headache and controlled the CSF pressure (8 cm 
H2O). After discontinuing the medication the symptoms returned promptly. A ventricular 




















peritoneal drainage operation was performed with excellent result. Physical examination 
showed a length far above the 99th centile, arm span on the 75th centile, weight on the 
80th centile and head circumference on the 90th centile. Her joints were hypermobile. 
Because of the high intracranial pressure and her body habitus, extensive analysis was 
performed for connective tissue disorders and diseases causing high intracranial pressure. 
Endocrinological tests, X-rays of the vertebral column, an extensive metabolic screen, 
including vitamine disorders, showed no abnormalities. MRI of the brain and spinal 
cord showed narrowing of the left transverse sinus and mild ectasia of the dural sac. At 
echocardiographic examination mild prolapse of the mitral- and tricuspid valves and aortic 
root dilation were detected. The clinical diagnosis Marfan syndrome was made according 
to the international criteria.2 The diagnosis was confirmed by a de novo missense mutation 
in the fibrillin-1 gene (7741T>A) leading to the amino acid substitution Cys2581Ser. 
Figure 1. Magnetic resonance T2-weighted turbo spin-echo images of the brain and spine 
of case 1. (A) Transverse brain image demonstrating bilateral plexus choroideus cysts 
(arrows). (B)  Transverse image showing the anterior sacral meningocele. (C) Sagittal 
image of the lumbosacral spine showing dural ectasia (arrow) and scalloping of the 
posterior lumbar vertebral bodies (arrowheads).
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Discussion
Although severe headache has been reported in Marfan syndrome due to intracranial 
hypotension caused by CSF leakage from dural ectasia,3,4  this is the first report of intracranial 
hypertension in Marfan patients. The choroid plexus cysts and the arachnoid cyst present 
in case 1 might have contributed to the raised intracranial pressure by impairment of CSF 
flow. Cerebrovenous sinus abnormalities, as present in case 2, are frequently found in 
idiopathic intracranial hypertension but whether such findings result from or cause the 
raised pressure is still unknown.5 The intracranial lesions as described in case 1 and 2 have 
not been previously associated with Marfan syndrome.
 Given the low incidence of both intracranial hypertension in children and Marfan syndrome, 
the concurrence of intracranial hypertension with Marfan syndrome in two young patients 
is unlikely to be coincidental.6 Marfan syndrome, and possibly other connective tissue 
disorders, may confer a predisposition to developing intracranial hypertension. Therefore, 
patients with Marfan syndrome and unexplained symptoms of headache and vomiting 
should be promptly investigated for possible intracranial hypertension, and conversely, 
in young patients with unexplained intracranial hypertension possible signs of Marfan 
syndrome should be noted and, if so, further investigations instigated.
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Summary
Thoracic aortic aneurysms and dissections have a high morbidity and mortality rate. 
Learning more about the aetiology and mechanisms of this aortic disease is a challenge, 
but may provide the opportunity to offer adequate treatment to at risk individuals. In 
contrast to abdominal aortic aneurysms, mutations in single genes play an important role 
and when a predisposing genetic factor for thoracic aortic disease has been identified in 
an individual, appropriate monitoring and timely surgical intervention may prevent aortic 
dissection. Marfan syndrome is caused by mutations in FBN1, the gene encoding fibrillin-1, 
and is one of the best known disorders with a strong genetic predisposition for thoracic 
aortic aneurysms and dissections at a relatively young age. 
This thesis concerns the clinical and genetic aspects of thoracic aortic aneurysms and 
dissections, in Marfan syndrome in particular. Chapter 1 provides a general introduction to 
Marfan syndrome, FTAAD and other syndromes associated with thoracic aortic aneurysms 
and dissections. Special emphasis is given to current knowledge of the pathophysiology 
of aortic disease in Marfan syndrome. Chapter 2 presents the Dutch multidisciplinary 
guidelines for diagnosis and management of Marfan syndrome. These guidelines contain 
practical directions for referring physicians and specialists involved in the recognition, 
diagnosis, monitoring and treatment of Marfan syndrome. The guidelines are evidence-
based when possible, but in the absence of sufficient evidence, guidelines are based on 
expert opinion. The revised Ghent nosology for Marfan syndrome, established by an 
international panel of experts, is presented in Chapter 3. The new nosology places greater 
emphasis on aortic root aneurysm or dissection and on ectopia lentis. The presence of 
these two cardinal features is sufficient to allow the diagnosis of Marfan syndrome. In the 
absence of either feature, the presence of a first-degree relative with Marfan syndrome, a 
pathogenic FBN1 mutation or a combination of systemic features is required to establish a 
firm diagnosis. 
Chapter 4 describes missense mutations in FBN1 that are predicted to substitute the first 
aspartic acid of various calcium-binding Epidermal Growth Factor-like (cbEGF) fibrillin-1 
domains. One of the mutations was found in a homozygous state in three cases from a 
large consanguineous family. Thirteen heterozygous carriers of the same mutation had 
no major skeletal, cardiovascular or ophthalmological features of Marfan syndrome. 
From literature, 14 other heterozygous missense mutations are known that lead to the 
substitution of the first aspartic acid of a cbEGF domain and result in a Marfan phenotype. 
These data show that the phenotypic effect of an aspartic acid substitution in the first 
position within a cbEGF domain can range from asymptomatic to a severe neonatal 
phenotype. The recessive nature of a specific cbEGF domain mutation in one family 




















suggests a threshold model in which reduced expression of FBN1 combines with a mild 
functional defect due to this particular mutation. This observation underscores the 
importance of careful interpretation of missense mutations, as pathogenic effects can not 
always be easily predicted. 
A series of ten patients carrying a whole-gene deletion of one allele of FBN1 is described 
in Chapter 5. The full spectrum of marfanoid features was observed in these patients, 
including aortic root aneurysms needing surgical intervention and ectopia lentis. These 
findings show that true haploinsufficiency can result in the full spectrum of Marfan 
syndrome and make a major contribution to pathogenesis.
Chapter 6 describes a three-generational family at risk for serious aortic disease as a 
result of an interstitial deletion of chromosome 15 that disrupts SMAD3. This deletion was 
detected incidentally, through a genomic microarray performed for mental retardation. 
Mutations in SMAD3 are associated with a recently discovered syndromic form of 
aortic aneurysms and dissections associated with skeletal abnormalities (aneurysms-
osteoarthritis syndrome, AOS). In the family described, family members were not aware of 
their risk and several carriers of the deletion were found to have a dilatation of the thoracic 
aorta and skeletal manifestations of AOS, while an obligate carrier had previously died as a 
consequence of aortic dissection.
Chapter 7 describes two unrelated children with classic Marfan syndrome and recurrent 
intracranial hypertension. To the best of our knowledge, this symptom has not previously 
been reported in association with Marfan syndrome. Both children displayed dural ectasia, 
one in a severe form with an anterior sacral meningocele. However, dural ectasia has been 
associated with intracranial hypotension (as opposed to intracranial hypertension) caused 
by cerebrospinal fluid leakage. One of the children is a member of the consanguineous 
family described in Chaper 4 and is a homozygous carrier of a substitution of the first 
aspartic acid in a cbEGF domain. The second child has a de novo mutation leading to the 
substitution of a cysteine in a cbEGF domain in FBN1.
Discussion
Victor McKusick, in 1955, was the first to classify Marfan syndrome as a connective tissue 
disorder and he included a review of all clinical features (McKusick, 1955). The discovery of 
the fibrillin-1 gene as the cause of Marfan syndrome confirmed McKusick’s prediction that 
Marfan syndrome is caused by a defect in an extracellular matrix protein (ECM) (Dietz et 
al., 1991). The finding that fibrillin-1 interacts with latent-TGFb-binding protein-1 (LTBP-1) 
and plays a role in the transforming growth factor b (TGFb) bioavailability represented a 
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paradigm shift, moving from the concept that Marfan syndrome is caused by a structural 
defect of the ECM to awareness that it is a developmental disorder involving perturbation 
of a signalling pathway (Annes et al., 2003; Isogai et al., 2003). This insight has important 
implications for treatment options.
1.1  Criteria and guidelines for diagnosis and management of Marfan syndrome 
From a clinical point of view, it is of the utmost importance that Marfan syndrome is 
recognised. Given the highly variable and pleiotropic manifestations of the disease, many 
clinicians may encounter an as yet undiagnosed patient. The four Marfan expertise clinics 
in the Netherlands together developed multidisciplinary guidelines for Marfan syndrome 
(chapter 2). These guidelines provide recommendations for Marfan clinic health workers 
concerning uniform diagnostic procedures, follow up and therapy. Furthermore, through 
the guidelines, referring specialists and general practitioners have easy access to up-to-
date information concerning both the syndrome and the criteria for referral. 
To establish a diagnosis of Marfan syndrome, the Dutch guidelines follow the revised Ghent 
criteria, formulated by an international panel of experts and published in 2010 (Loeys et al., 
2010). An important revision of these criteria, opposed to the former criteria published in 
1996, places greater emphasis on cardiovascular manifestations (De Paepe A. et al., 1996; 
Loeys et al., 2010). Although aortic root aneurysm together with ectopia lentis is sufficient 
for the diagnosis of Marfan syndrome, with the presence of a first-degree family member 
with Marfan syndrome the diagnosis can be established on the basis of an aortic root 
dilatation or ectopia lentis alone. Dural ectasia was a major feature in the former criteria, 
but is now part of a new scoring system for systemic features. If DNA analysis is available, 
a pathogenic FBN1 mutation together with either an aortic root dilatation or ectopia lentis 
is sufficient for diagnosis. The revised Ghent criteria offer directions for further testing in 
case of findings that are not specific for Marfan syndrome. In cases with an alternative 
diagnosis, the paper includes recommendations for counselling, follow-up and treatment.
As aortic root dilation is the key diagnostic criterion, it is very important to use reliable 
nomograms. Although international guidelines provide recommendations for the 
measurement procedure, there is still controversy regarding the upper limits for the aortic 
root. The Roman nomograms correlate the body surface area (BSA) with the aortic root 
diameter and are considered to be the gold standard by many cardiologists (Roman et al., 
1989). Although the regression line of the Roman nomograms appears to be linear, above 
38 mm the linear relationship has to be extrapolated, with the largest aortic diameter 
measured at 38 mm. Later studies showed a nonlinear threshold above a certain BSA or 
height (Reed et al., 1993; Kinoshita et al., 2000; Pelliccia et al., 2010). Using the Z-scores 
advised in the revised Ghent nosology, based on the Roman nomograms, aortic root 




















measurements above 40 mm would be classified as normal in patients with a high BSA (>2 
m2). As patients with Marfan syndrome often have a higher than average BSA, a diagnosis 
may be missed. A maximum aortic root diameter of 38 mm was found in a retrospective 
study of 38 healthy individuals with a high BSA (Radonic et al., 2011). On the basis of these 
studies, the Dutch guidelines recommend considering an absolute aortic root diameter of 
more than 40 mm as dilated. It now appears that age, gender and body surface area should 
be accounted for regardless of the method used, and use of the Z-score can help in deciding 
whether an aortic root is or is not dilated. 
Another shortcoming of the revised Ghent nosology is in the definition of pathogenicity of 
FBN1 mutations. The criteria presented to define causality in the revised Ghent nosology 
are incomplete and need adjustment or further specification, due to the prominent role 
given to the presence of a FBN1 mutation. For example, one of the criteria is presented as 
‘missense affecting conserved residues of the EGF consensus sequence ((D/N)X(D/N)(E/Q)
Xm(D/N)Xn(Y/F) with m and n representing variable numbers of residues; D aspartic acid, 
N asparagine, E glutamic acid, Q glutamine, Y tyrosine, F phenylalanine’. This EGF consensus 
sequence formula implies that aspartic acid can be replaced by asparagine, and glutamic 
acid by glutamine. However, as shown in Chapter 4, the negatively charged aspartic acid 
in the first position of a cbEGF domain is crucial for calcium binding, and the substitution 
of aspartic acid has been shown to be deleterious in several cases (Hilhorst-Hofstee et al., 
2010b). 
Complete FBN1 allele deletions were shown to cause Marfan syndrome in Chapter 5 and 
should now be added to the list of causal mutations (Ades et al., 2006; Faivre et al., 2010; 
Hilhorst-Hofstee et al., 2010a; Hiraki et al., 2008; Hutchinson et al., 2003). 
Although less specific features of Marfan syndrome were removed or given less weight in 
the new nosology, the scoring of systemic features remain rather subjective. No objective 
criteria exist for the wrist and thumb sign, pectus deformities, foot abnormalities, dural 
ectasia, facial features or skin striae, and the assignment of 1, 2 or 3 points for the systemic 
score are entirely based on expert opinion. 
In most individuals with a clearly pathogenic mutation, DNA analysis will establish a 
definite diagnosis. However, in cases where DNA analysis is inconclusive, the clinician 
must rely on clinical features when seeking to decide whether a diagnosis of Marfan 
syndrome is justified, meaning that interpretation of clinical features will remain the 
core of the diagnosis. The Dutch guidelines are based on the best available evidence and 
provide professionals with recommendations on most of the important aspects of Marfan 
syndrome such as recognition, referral to expert clinics, diagnostic procedures, follow-up 
and therapy.
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1.2  Pathogenesis of thoracic aortic aneurysms and dissections 
In Chapter 4, 5 and 6, three different genetic causes of thoracic aortic aneurysms are 
described. First mutations with an expected dominant negative effect are described 
in Chapter 4. In Chapter 5 and 6 true haploinsufficiency of FNB1 and SMAD3 caused by 
deletions are presented. 
All cbEGF domains in the human FBN1 gene begin with a codon for aspartic acid. This amino 
acid is crucial for calcium binding and substitutions are expected to reduce the binding 
of calcium, with a disturbance of the tertiary structure, susceptibility for proteolytic 
degradation and disturbed protein-protein interaction as a consequence. In Chapter 4, a 
series of substitutions of the first aspartic acid of a cbEGF domain are described (Hilhorst-
Hofstee et al., 2010b), substitutions that are predicted to affect the binding of calcium. 
Calcium binding to fibrillins is necessary for structural stabilisation, protein-protein 
interaction and the prevention of proteolytic degradation (Cooke et al., 1987; Dietz et al., 
1993; Handford et al., 1991). Around half of the mutations described were predicted to result 
in aberrant splicing, and in one case this was demonstrated experimentally. Mutations 
causing aberrant splicing and consequent exon skipping will generally result in a shorter 
protein rather than a frameshift, due to the fact that nearly all FBN1 exons harbour an 
exact multiple of three bases. A shorter protein is expected to exert a dominant negative 
effect. Most of the known aspartic acid substitutions lead to a classic Marfan phenotype or 
even a severe neonatal phenotype. In one family, however, the substitution of the aspartic 
acid at cbEGF domain 39 (p.Asp2485Val) only resulted in Marfan syndrome when in a 
homozygous state. This is thought to be due to a relatively mild reduction in expression of 
the mutant allele (leading to a possibly mild functional defect), with just enough normal 
function in the heterozygous state but below a certain threshold in a homozygous state to 
express the phenotype. One explanation might be the presence of an additional variant in 
the promoter region in cis with the mutation, leading to reduced expression of the mutant 
allele.
Despite the suggestion in an earlier report that FBN1 haploinsufficiency leads to a milder 
phenotype (Milewicz et al., 1995), Chapter 5 describes 10 Marfan patients with a complete 
deletion of one FBN1 allele, demonstrating that complete haploinsufficiency of FBN1 leads 
to a classic Marfan phenotype including ectopia lentis and aortic root aneurysm needing 
surgery at a relatively young age. This accords with the observation of  Marfan syndrome 
fulfilling the Ghent criteria in patients with a deletion of the promoter region, which was 
shown to result in a complete loss of transcription of the corresponding allele (Matyas et 
al., 2007). Three other reports have described a complete deletion of one FBN1 allele and 




















marfanoid features (Ades et al., 2006; Faivre et al., 2010; Hutchinson et al., 2003). Although 
no mouse models with true haploinsufficiency of one FBN1 allele are known, several studies 
in mice have shown that a haploinsufficiency state, due to expression of very low levels of 
fibrillin-1 with or without a dominant negative potential, can be associated with mild to 
severe phenotypes (Dietz and Mecham, 2000; Judge et al., 2004; Mariko et al., 2011; Neptune 
et al., 2003; Pereira et al., 1997; Pereira et al., 1999; Lima et al., 2010). Overexpression of a 
mutant allele in a normal mouse background does not result in a disease phenotype, while 
introducing a wild-type allele in a heterozygous mutant background rescues the aortic 
phenotype of the mutant (Neptune et al., 2003). Using a mouse model, Lima et al. showed 
a negative correlation between Fbn1 expression and the severity of the phenotype (Lima 
et al., 2010). This protective effect of higher levels of normal fibrillin-1 has also been shown 
in a patient carrying a deletion and in three related patients carrying a mutation causing 
a premature termination codon (Hutchinson et al., 2003). These observations in humans 
and mice show that haploinsufficiency of fibrillin-1 is a major pathogenetic mechanism 
in the development of the Marfan phenotype, and that a higher level of normal fibrillin-1 
correlates with a milder phenotype.
Mutations in SMAD3 have been shown to cause an autosomal dominant syndromic form 
of aneurysms and dissections, the aneurysms-osteoarthritis syndrome (AOS) (van de Laar 
et al., 2011; van de Laar et al., 2012; Regalado et al., 2011). In Chapter 6, a family is described 
with an interstitial deletion of chromosome 15 that disrupts the SMAD3 gene. This was an 
unexpected result from a microarray analysis and unrelated to the clinical features of the 
proband. All family members carrying the deletion showed vascular involvement and one 
obligate carrier died as a consequence of a thoracic aortic dissection. 
The family described here showed similarities in vascular and skeletal phenotype to
other families with mutations in SMAD3, the result of the disruption and resulting 
haploinsufficiency of SMAD3. SMAD3 encodes a member of receptor-regulated SMADs and 
forms a complex with SMAD2 and SMAD4. This complex, in combination with transcription 
factors, regulates gene expression via activation of TGF-b receptors (Ten Dijke and Arthur, 
2007; Ten Dijke and Hill, 2004) and is the mediator of most responses to activation of 
TGF-b (Massague and Gomis, 2006). Thirteen mutations in SMAD3 have been described 
to date (van de Laar et al., 2011; van de Laar et al., 2012; Regalado et al., 2011), four of which 
introduce a frameshift and one a stop codon. One frameshift mutation, c.741-742delAT; 
p.Thr247ProfsX61, was shown to cause nonsense-mediated RNA decay and was predicted 
to behave as a functional knock-out (van de Laar et al., 2011). It has been suggested that 
all mutations lead to impaired heterotrimer formation with SMAD4, with a consequent 
impairment in the propagation of TGF-b signalling. 
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The similarities of the aortic and skeletal phenotypes in families with mutations in SMAD3, 
compared to the described family, suggests a major role for haploinsufficiency of SMAD3. 
While SMAD3 knockout mice do show intervertebral disc abnormalities and osteoarthritis, 
aortic disease was not investigated (Li et al., 2009; Yang et al., 2001) and information on 
mice with heterozygous null alleles is unavailable.
1.3  Intracranial hypertension in Marfan syndrome
We are still puzzled by the observation of intracranial hypertension in two unrelated 
children with Marfan syndrome, described in Chapter 7. One of the patients carried a 
homozygous missense mutation (p.Asp2485Val) and is a member of the family harbouring 
a recessive mutation described in Chapter 4, while the second child had a cysteine 
substitution (p.Cys2581Ser) in FBN1. Both children showed the classic features of Marfan 
syndrome and both had dural ectasia. One of the patients had bilateral choroid plexus 
cysts and a small arachnoid cyst, while the other patient had a narrow left transverse 
sinus, frequently encountered in children with idiopathic intracranial hypertension. Dural 
ectasia predisposes for intracranial hypotension caused by cerebrospinal fluid leakage, 
rather than hypertension. Although, to date, no other reports of intracranial hypertension 
in combination with Marfan syndrome or another connective tissue disorder are known 
to us, it is important to be alert to a possible relationship between a connective tissue 
disorder and intracranial hypertension, in order to allow rapid and effective investigation 
in cases of unexplained headache and vomiting.
1.4  Counselling
Some important counselling issues can be addressed with the help of studies described 
in this thesis. Firstly, mutations in FBN1 have to be carefully assessed, as shown by a 
seemingly pathogenetic mutation that was not as deleterious as initially expected, as 
described in Chapter 4. Secondly, careful clinical assessment of family members and the 
interpretation of laboratory results by an experienced clinical and molecular geneticist 
are a prerequisite. Although descriptions of the phenotype may be partly subjective, in 
most studies clinical observations and descriptions are very valuable to clinicians dealing 
with families with a genetic disorder. As shown in Chapters 4, 5 and 6, the data are of no 
use without the accompanying medical information. Furthermore, unexplained features 
such as intracranial hypertension in two unrelated patients with Marfan syndrome, as 
described in Chapter 7, require publication because such observations might lead to the 
recognition of health problems that were previously overlooked. With the emergence of 
whole genome analysis, we will soon be facing a dramatic rise in unexpected results that 
are unrelated to the phenotype of the individual tested. This issue is discussed in Chapter 




















6, in which an unrelated microarray analysis led to the discovery of a SMAD3 copy number 
variant with serious health risks for the family, including vascular disease and osteoarthritis 
at a young age. The unexpected results of whole genome analysis have been described 
in only a handful of studies and to the best of our knowledge, vascular disease has not 
been previously addressed. The identification of at risk members of this particular family 
allowed early detection of vascular disease, appropriate counselling and will facilitate 
possibly life-saving follow-up and treatment.
1.5  Future perspectives
Marfan syndrome
The Dutch guidelines for Marfan syndrome aim to realise improved and better coordinated 
care for Marfan patients. In the process of developing the guidelines, we were faced with 
many issues lacking an evidence-base. While some of these issues concerned the features 
on which clinical diagnosis relies, others concerned treatment options such as timing of 
surgical repair of the aorta or medication to slow aortic dilation. Future studies to validate 
the clinical items in the diagnostic criteria of Marfan syndrome would therefore be valuable. 
On the other hand, clinical diagnosis in individual cases might not always meet the 
requirements of the criteria, even if all items were validated and objective. This is partly due 
to the variability of the phenotype. A major future challenge will be the characterisation of 
the individual patient based on genetic background, the modifying factors that influence 
the expression of the disease and the effect of certain treatment options in relation to 
these differences. Detailed clinical descriptions that are related to specific pathogenic 
mutations and studies of modifying factors are needed to provide greater insight into the 
causes of the variability of Marfan syndrome. Without these detailed clinical descriptions, 
investigations of modifying factors that determine the severity of Marfan syndrome are 
useless. This also applies to the characterisation of the effect of FBN1 mutations. Validated 
criteria to differentiate between pathogenic mutations in FBN1 or neutral variants without 
effect on the clinical phenotype are strongly needed. Knowledge of modifying factors such 
as variants in the promoter region, stochastic variation in gene expression, environmental 
factors, or variations and mutations in modifying genes may all provide opportunities to 
intervene in pathogenesis and develop treatment options on an individual basis.
Many countries, including the Netherlands, have undertaken prospective and randomised 
studies to test the effectiveness in patients of the angiotensin II type 1 receptor blocker, 
losartan (Detaint et al., 2010; Forteza et al., 2011; Gambarin et al., 2009; Lacro et al., 
2007; Matt and Eckstein, 2011; Moberg et al., 2011; Radonic et al., 2010). Losartan has 
a negative effect on the TGFb signalling pathway and is thought to slow or halt aortic 
growth and other phenotypic features. While the results of these studies are still awaited, 
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it is expected that the possible positive effects will differ in different individuals. In 
order in individualise treatment, future studies should focus on factors that determine 
the effectiveness of certain drugs. In cases of fibrillin-1 haploinsufficiency, a method to 
upregulate fibrillin-1 production pharmacologically, or by gene therapy to compensate for 
the deficiency, might have a beneficial effect. Evident obstacles such as delivery, sustained 
expression and avoidance of deleterious side effects remain major challenges. Although 
influencing a signalling pathway seems less complicated from a pharmacological point of 
view, interfering with complex signalling pathways may have unwanted side effects. Close 
monitoring of short and long term effects are inevitable.
As the life expectancy for patients with Marfan syndrome grows, more patients will 
be confronted with the morbidity associated with aging. Little is known about clinical 
manifestations in elderly Marfan patients. A questionnaire study of 60 patients with 
Marfan syndrome, aged 50 or older, suggested a pattern of premature ageing (Hasan et 
al., 2007). Close monitoring of elderly Marfan patients in clinical and research settings is 
needed.
With advances in knowledge of pathogenesis, clinical guidelines should be revised on a 
regular basis, thus allowing the translation of scientific knowledge into useful and practical 
information for clinicians and patients.
Familial thoracic aortic aneurysm and dissections (FTAAD)
In contrast to Marfan syndrome, FTAAD is genetically a highly heterogeneous disease. 
Several genes have been found to cause FTAAD, with or without additional features. With 
the emergence of next generation sequencing (NGS), it will be easier and cheaper to detect 
mutations in known or unknown genes. In a diagnostic setting, a multigene NGS panel 
targeted at aortic aneurysms will provide a much more rapid diagnosis at a lower cost 
than conventional sequencing of individual genes. In a research setting, whole exome or 
whole genome sequencing has replaced the classic approach of linkage in large families 
and the sequencing of individual genes. One advantage of these new technologies is the 
possibility of gene identification in small families or even in isolated patients. Furthermore, 
the identification of susceptibility genes or modifying genes becomes feasible. One of the 
challenges of NGS is in handling the vastly increased numbers of unclassified variants 
that require further investigation through approaches such as segregation analysis and/
or functional assays.
Similarly to Marfan syndrome, clinical studies of family members will be important in 
providing insights into the various phenotypes related to a specific mutated gene. Future 
studies of modifying factors are also expected to open new avenues to effective treatment 
options.
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Nederlandse samenvatting
De grote lichaamsslagader (‘aorta’) verloopt van het hart tot aan de liesslagaders en vervoert 
het zuurstofrijke bloed dat via meerdere vertakkingen geleid wordt naar alle weefsels 
en organen. Een scheur in de binnenbekleding van de aorta (‘aortadissectie’) waardoor 
bloed tussen de binnen- en buitenbekleding stroomt wordt meestal voorafgegaan door 
een verwijding (‘aneurysma’). Een aneurysma van de aorta kan verschillende oorzaken 
hebben. Bij het ontstaan van een aneurysma van de aorta in de borstkas (‘thoracale aorta- 
aneurysma’s’) spelen erfelijke factoren een belangrijke rol. In tegenstelling tot thoracale 
aneurysma’s spelen bij buikaneurysma’s vooral niet-genetische factoren een rol zoals 
atherosclerose. Aneurysma’s en dissecties van de aorta in de borstkas leiden tot ernstige 
complicaties en een hoge sterfte. Vroege herkenning van mensen met een verhoogde 
kans op een dissectie is van groot belang, omdat tijdig herkennen van de verwijde 
lichaamsslagader, gevolgd door operatieve reconstructie met een prothese de kans op 
ernstige complicaties en overlijden kan verkleinen. 
Marfan syndroom is één van de bekendste aandoeningen met een sterk verhoogde kans op 
aneurysma’s en dissecties van de thoracale aorta op relatief jonge leeftijd. Marfan syndroom 
wordt veroorzaakt door mutaties in FBN1, het FBN1-gen dat codeert voor fibrilline-1. Op 
enkele uitzonderingen na, zoals ook beschreven in Hoofdstuk 4, leidt een mutatie in één 
van beide kopieën van het FBN1-gen vrijwel altijd tot de ziekte (dominante overerving). 
In dit proefschrift worden de klinische en genetische aspecten behandeld van aorta-
aneurysma’s en -dissecties in de borstkas, met speciale aandacht voor Marfan syndroom. 
Hoofdstuk 1 is een algemene samenvatting van de stand van de kennis over Marfan 
syndroom, familiare thoracale aorta-aneurysma’s en -dissecties (FTAAD) en andere 
syndromen die geassocieerd zijn met TAAD. Er wordt extra aandacht geschonken aan 
de ontstaanswijze van de aortaproblematiek in Marfan syndroom. Hoofdstuk 2 is de 
Engelse vertaling van de Nederlandse richtlijn voor de diagnose en behandeling van 
Marfan syndroom. Deze richtlijn is opgesteld door verschillende specialisten die betrokken 
zijn bij één van de vier marfanpoliklinieken in Nederland. De richtlijn bevat praktische 
aanbevelingen voor verwijzers en behandelaars die betrokken zijn bij de herkenning, 
diagnose, controle en behandeling van patiënten met Marfan syndroom. Voor zover 
mogelijk is de richtlijn gebaseerd op wetenschappelijk bewijs, echter bij het ontbreken van 
voldoende bewijs, is uitgegaan van de ervaringen en inzichten van deskundigen (‘expert 
opinion’). Door het beschikbaar komen van de richtlijn hebben huisartsen en andere 
verwijzers gemakkelijk de beschikking over recente en betrouwbare informatie over Marfan 
syndroom en verwijscriteria. De herziene Gentse criteria (‘the revised Ghent nosology’) 
voor de diagnose Marfan syndroom worden gepresenteerd in Hoofdstuk 3. Deze criteria 




















zijn opgesteld door een internationaal panel van deskundigen. Een belangrijke verandering 
ten opzichte van de eerdere criteria (Ghent nosology, 1996) is dat er meer gewicht wordt 
gegeven aan de twee hoofdkenmerken van Marfan syndroom, namelijk een verwijding 
of scheur van de aortawortel en het los liggen van de ooglens (‘lens(sub)luxatie’). In de 
afwezigheid van één van deze twee criteria, wordt het hebben van een eerstegraads 
familielid, een ziekteveroorzakende FBN1-mutatie óf een combinatie van bijkomende 
(systemische) kenmerken, verlangd. Een ander belangrijk verschil is, dat de aanwezigheid 
van een verwijding van de ruimte waarin zich de vloeistof van het ruggenmerg bevindt 
(‘durale ectasieën’) een belangrijk kenmerk was in de voorgaande diagnostische criteria. Nu 
maakt dit verschijnsel deel uit van een nieuw scoringssysteem voor marfankenmerken, de 
systemische score. 
Naast criteria voor het stellen van de diagnose Marfan syndroom worden ook mogelijke 
alternatieve diagnoses gegeven. In Hoofdstuk 4 worden specifieke mutaties in het 
FBN1-gen beschreven, die ertoe leiden dat het eerste asparaginezuur van een ‘calcium-
binding Epidermal Growth Factor-like’ (cbEGF) domein vervangen wordt door een ander 
aminozuur. Een dergelijke missense mutatie werd vastgesteld in beide kopieën van het 
gen (‘homozygoot’) bij drie marfanpatiënten uit een grote familie met een hoge mate 
van bloedverwantschap. Uit onderzoek bij familieleden bleek dat dertien heterozygote 
dragers (mutatie in één van beide kopieën van het gen) geen belangrijke cardiovasculaire, 
oogheelkundige of skeletkenmerken van Marfan syndroom hadden. Vergelijkbare 
heterozygote mutaties in 14 andere gepubliceerde en geobserveerde patiënten bleken te 
resulteren in Marfan syndroom. De verzamelde klinische gegevens laten zien dat de uiting 
van de mutaties op één allel kan variëren van asymptomatisch tot een ernstig, al op de 
babyleeftijd optredende vorm van Marfan syndroom. Asparaginezuur op deze positie 
in de verschillende cbEGF-domeinen is belangrijk voor  de binding van het calcium dat 
een rol speelt bij de stabilisatie van de eiwitstructuur, de interactie tussen eiwitten en 
het voorkomen van eiwitafbraak. De verwachting is dan ook dat het vervangen van een 
asparaginezuur op deze plek in het gen door een ander aminozuur, ziekteveroorzakend zal 
zijn in heterozygote vorm. Dit is in tegenspraak met het ontbreken van symptomen bij de 
heterozygote dragers in de consanguine familie. De recessieve overervingsvorm in deze 
familie suggereert dat deze specifieke mutatie een mild functioneel effect heeft en mogelijk 
gecombineerd met verminderde expressie van het FBN1-gen beneden de drempelwaarde 
voor een klinische uitingsvorm blijft. Deze klinische bevindingen benadrukken het belang 
van een zorgvuldige interpretatie van missense mutaties, omdat het effect in de patiënt 
niet altijd goed voorspeld kan worden. 
In Hoofdstuk 5 wordt een serie van 10 patiënten beschreven met het ontbreken (deletie) 
van één van de twee kopieën van het gehele FBN1-gen. Bij deze patiënten wordt het gehele 
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spectrum van marfanoïde kenmerken gezien inclusief lens(sub)luxaties en aneurysma’s 
van de thoracale aorta waarvoor operatief ingrijpen noodzakelijk was. Hieruit blijkt dat 
pure haploinsufficiëntie, waarbij maar één van de twee kopieën van het gen werkzaam 
is, voldoende is om het gehele spectrum van Marfan syndroom tot uiting te laten komen. 
Hieruit is geconcludeerd dat haploinsufficiëntie in belangrijke mate bijdraagt aan het 
ontstaan van de ziekte. Dit komt overeen met onderzoek bij muizen, waarbij één exemplaar 
van het  FBN1-gen is uitgeschakeld.
Hoofdstuk 6 beschrijft een familie van 3 generaties met een genetische aanleg voor aorta-
aneurysma’s en -dissecties doordat een klein stukje van chromosoom 15 mist (‘interstitiële 
deletie’) met betrokkenheid van het SMAD3-gen. De deletie werd ontdekt tijdens 
chromosomenonderzoek door middel van een SNP-array, die uitgevoerd werd vanwege 
een verstandelijke beperking bij één familielid. De deletie houdt geen verband met de 
verstandelijke beperking en was een toevalsbevinding. Mutaties in SMAD3 zijn recent 
geassocieerd met een syndromale vorm van aorta aneurysma’s en dissecties geassocieerd 
met skeletafwijkingen (‘AOS, aneurysms-osteoarthritis syndrome’). De familie was zich 
niet bewust van een verhoogde kans op aortaproblematiek. Meerdere dragers van de 
deletie bleken een verwijding van de thoracale aorta te hebben en skeletafwijkingen zoals 
beschreven bij AOS. Eén familielid was overleden aan de gevolgen van een dissectie van 
het eerste deel van de aorta. Hij kon niet meer onderzocht worden op dragerschap van de 
deletie, maar was per definitie drager vanwege zijn positie in de stamboom. Deze familie 
laat zien dat haploinsufficiëntie van SMAD3 waarschijnlijk ook een belangrijke rol speelt in 
de ontwikkeling van AOS.
Twee ongerelateerde kinderen met Marfan syndroom en herhaalde verhoogde hersendruk 
(‘intracraniële drukverhoging’) worden beschreven in Hoofdstuk 7. Voor zover bekend is 
intracraniële drukverhoging niet eerder beschreven in associatie met Marfan syndroom. 
Beide kinderen hadden durale ectasieën, en één van beiden had daarbij een uitstulping van 
de spinale ruimte vóór het heiligbeen (‘anterieure sacrale meningocèle’). Durale ectasieën 
zijn geassocieerd met verlaagde hersendruk (in tegenstelling tot  hersendruk), veroorzaakt 
door lekkage van hersenvocht.
Eén van de kinderen maakte deel uit van de grote familie beschreven in Hoofdstuk 4 
en heeft in beide kopieën van het gen een mutatie die leidt tot de substitutie van het 
eerste asparaginezuur van een cbEGF-domein. Het tweede kind had een klassieke mutatie 
van een cysteine in een cbEGF-domein in FBN1. Hoewel er geen duidelijke verklaring is 
voor de intracraniële hypertensie bij deze twee patiënten met Marfan syndroom, is het 
van belang te weten dat er mogelijk een relatie is tussen intracraniële hypertensie en 
bindweefselaandoeningen, zodat bij onbegrepen hoofdpijn en braken snel de correcte 
diagnose gesteld kan worden.




















In Hoofdstuk 8 wordt een samenvatting van dit proefschrift gegeven. Aansluitend wordt 
de inhoud bediscussieerd. Er wordt behandeld wat het praktisch belang is van de richtlijn 
voor de diagnose en behandeling van Marfan syndroom. Enkele tekortkomingen van de 
herziene Gentse criteria worden bediscussieerd zoals het gebruik van normaalwaardes 
voor de aortawortel op basis van het lichaamsoppervlak en de lengte (‘Z-scores’). 
Tenslotte wordt in dit laatste hoofdstuk besproken welke implicaties de bevindingen in 
eerdere hoofdstukken hebben voor de diagnostiek, voorlichting, klinische zorg en het 
wetenschappelijk onderzoek gericht op patiënten met Marfan syndroom of een erfelijke 
vorm van thoracale aorta- aneurysma’s.
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lief en leed te delen
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Marietta, Michel en Rám, voor jullie toewijding aan deze patiëntengroep. Dankzij jullie is de 
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Een dankbaar woord ook voor de werkgroepleden van de richtlijn Marfan syndroom. 
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Beste vrienden, buren, kennissen en tena-ladies, die mij beschouwen als de eeuwig 
met promoveren bezig zijnde erfelijkheidsdokter uit het LUMC. Bedankt voor jullie 
belangstelling en de mogelijkheden tot afleiding die jullie me boden. 
Beste schoonfamilie, lieve ma, ik voel me altijd erg welkom in Hoogland, bedankt daarvoor. 
De familieperikelen leiden me prima af van mijn drukke werk.
Lieve heit en mem. Jullie zijn op de achtergrond altijd erg belangrijk voor me. Bedankt voor 
alle mogelijkheden die jullie me hebben geboden waardoor ik ben wie ik nu ben! En dat 
geldt ook voor jullie, Marcel en Ingrid, broer en schoonzus.
En dan het middelpunt van mijn bestaan, mijn lieve kanjers Rixt, Jelle en Sjoerd. Door jullie 
kan ik mijn werkbeslommeringen gemakkelijk achter me laten. 
Bedankt voor jullie suggesties voor de voorkant van mijn proefschrift. Jelle, bedankt voor 
de moeite die je gedaan hebt om van alle ideeën een bruikbaar ontwerp te maken, het is 
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Yvonne Hilhorst-Hofstee werd geboren op 23 juni 1964 in Drachten. Ze behaalde haar VWO 
diploma in 1982. Na 1 jaar op de school voor Hoger Laboratorium Onderwijs (HLO), startte 
zij haar studie Geneeskunde aan de Rijksuniversiteit Groningen in 1983. Haar co-schappen 
deed zij in het Medisch Spectrum Twente te Enschede van 1988-1990 en zij werkte 
daarna ruim 1 jaar als arts-assistent kindergeneeskunde in het Streekziekenhuis Midden 
Twente te Hengelo (Ov). Daar werd haar interesse in de klinische genetica gewekt door 
het doen van een inventariserend genetisch onderzoek bij kinderen met gespleten lip- en/
of gehemelte onder leiding van Drs. N. Kors en Prof. Dr. R.C.M. Hennekam. In 1992-1993 
verrichtte zij wetenschappelijk onderzoek naar het fragiele X syndroom aan de Universiteit 
van Tsukuba (Japan) onder leiding van Prof. H. Hamaguchi. In 1993 startte zij haar opleiding 
in Leiden en sinds november 1996 werkt zij als klinisch geneticus in het Leids Universitair 
Medisch Centrum onder leiding van Prof. Dr. M.H. Breuning en sinds kort onder Prof. Dr. 
C.A. van Asperen. Zij houdt zich met name bezig met bindweefselaandoeningen in het 
bijzonder Marfan syndroom en familiaire  thoracale aorta aneurysma’s en dissecties. Haar 
klinische werk aan dit onderwerp onder leiding van Prof.Dr. M.H. Breuning als promotor 
en Dr. G. Pals als copromotor heeft geresulteerd in dit proefschrift. Daarnaast heeft zij 
speciale belangstelling voor de genetische aspecten van ontwikkelingsachterstand en/of 
aangeboren afwijkingen. Zij is getrouwd met Richard Hilhorst en heeft 3 kinderen, Rixt van 
14 jaar, Jelle en Sjoerd van 13 jaar.
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